0001193125-12-017920.txt : 20120120 0001193125-12-017920.hdr.sgml : 20120120 20120120100503 ACCESSION NUMBER: 0001193125-12-017920 CONFORMED SUBMISSION TYPE: 485BPOS PUBLIC DOCUMENT COUNT: 7 FILED AS OF DATE: 20120120 DATE AS OF CHANGE: 20120120 EFFECTIVENESS DATE: 20120120 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PUTNAM GLOBAL HEALTH CARE FUND CENTRAL INDEX KEY: 0000357295 IRS NUMBER: 046471950 STATE OF INCORPORATION: MA FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 485BPOS SEC ACT: 1933 Act SEC FILE NUMBER: 002-75863 FILM NUMBER: 12535993 BUSINESS ADDRESS: STREET 1: ONE POST OFFICE SQ STREET 2: MAILSTOP A 14 CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 8002251581 MAIL ADDRESS: STREET 1: ONE POST OFFICE SQ STREET 2: MAILSTOP A 14 CITY: BOSTON STATE: MA ZIP: 02109 FORMER COMPANY: FORMER CONFORMED NAME: PUTNAM HEALTH SCIENCES TRUST DATE OF NAME CHANGE: 19920703 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PUTNAM GLOBAL HEALTH CARE FUND CENTRAL INDEX KEY: 0000357295 IRS NUMBER: 046471950 STATE OF INCORPORATION: MA FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 485BPOS SEC ACT: 1940 Act SEC FILE NUMBER: 811-03386 FILM NUMBER: 12535994 BUSINESS ADDRESS: STREET 1: ONE POST OFFICE SQ STREET 2: MAILSTOP A 14 CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 8002251581 MAIL ADDRESS: STREET 1: ONE POST OFFICE SQ STREET 2: MAILSTOP A 14 CITY: BOSTON STATE: MA ZIP: 02109 FORMER COMPANY: FORMER CONFORMED NAME: PUTNAM HEALTH SCIENCES TRUST DATE OF NAME CHANGE: 19920703 0000357295 S000005666 PUTNAM GLOBAL HEALTH CARE FUND C000015515 Class A Shares PHSTX C000015516 Class B Shares PHSBX C000015517 Class C Shares PCHSX C000015518 Class M Shares PHLMX C000015519 Class R Shares PHSRX C000015520 Class Y Shares PHSYX 485BPOS 1 d276138d485bpos.htm PUTNAM GLOBAL HEALTH CARE FUND Putnam Global Health Care Fund

As filed with the Securities and Exchange Commission on January 20, 2012

Registration No. 2-75863

811-03386

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM N-1A

REGISTRATION STATEMENT

UNDER

  THE SECURITIES ACT OF 1933    x     
  Pre-Effective Amendment No.    ¨     
  Post-Effective Amendment No. 33    x     

and

REGISTRATION STATEMENT

UNDER

  THE INVESTMENT COMPANY ACT OF 1940    x     
  Amendment No. 34    x     
  (Check appropriate box or boxes)   

 

 

PUTNAM GLOBAL HEALTH CARE FUND

(Exact name of registrant as specified in charter)

 

 

One Post Office Square, Boston, Massachusetts 02109

(Address of principal executive offices)

Registrant’s Telephone Number, including Area Code

(617) 292-1000

 

 

It is proposed that this filing will become effective (check appropriate box)

  ¨ immediately upon filing pursuant to paragraph (b)
  x on January 20, 2012 pursuant to paragraph (b)
  ¨ 60 days after filing pursuant to paragraph (a) (1)
  ¨ on (date) pursuant to paragraph (a) (1)
  ¨ 75 days after filing pursuant to paragraph (a) (2)
  ¨ on (date) pursuant to paragraph (a) (2) of Rule 485.

If appropriate, check the following box:

  ¨ this post-effective amendment designates a new effective date for a previously filed post-effective amendment.

 

 

BETH S. MAZOR, Vice President

PUTNAM GLOBAL HEALTH CARE FUND

One Post Office Square

Boston, Massachusetts 02109

(Name and address of agent for service)

 

 

Copy to:

JOHN W. GERSTMAYR, Esquire

ROPES & GRAY LLP

Prudential Tower

800 Boylston Street

Boston, Massachusetts 02199-3600

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933 and the Investment Company Act of 1940, the Registrant certifies that it meets all of the requirements for effectiveness of this Registration Statement under Rule 485(b) under the Securities Act of 1933 and has duly caused this Amendment to its Registration Statement to be signed on its behalf by the undersigned, duly authorized, in the City of Boston, and The Commonwealth of Massachusetts, on the 20th day of January, 2012.

 

PUTNAM GLOBAL HEALTH CARE FUND
By:   /s/    JONATHAN S. HORWITZ,        
 

Executive Vice President, Treasurer,

Principal Executive Officer and

Compliance Liaison

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated:

 

Signature

   

Title

 

Jameson A. Baxter*

   

Chair, Board of Trustees

 

Robert L. Reynolds*

   

President and Trustee

 

Jonathan S. Horwitz*

   

Executive Vice President, Treasurer, Principal Executive Officer and Compliance Liaison

 

Steven D. Krichmar*

   

Vice President and Principal Financial Officer

 

Janet C. Smith*

   

Vice President, Assistant Treasurer and Principal Accounting Officer

 

Ravi Akhoury*

   

Trustee

 

Barbara M. Baumann*

   

Trustee

 

Charles B. Curtis*

   

Trustee

 

Robert J. Darretta*

   

Trustee

 

John A. Hill*

   

Trustee

 

Paul L. Joskow*

   

Trustee

 

1

 

Kenneth R. Leibler*

   

Trustee

 

Robert E. Patterson*

   

Trustee

  

 

George Putnam, III*

   

Trustee

  

 

W. Thomas Stephens*

   

Trustee

 

By:   /s/    JONATHAN S. HORWITZ,        
  as Attorney-in-Fact January 20, 2012

 

* Signed pursuant to power of attorney filed in Post-Effective Amendment No. 31 to the Registrant’s Registration Statement on December 29, 2010.

 

2

EX-101.INS 2 pghcf357295-20111230.xml XBRL INSTANCE DOCUMENT 0000357295 pghcf357295:S000005666Member pghcf357295:C000015516Member 2010-12-31 2011-12-30 0000357295 pghcf357295:S000005666Member pghcf357295:C000015517Member 2010-12-31 2011-12-30 0000357295 pghcf357295:S000005666Member pghcf357295:C000015519Member 2010-12-31 2011-12-30 0000357295 pghcf357295:S000005666Member pghcf357295:C000015520Member 2010-12-31 2011-12-30 0000357295 pghcf357295:S000005666Member pghcf357295:C000015518Member 2010-12-31 2011-12-30 0000357295 pghcf357295:S000005666Member pghcf357295:MsciWorldHealthCareIndexMember 2010-12-31 2011-12-30 0000357295 pghcf357295:S000005666Member pghcf357295:ReturnBeforeTaxesMember pghcf357295:C000015515Member 2010-12-31 2011-12-30 0000357295 pghcf357295:S000005666Member rr:AfterTaxesOnDistributionsMember pghcf357295:C000015515Member 2010-12-31 2011-12-30 0000357295 pghcf357295:S000005666Member pghcf357295:ReturnBeforeTaxesMember pghcf357295:C000015519Member 2010-12-31 2011-12-30 0000357295 pghcf357295:S000005666Member pghcf357295:ReturnBeforeTaxesMember pghcf357295:C000015518Member 2010-12-31 2011-12-30 0000357295 pghcf357295:S000005666Member pghcf357295:ReturnBeforeTaxesMember pghcf357295:C000015516Member 2010-12-31 2011-12-30 0000357295 pghcf357295:S000005666Member pghcf357295:ReturnBeforeTaxesMember pghcf357295:C000015517Member 2010-12-31 2011-12-30 0000357295 pghcf357295:S000005666Member pghcf357295:ReturnBeforeTaxesMember pghcf357295:C000015520Member 2010-12-31 2011-12-30 0000357295 pghcf357295:S000005666Member rr:AfterTaxesOnDistributionsAndSalesMember pghcf357295:C000015515Member 2010-12-31 2011-12-30 0000357295 pghcf357295:S000005666Member pghcf357295:C000015515Member 2010-12-31 2011-12-30 0000357295 pghcf357295:S000005666Member 2010-12-31 2011-12-30 0000357295 2010-12-31 2011-12-30 iso4217:USD xbrli:pure false 2011-12-29 2011-12-30 2011-08-31 485BPOS 0000357295 PUTNAM GLOBAL HEALTH CARE FUND <div>&lt;div style="display:none;"&gt;~ http://putnam.com/role/AnnualFundOperatingExpenses ~&lt;/div&gt;</div> -0.1984 -0.2038 0.1850 0.0715 0.1356 0.0299 -0.0063 -0.1712 0.2517 0.0206 Average annual total returns after sales charges <i>(for periods ending 12/31/10)</i> Class A Class Y Class C Class B Class M Class R Class A Class A MSCI World Health Care Index (ND) before taxes before taxes before taxes after taxes on distributions and&#160;sale of fund shares before taxes before taxes after taxes on distributions before taxes 0.0241 -0.0128 -0.0339 -0.0198 0.0037 0.0182 -0.038 -0.0469 0.0232 0.0188 0.0137 0.0024 -0.0078 0.0188 0.0086 0.004 0.0042 0.006 0.0076 -0.0027 -0.0078 0.0022 -0.0077 -0.0062 -0.0088 -0.0152 -0.0066 Performance <p>Year-to-date performance</p><p>through 9/30/11</p><p> -8.11%</p><p>Best calender quarter</p><p>Q3 2010</p><p>12.45%</p><p> Worst calender quarter</p><p>Q1 2001</p><p>-22.70%</p> The bar chart does not reflect the impact of sales charges. If it did, performance would be lower. Annual total returns for class A shares before sales charges 0.1245 2010-09-30 -0.2270 2001-03-31 <div>&lt;div style="display:none;"&gt;~ http://putnam.com/role/AnnualTotalReturnsBarChart ~&lt;/div&gt;</div> -0.0811 2011-09-30 0.0075 0.0025 0.0050 0.0100 0.0100 You may qualify for sales charge discounts if you and your family invest, or agree to invest in the future, at least $50,000 in Putnam funds. More information about these and other discounts is available from your financial advisor and in <i>How do I buy fund shares?</i> beginning on page 57 of the fund&#8217;s prospectus and in <i>How to buy shares</i> beginning on page II-1 of the fund&#8217;s statement of additional information (SAI). 50000 Class C Class M Class B Class R Class Y Class A Example The following hypothetical example is intended to help you compare the cost of investing in the fund with the cost of investing in other funds. It assumes that you invest $10,000 in the fund for the time periods indicated and then, except as indicated, redeem all your shares at the end of those periods. It assumes a 5% return on your investment each year and that the fund&#8217;s operating expenses remain the same. Your actual costs may be higher or lower. Class B (no redemption) Class C (no redemption) <div>&lt;div style="display:none;"&gt;~ http://putnam.com/role/ExpenseExampleNoRedemption ~&lt;/div&gt;</div> 204 204 630 630 1083 1083 2338 2144 <div>&lt;div style="display:none;"&gt;~ http://putnam.com/role/ExpenseExample ~&lt;/div&gt;</div> 154 103 696 304 704 523 630 477 930 885 952 322 1283 1083 1271 1227 824 558 2144 1236 1802 2010 2338 2351 Fees and expenses The following table describes the fees and expenses you may pay if you buy and hold shares of the fund. You may qualify for sales charge discounts if you and your family invest, or agree to invest in the future, at least $50,000 in Putnam funds. More information about these and other discounts is available from your financial advisor and in <i>How do I buy fund shares?</i> beginning on page 57 of the fund&#8217;s prospectus and in <i>How to buy shares</i> beginning on page II-1 of the fund&#8217;s statement of additional information (SAI). 0.0126 0.0101 0.0151 0.0201 0.0176 0.0201 Best calender quarter (no deduction for fees, expenses or taxes other&#160;than withholding taxes on reinvested dividends) Worst calender quarter 0.0063 0.0063 0.0063 0.0063 0.0063 0.0063 0.0100 0.0100 0.0000 0.0500 0.0000 0.0065 0.0000 0.0575 0.0000 0.0000 0.0350 0.0000 Goal Putnam Global Health Care Fund seeks capital appreciation. Annual fund operating expenses <i>(expenses you pay each year as a percentage of the value of your investment)</i> Class C Class Y Class A Class M Class R Class B 0.0038 0.0038 0.0038 0.0038 0.0038 0.0038 putnam.com The performance information below gives some indication of the risks associated with an investment in the fund by showing the fund&#8217;s performance year to year and over time. The performance information below gives some indication of the risks associated with an investment in the fund by showing the fund&#8217;s performance year to year and over time. The bar chart does not reflect the impact of sales charges. If it did, performance would be lower. Please remember that past performance is not necessarily an indication of future results. Monthly performance figures for the fund are available at putnam.com. Please remember that past performance is not necessarily an indication of future results. Monthly performance figures for the fund are available at putnam.com. <p>After-tax returns reflect the historical highest individual federal marginal income tax rates and do not reflect state and local taxes. Actual after-tax returns depend on an investor&#8217;s tax situation and may differ from those shown. After-tax returns are shown for class A shares only and will vary for other classes. These after-tax returns do not apply if you hold your fund shares through a 401(k) plan, an IRA, or another tax-advantaged arrangement.</p><p>Class B share performance does not reflect conversion to class A shares.</p> Actual after-tax returns depend on an investor&#8217;s tax situation and may differ from those shown. After-tax returns are shown for class A shares only and will vary for other classes. <div>&lt;div style="display:none;"&gt;~ http://putnam.com/role/AverageAnnualTotalReturns ~&lt;/div&gt;</div> After-tax returns reflect the historical highest individual federal marginal income tax rates and do not reflect state and local taxes. Portfolio turnover 0.35 The fund pays transaction-related costs when it buys and sells securities (or &#8220;turns over&#8221; its portfolio). A higher turnover rate may indicate higher transaction costs and may result in higher taxes when the fund&#8217;s shares are held in a taxable account. These costs, which are not reflected in annual fund operating expenses or the above example, affect fund performance. The fund&#8217;s turnover rate in the most recent fiscal year was 35%. 2011-12-30 -0.0100 -0.0100 -0.0100 -0.0100 -0.0100 -0.0100 Risks It is important to understand that you can lose money by investing in the fund. <p>It is important to understand that you can lose money by investing in the fund.</p><p>The prices of stocks in the fund&#8217;s portfolio may fall or fail to rise over extended periods of time for a variety of reasons, including both general financial market conditions and factors related to a specific company or industry. Growth stocks may be more susceptible to earnings disappointments, and value stocks may fail to rebound. These risks are generally greater for small and midsize companies. The health care industries may be affected by technological obsolescence, changes in regulatory approval policies for drugs, medical devices or procedures and changes in governmental and private payment systems. Our policy of concentrating on a limited group of industries and the fund&#8217;s &#8220;non-diversified&#8221; status, which means the fund may invest in fewer issuers than a &#8220;diversified fund,&#8221; can increase the fund&#8217;s vulnerability to adverse developments affecting a single industry or issuer, which may result in greater losses and volatility for the fund. The value of international investments traded in foreign currencies may be adversely impacted by fluctuations in exchange rates. International investments may carry risks associated with potentially less stable economies or governments, such as the risk of seizure by a foreign government, the imposition of currency or other restrictions, or high levels of inflation or deflation. International investments, particularly emerging-market investments, can be illiquid. Our use of derivatives may increase these risks by increasing investment exposure or, in the case of many over-the-counter instruments, because of the potential inability to terminate or sell derivatives positions and the potential failure of the other party to the instrument to meet its obligations. Our use of short selling may result in losses if the securities appreciate in value.</p><p>The fund may not achieve its goal, and it is not intended to be a complete investment program. An investment in the fund is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency.</p> Our policy of concentrating on a limited group of industries and the fund&#8217;s &#8220;non-diversified&#8221; status, which means the fund may invest in fewer issuers than a &#8220;diversified fund,&#8221; can increase the fund&#8217;s vulnerability to adverse developments affecting a single industry or issuer, which may result in greater losses and volatility for the fund. An investment in the fund is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency. PUTNAM GLOBAL HEALTH CARE FUND Shareholder fees <i>(fees paid directly from your investment)</i> Class A Class R Class M Class B Class Y Class C <div>&lt;div style="display:none;"&gt;~ http://putnam.com/role/ShareholderFees ~&lt;/div&gt;</div> Investments For this non-diversified fund concentrating in the health care industries, we invest mainly in common stocks (growth or value stocks or both) of large and midsize companies worldwide that we believe have favorable investment potential. Potential investments include companies that manufacture health care supplies or provide health care-related services, and companies in the research, development, production and marketing of pharmaceuticals and biotechnology products. We may purchase stocks of companies with stock prices that reflect a value lower than that which we place on the company. We also consider other factors that we believe will cause the stock price to rise. We may consider, among other factors, a company&#8217;s valuation, financial strength, growth potential, competitive position in its industry, projected future earnings, cash flows and dividends when deciding whether to buy or sell investments. We may also use derivatives, such as futures, options, certain foreign currency transactions, warrants and swap contracts, for both hedging and non-hedging purposes, and may engage in short sales of securities. For this non-diversified fund concentrating in the health care industries, we invest mainly in common stocks (growth or value stocks or both) of large and midsize companies worldwide that we believe have favorable investment potential. Year-to-date performance This charge is eliminated after one year. Applies only to certain redemptions of shares bought with no initial sales charge. This charge is phased out over six years. EX-101.SCH 3 pghcf357295-20111230.xsd XBRL TAXONOMY EXTENSION SCHEMA 020060 - Schedule - Average Annual Total Returns {Transposed} link:presentationLink link:calculationLink link:definitionLink 020050 - Schedule - Annual Total Returns (Bar Chart) link:presentationLink link:calculationLink link:definitionLink 020040 - Schedule - Expense Example, No Redemption link:presentationLink link:calculationLink link:definitionLink 020030 - Schedule - Expense Example link:presentationLink link:calculationLink link:definitionLink 020020 - Schedule - Annual Fund Operating Expenses link:presentationLink link:calculationLink link:definitionLink 020010 - Schedule - Shareholder Fees link:presentationLink link:calculationLink link:definitionLink 010000 - Document - Risk/Return Summary {Unlabeled} link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 pghcf357295-20111230_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 5 pghcf357295-20111230_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 pghcf357295-20111230_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 7 pghcf357295-20111230_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ZIP 8 0001193125-12-017920-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-12-017920-xbrl.zip M4$L#!!0````(`*=0-$"4F=.0`QL```+C```8`!P`<&=H8V8S-3&UL550)``.J@AE/JH(93W5X"P`!!"4.```$.0$``.Q=6W/C-K)^ M3U7^`]9GDYJILBZD+%OR>&;+EW'&M?9XUO:<;)Y<$`E).$.1"B^RM0_[VT]W M@Z1(B90IB[HX]MDZ22R"C:\;#72CT0T>_>-Q8+&1<#WIV!]WM&I]APG;<$QI M]S[N!%Z%>X:4.__X]/-/1W^K5/Y]$*[@N3/4B_STZ6M+^,:QDV!D"GCMDFZ^S7U M,&IJBJEV@5>#W[!INU+7*@TM:NFZZ8:>,*H]9U1S791)O5+7*WHK:CSL]8UN MHWF@MYOQ6\/`M_F@:C@#?$'3]$8]"5@N(+I'3V9)`MIJM7]?7=X:?3'@E>FW MI.?LZ=K!O'Y4BQT84\:.4*2''M&Z$5U&(C[TQT/Q<<>3@Z&%A.FWOBNZ'W<2 M/%JI-C^^+19[?"\$$727O@B1'^+,V/.W-^IGPD"*][=U_+_F_O[^_948=(1[?XH_:,VF%OVBL`--F!G2'X=_P=_2 MQ%^Z$F8"\2126U"RA,]G'CQ#_"3TJI#\3BTI"%] MA869$MJI*0U*=7@I>MSZ3+B.'Z6W\RDALL,);^KEHUHFS84Z==W#;Z[C#4': M@7?;YZXXM;CGS78^$6.QSH]J:1DNQZUW_2H##UJ MOW(]TNMO>E2"'NGU5ZY'6NM-C\I8CUJO5(^N8/]Y_[L#/-]_$=SR^_>G(*W[ M"WCQ\4VSLC5+N%W''>`.[$IP+W#%;-EN_B)*_VH./N5&68]N\O^76 M6W1Q:;V?%V\!*9.0W^(N&SSW>U/H-SUZOAZ]&JUYV0.W\F':$G'\K5+Y;LN9 M]-$`?T,1?;\]BT4Q4&;J4YC3>@C/CFK1CXHVOC=%X1L\G2%!Z;F'0_C/?`H` M[2X86F(:&_S^V1*4ISWU!'7X&!Z8^/#+'([$\SI#5<@E-]O;-]*2STIW%NRM MWB+]S"4WV]O=>+A`)WNMYLFWZ]MT#TAB0E@M7*?PN\LM.O/_IQ@7[R$Y6W/) M3?=V(WKHGW';_\H'"[#S[?O=U^,K]MOE]L<0=P#BQ'.-'44Q9ENI7 MR_]@RM&O/?_#KWPP_*#^9)X_MF#9,Z4WM/CXT'9L\6&'&D##__[\TVQVONM8 MHC8'\L\__3?JH(8=AK1^C?Z&_SZJ+<+UE)S4_A&3^9\OC@P'D.%B191HD6.F M,.0`%I*/.WL[GRKUJM9N[25P3U#DP=/7"D^O-UI9\/0\>(WUP0/AM9KU+'2- M/'1[ZT17/]":6>CV\M`UURJ[1G,_"UTS#]W^6F6GM]M9Z/;ST!VL=5H`D$86 MO(,\>*WU+BH'FIX%KY4'K[W.L=6;VD$6NG8..JV^7LVK9\T+K3Y!-P*[TA/) MYZ=\B![:,H8TI,HXD66^X\,_7:+N,8[1'N9A7(<9L'/NP;_1\DDT>^^ZCLN4 M^^XQ\$O!XC%-KS6TFE9_3_913JQC+O:Y[#E6,+`7<5]6$1ND:`$[SN4C!KER M5A:+Y2OF<%^]$-SM*=PW6X#[F4F>+VIA M*1OW)>\(:PG(A6H4KFY/+Q@U8JH1PT:,&K%W7\_>Y_%`Z%8)?[&EI4/-F(_- MMAIR^^5!/M@NR$N[*\IG(R;PD@J12K@V6S%2BUG9K8#\3$,U3Z6V6OS-C'!H>FN#["UDEI_DI=%H;SDOK>+CTM[V<3DH.H/JC8,M9Z5=E!6M MI6\Y*\5G?F.3"O8\R_@D3WO[6[X"3)RJ)^U.8UE56^:5NB:.;@RW7ON)+P?9/I.*^0&M_RUDIYJ(A*YN< M-.6Y`L3)?%.S>5:*[0'HP'8Y3I8ZA"S#:-8/YG(P_WQR:0[*,YJT!.MSK>86 M\%)\;_F$.=D\+\7-25V?.]TWSTI!1$>#XS8"P!FLO^#(`=X6:T^U>#8;Y2QA--K^XULTCCV6Q!XAK#[-2, M)Q5=KQ[4$]138S0M^)F1.7.$]]7!@;"$X9/*7CK<])89H;N^8!WN4LJ4STSH M@=F.SUS5!_/AL1P,.?RGTTUG5U7919=)>$>:N\DA90].8)FL(YCE/`BWFN(Q MCX497DN8"\=9:6*8"&:HI(#P')&%YRTIYE*@\V;*%]GK@\+]2VF"-5;S?0G( M3^6CZGO--+!,``5Q+E*>D"5>*JBIMZD\HE!G,[@N03_6)C[,U-8/TE@S`12# MN;STZEJEWJ!RCR)]S:#:[OJ$.YQT"KT7(2Y:GI#-X8P`T*3<.2B;E2M.O:6E MAVFZ[R?!E3#9M(S)EM5-C"7IY6#)LW!'TA":WM'.A?"NP5,Y]CSA+V$^GA/Y M.5!+6%%P&^%F@>COJKEY].2A+:V/.[X;`(#EFP1V>)?!B[SG"@%>9/@;_(N\XFX` M"Z[89=QGEN#P^]^;]5T`@L^_D4VD9#5PDZ_0NY0V^<=4`L$[3D"NM2>H8P?^ MTTUB\A@?<6FA_6-=UQF$T*0-_K4$9Y:;(^DA-'@9NHO+'+XX#^#"LPO6"<;) M5+E_3$H/#>/+"#+[`J%@3ZJ3 MN7U<7%2TW%X\'\P652)#"VZ:$J4$;"9E]N[V^.*]VDODZTR^6EU)6PZ"P04- M(79U(_X,I"O,XP&^68KO@$7>B9EQ\?5\YU,3FV>C?@+2-"^?'SE^VNADC#:_ ME$SJ)^H9YO>[1GC9Z?];`R^[JF)KX&47(6P+O)P:H&V!EU-)\"QX)40T0DH9 M&*9#%.FG7[F+9=ZCH/+1BLN%SV!H@@&8=[\/ MYA@["FWUW[78)L>4T1G`/WPY$'%-H+1-8``_*(AV#A[;N\",(89(>_)TE\'Z M+,2`<T#2%6X#T0'/&33`R6LLC^0-@?;S2T2HDP/D9H7'1M$@&Z MIQ0F3[.<&Q#(@,HCU[*XLG>V0X.@^GR?!7X.I@VQ,6-A5\_&ML:'\A&SH@&B MHDP7D-+2>8OS]DI9#J$>IKX\!6FMV#-VK>O`7LI%&`7EOM^H%\'>6"OV@G(O M&WLIEV@4E+M6;S6*@&^N%7Q!P9<-OIQK&HK.UD:8I?X4IK6"+[I,:GM%UII< M\+^#^_C2;.'SS-\\3G.$4Y[AR`C>9LZC9M9@SC46I6',BG=GS_6LJ;X>C%D' M#IF&H+V_.8P%EYU&II.P)HP%5Y>#36+,."K+C!SJS]/'S3LFN;[N MMCCG:P)9<-9H^H&V.9`%IXVFZ[EKY.I!%ES'6WJNS5XYQJ)SN]G,VG$]B7$; M=E9S=U.E@2SLC.N-/$]W]2`+[VI:];RE?`T@"\YMS-+<',CE0A5K`EEP*=<; MS;RE?!9D"8=]F#%#QT#1$4^R\YSSOE4>]/F4CF(*SW!EA\[:X.DT1CI\PW.F M(?Q_F%N#*2+8IN]844)*,A6$3JK>TG7^ZNDZ3Q\I;BJ)4]-3MF9.FEJY"!AA\:35`C+,+O]8\@*UG4^9A5V$ M94Z',2BJ(O_JG`DSH"^=G#LN6M?)1P_PMK@5W^^)!_YF!(!,'!K/W8GE=.)K MZ]"^3*X^]/O7V[E"V3AA@C4:X;=Q3$]E$A1A.)9.9LW)TB.6 M72Y'Z/([C#%=<1OL$'T^9G,YVM$-]GE@UH)V@>L;M@!M\3J0;4!;O/9@"]`N M<$G!%J!=H(:F.-I'3)@^$UWAND)]PO&4-@C8^)J\6U#)T:?A][U=1>(@=/WS95&N9FH"P[38D@WSV?A=:YYT'S! M?#Y[+7QA?#Y[>7EI?!9>=1K-%\UG\6U-*>-YW?D_]K?+*?#K=0W0LXI="S$#W#<^5#B=2=\.'1!D!2,K:;!3F.: MH)[^&&09G^Q2=[!0<#NC:&7R@:[4`0(>'B1*8;!L!MXU8&N`P>DP+CWB5D!_ M3!713'_/*X^M.7ROH;IR3J=K`I93>K=Y8#E%=UL`++L2=0N`91=Y;@&P[.+8 M0L#07]YPO#NZYST'RSJP%O=[-H^UN$W?/-;BX:F-8UW`Q]\XU@5VS06Q)JXM M/%:G[-*2_OAWT;F5OC@V35=X2UT6,BG*(#R%^LM"=S$Y_KZPK`"_-NX+[W^Y M*T,2U]WP0JQE6`]\/(]YSD!$=B.BW9XK+*DG3Y M62XO3Z)L]1K1AY@\DY*7ZM@6!DP,&$%KK+A/"DIEWP`E M+[!\RK&!P8&&23I=V0LP-2BJSR=IX?9FDER#W<>S=4:IYF28)%I]`_SA+907 M85G_N4*WS-YL59*:YC$7?1:K5`Q6YG6N*QFV3)2Y[)0[]^.;6>F"X(K/'^.+ M0I,3J2\]WW'IAHN^2C>@41M)DS:WP@1WUF*PJ^Y)E0AEX%I!U'!=HZEK.JGY M24E4]`!XP%M*\4B^RH[5?0U\!HXIAG2YA#U96APWM7!@:T_"ZRII#1IC3ITI M,1ZBTM+4M12X^MC0TTP7.&CT,.N25,>V5!;?@[0LV'N[*DU/Y<)16X1_IY+D M9M$KYOEP:,5I@90.J#+E)JEO++K]E[.]NO;NQWLVM+B]BTQ?W!RK!#];=0KT M*]P<<0H*H,JYW%;GA]6,JW>CZR.HFY0"SRR=H$^PS'HH15A[TW*H3MW=^[1Z MYFLR7H-K"63@SKGCC]&YP5+AEG6I3S;S.1SEBN#:%C0NUUW21GCEEO1O&0FL M0*TSF^L-%-[@1CI0>>L"S8!@@C<*4O M03G>P4H1K:%Z_8/2/L09_ZA]``K@TT>,O`>[&]V_%(T/:1HMMM$U4W&+";80 M4[0L*_<0]Q514\H)),C9.=OA-56P%O:%1:GA'%]2_IE!F>R1^::N=H&8-/KT M1D+[A7IU?E0_]`1Y!]B+K@0#$PZ6!*:/$OUDHJB=S`S@M'3"#=0`[P)S!1X$ M@-_IX>RCK=$#]UBC^4LU6ZYG#6Y@U/;J%.4TFICZYC>%_B59-8+<`E?LL$XXU"Q0&!;77#9G2))48D\5)+W,%PW,Q(X8_Q M5U=PS['!IH-_:P6D6AW8XK">L,G_G92J@2?\0]`66)5U*9>C"TZ(XZ)GK1PD M@,$9FC[9E8:ZU-,>(TCP8#"8.ZZRWUSG`7H(60UOGAS0=U8"#^_5E.AY`"&P MWUAZYF%!'1_2S ML9QP@&(D]TF:GOR/"%'+,&H!7A'E4QB+"5`H[`E=G%"*O=$S2TKN@%("T'=I28C.$`)S"REC1D&"PSW:`'7`Z$ M281,,5+ZX6(9GR%,BJHAX@31'@Z\C?+ABAM0JA%]4HF/*=+LC3U?#("GZ\!5 MW9$"P'BBTQ0Z:KB_9Y8<2.2HYSK!4%VP&G,=WH$ZJYH);QMLHNU$.6'LO0`W#UY\1$+KGI#_P>`V0.4Q343@\9)W&005E0/:@I+0I\B@>B#L@``7CZ2G!=JTPF@YS3(1_S&%^%R:/ MZTL#9JL+[(F!P&!`KQ(NA:F6J'$@?FE9\L]`FFJ:!1Z-*!@,G(MT5J24?**9 M\0K5B7]75F-R\^\CL(W"<=S=R#(87%$>T.HZPC!'7U1HKX:3Q@9!!"&PCC!X MB`/?C,<+6B6T'UX;P`\^]D+;V13H2.Z3^3\A@\LNH5/TU5"@W!1='+<8#OXR M$"@ZT"RG8\F>4LF4M+P^6#G"@()(3ZIP,DG55V+#'6>UT8Z0YE*>M8W7&HH[ M&WT)"D*`>@ZWE&V1?G0BD[RK&F<7&0=+4#?Q",&JW'/Y`';PN6=[,3D<29/F M1,!A$^^+T'1`PS`0Q,X$R1OT$AI3(/K4<<'TQ[I+@TYRGDP1QGLX&Z:CT-F^ M4=IU0HL>KZ6WM$(OXSR]V9=MLR\33<@8ZBE=\"^4BH9*"$X*_.!+/U@^WW/C M]B1`HFZPW+F$UGWR<2<72IDC/=%EN@.J/_% M@S2%"IA!AQUAD=?=Y_"/+A^!_>Y8:96C(,H>"5&\GE\P.>I[]*%,:8)\5"(X'X)[AK]W:0;MXL4H^L[ MU#D<[@_)W^VR(6CF@!LBH._@*$>M(YTX5C2.WH9=T._JM&\85BW%@NXFI2FC MX%D4-R3&HS-H'HX1)>HIMU9)G5Q(D#U,1_":G'`?J0)TU#.`.44X_:D,>"-4XSXP"QUEEN2:0@G?GZ2Q6\\Z2;ZP0A@ MG"*3@,5KD)>K[[&=?7NQ%\YJ1A>/^6W[//YD&`3IDZ&PH=-VOQA-3@WQB7*\=Y3-,2_+C`6@:<-.%P M51PE[W=;J7R"%ZNFHG*?@8&@2Q6VE*(5,+?%.JBJRJW7>>RF>3CQIE.?C01L M:!-P!0]2V(&*^3>@7Q3H+D=67)OC/[@T1O3-H2`O\3K6FV[[6"_R+GB8`A0( M/!Y!65I,4.4Y"E$_1[^JAX+\*)W;RE'"._SDQ;(U)UR6;G0F>G1J1+=[>-_)':/6/=U>&9O7&PE-; M::&\B&KJK6*0A%X9SEU0?C]!Y.#A"U!+`P04````"`"G4#1`@N>B.YT#``!O M$0``'``<`'!G:&-F,S4W,CDU+3(P,3$Q,C,P7V-A;"YX;6Q55`D``ZJ"&4^J M@AE/=7@+``$$)0X```0Y`0``S9?=;MLX$(7O%]AWF%5OML#*LN2X71MVBZ1) M@0))4]@IT+L%+8UEHA0ID%3L(.B[EY0EMY+\BY6!)!>QK#F'GSC4S&3T?I4P M>$2IJ.!CQ^]T'4`>BHCR>.QDRB4JI-0!I0F/"!,AEKXSUO6]W MM]-P@0EQ*;<;$_Y269MM.G\P&'CY71.JZ%#E^EL1$IUO_$$NV!EAK]PRS+5? MN7[@]OS.2D6.V0.`D10,)SB''&"HGU*31463E%GP_+N%Q/G82>-%.._UWP:# MOC'R?3_H=:W-JPE5WR>H,\FG69(0^>2`]?PZ^;1!3S/-2=()1>+96]X6B=<2 MS71A#LU"L`CE1T1UF*4A:(ODDO.,L(\9C^Y3E":7/+Y9IX(-Z^H/6,V8_O@=D=N$'_+\Z6LTA(9EI;F8R7)S?6S:4: MDU(_ER+9N5W%FN(`LI#FD(X=LYH#F3(L(B_KA#FP1!HOM!E)'4@E%9+JI_SB MS(FXIDI+.LORS>/1%.4C#=$/9OZAQ!RO?+&).OX1BL1=O)S$W>L%RF/>[IV! M+S8M.XF+++PY.0LCK]8+6FX0]2FRT1-ZM9Y0"*`^=YZ)J#I#-N@N]M/]`Y\% M;!E"6^ZOVP?*!FQ_>WO-U5#(X6]C`+G#ZS/@[AXP&[1OZK1K[7;JYP=)N$J% M.CQ950!/F"GW/72)?5&.@52%3*A,8FT07!N"=83G&Y:W.E40CS;_PIN+GU!+ M`P04````"`"G4#1`OU[)8:,3``#U?0$`'``<`'!G:&-F,S4W,CDU+3(P,3$Q M,C,P7V1E9BYX;6Q55`D``ZJ"&4^J@AE/=7@+``$$)0X```0Y`0``[5U;<^.X ML7Y/5?X#XWU)JJ*1)5FVY1IGRY>9&E=\B^W-;IZV8!&2F*%(!R1]J:W][P$H MTJ*(*RT+!+PX>3@[5C?QX6L0:'8W@,\_/L]#[Q&B)(BCPZW>I^TM#T;CV`^B MZ>%6EG1`,@Z"+2])0>2#,([@X584;_WXCS__Z?-?.IU?CF_./3\>9W,8I=X8 M09!"WWL*TIEW'#]%T+L#TRE$7B[W)0+W(?['_4OQXVT\29\`@F7[7F_[$_E? MK[?3Z10M'(,$/Q'_EC^B_ZGW^LM)T5H<'7B];F_0[6_W^M[HH-<[V!YY1Q<+ MP3"(OM_C9WBXGU%RN#5+TX>#;O?IZ>G3\ST*/\5HBA6W!]U2<&LA>?"+\=CR#<]`)(L+,>*E%'L/2ZXU&HV[^*Q9-@H,DUS^/QR#-F9?B M\K@2Y%^=4JQ#_M3I]3N#WJ?GQ'_%A67\]+69Z@.&W<6/6Y@NS_N,XA#>P(F7 M8SU(7QZPQ9-@_A"2/N9_FR$X.=QZF,[&D\%PKS\:XC9[O5Y_L$U:_.%VADTZ MBT,?HJ\0)EL>>>)/-V>OC3]D:03FG\;QO$M^ZE(*W7="08+)1FHNOQF<%S&-]"'\P MQ2D(;V":H2@Y!N@$CYM4U9!LW7?#AV@<78/.WZ`5YHD'UM%0Q1:\I0@2KM8M%O(=)D/V"#@UU8Z M?CP'04.TM+8>J'`"LC!],]92?8-@01@V@Y%:0$C4\ M->'_\SK>:>E+=CRBTUTH>866]]M/40CN80C]WQ?N"L88QN,58"'QJ6*TSMR( MT*_7*$X>X#C-DCOBM99/RUL_W&()=-\"*`7/<13/`Y@L!EJ6=+'3/07@@8RW M43?"+U;^+Q\&9-2-.MN]PK7[`?_IUW,X!>&7"-/X7.Y]7?OCUELR2V\/=W=V+ M8M58H4\L:N+P%",NV-QY\U!5G^Z7"]31?9(B,$[I&9\ELR%2<[>E-GGR(1(F M6;-KE;^%XW(P#N,$^H=;*-5=ZPI^0R@:\^TZDQ>W?\7&SYXA%PB:0DS>:1Q:IP%7AN_1@'Q-^_P M6W&,'_U=P"$M^=2QF@A21;&@W4#73`@TZ4)I$X_)8)*-D M;D9=S$RJ.6"7GQ>Z:6W@?`@T;"!;X(KT=2R8JVA^#M+9,KLJFV*:Z-I@"W$/ M2JOH6%?Y&>]F-A%IVF`1$?[2'CK6X>L8I9,X#.([C#Q^A(@[[_,ES>2;C[?D M5\>B2J$0C'"1K"4:7CFQ+AC$U M9G4L8F7CLF\VGIS9E'*^QW9TK'(EAI,P3K!9%;BE)!'#R@+X MN;M:A?V^E=G4YJOB245=-MGN1NJRR78W/PLA^<^EAI>KN$)L5XAM4-&PF96N M[UF([6J%6ZT57KX\^51X$H(D8;SS0DDSWWTA9(T,+YMFOO%,B5:&K,)HJ)8% MK0#66![S1_(,+B*KC,T MGH$$)E>/$%U-)A`%T?0:!6.&"=[X&(/-\\8>:?RJ+A">0@P`0;^"-,>5SJBU M057)?+.(\6O<`+FLF,6@"83J<5EU\H7"!I,NQ$T[YYO-<`@/WV`RWVXW(?+?;CWB^!BXS`%32:<1"MFUCE@!IU77>K-YB_I=+U2J8E!+ M510*7JGAMLJM/:V M[:*5X&TY@[!Z,SN53=@19Q/^[EW&7N4!+KG@D@LNN>"2"RZYX)(++KG@D@LN MN>"2"RZYX)(++KG@D@LNN6!L/D3 M_N92+B[EXE(N+N7B4BXNY>)2+B[E8FO*I?$H7;G2DA^TXHAIC%,)@=H:FJK> MPTAN@Z.)IR5:^8!089^&JC%^5&N\+V6R;P^3?:TS0JUQ1LB'EK"%2;U1G%KC M.U(F=^QAE M*O?T)E)KK>]+J=RWA\K])94MK#HC*94C>Z@<+:G4O^RPXOVTA"545D+X?7TA M_.KM\]5(/B."OUN/X"]TV9'\W^X0B)+\1IC?72C?A?)=*-^%\O\XH7R()C&: M@V@,+R!(,@0Y@7R.G)GOO0!PJ]SR@OE\R=;BT,)QP>6XA2NTUV>Y[2NUUZ%: MR\7:"T_I&&($\`X\PT0Z"W,US!W/2O!UAE(G*41YXU=1]0Q?-ODJ"N9RKX)> M9^R5AX6X<_%9^GL M(U,TE_TFO=`9^/UC5WSHF'-K^'";;-MGU6VR=9ML;6'5;;)UFVRMH;6= M3;8K6:/%9SV_4%$HK+%<40&TI&AQW]BB1;IKHBVT$O%6\J7JUI&@UUGA2",Y M)R0K,5Y(VD=V`5QCT"[_0+^,3Z&?C0E!7V-$;MDJKRW*@RHTYVI:AO.OU@F= M43P:.F\[N$#4<-8%R'666')0L&HM^:*64JV[!I,-@UE@Q!>UD^OJWN'^I@J/ MZJ;(.W83)-\7.$YA"H+P%*3@%7-1>+1#/%VOXYT&"?&Y,D1*CXAB=Z'I+50] MHNO]5KA>B:LYS64*X?'GNO MV?D$04!(DDS.JV*&DLP&N_[I8>_%]9?)!'M*P2.4D%V3,YSM&EJ=#O32^60P MROC=0"89*'4>++8$]PT"/XCJ,RQ;Q$P>&4!U'BQV=?_?Q7O`99*6,)-(&B?C M5+'-\WB-@CE`+W?X*_$8/_J[@%!:U'!F:<`EQ9N*YWS-(I\4?A]%?EG[S8DZ M*&L9R+$R]I)NC1=P<>>%^N_Z>6TX4%8O%&+,$KHHO00(`?(^"28)@:AE1+.Z ML.'\6M'R,?:HOS_$N*.DB#K.HE1E\E!1ML($33NE_U8Y!ASNF\"4;=<.ZL-L M]8U@=D7_-+2$<8&YFV?SL^@1)BGY.KJ!_\L"!/VC.4&G8!/I$VRWE+2#NN_S MF<4A;C"?!KAI&*Z@%?.7J`,:MZ/5,)R`_/)!*=FO";35UYK2L[GGL*S>7Y(]55TG:'Q#.!W\.H1HJO) M!"+L%N,OO3'#!&]\C,'F>6./-/I*!<)3B`'@]::"-,>5SEAETTI*YIM%C%_C M(K"\=1:#)A"6?V#$'D7"!I,NQ*VS-OKJ`9)/QF@JB?F(16UQ<@1=:)5TKJ?# MEVQE<$M'"X_G-OP=&H3`XQ$*6\9U6WY/!*9YK19Y%\F<=I0DD!5FX$L:330? MMD87I;JEB>QH@N@1>TF]_GU/QKJZIM%64.^&1I\E]Y)*X"(C<`6-YIR+6N>B MJ4*O=7*V.'X\_.UQ+4OVU<5:&<;BX<'DML5D7X&@ M066!H?P0Q5CVI3QVY<-Q'80@ M("F2M9?U=F*2%(P;]N9/MIB];-]4=X=J.?8/PTKA](4[DU`"!NX(8\$L)PF= M)*JD+42R9E,K2%/TM926%SA>7YJ3.!KG9UEP2LPE\F:SS4-=,#[0$?4E8(5[ MQ@V?%%8@EL3I!4EDUF70%]^-VSNV(-KD*25X\T5CSW@:AG(MC+VDFX="]TQ M0&2C27J$\2RQY,=$U+31YCH;V:=$]C5*1\K4]C MF.#E[09.0CA.\WUUYS'P&2:3:]AB'7E/-&9_*G`)^@+3&7;S\-/AUPP/#598 M4$G+%H.H]4;K;2RUI>XDQ&Y?-%5;:3@:%EJ#TQ.=]6-5O(\@"(M9\V=X?QND M\,CW$4S$"XQ(S4*;B+JCL^"IG$7S,<*O.>.(V4(\![[.G&@)0?JYT6ZL4C@> M:FRV\>50O>X9M\>ZJ)V2,)9(&JK.>Q-7&^]+F>S;PV1?[S6(JXTS"M]H"5N8 M'&AUHVN-[TB9W+&'R1V]OF^M=489("UA"Y6:-S_46M^54KEK#Y6[>MW-6NM[ M4BKW[*%R3Z]#66M]7TKEOCU4[NL]+KW6^DA*Y<@>*D=Z3TQ?;9U5]DQ+6$)E MI9+Y+2>CO_F+41ZUXDL:2RT?LL[3T$F!^EU,KKI8&/F<4$KSRQ$SEEP.7IVE MAB7,.A3VY2AB:6-Y%L/667/(0Z).M84TZRTR_!9,9S!)_Y5A)!"%+\(90RAL M+-%"U#KK$E\CC$Q`XCE$I&,L\RK@=98OBO$T)=]:XO46/9['3\H3C$C66+)% MH'56/Y98F7C$LXM`Q5C:%;"O4?KXONPW9-Y6UO56/QX]0@2FL/HYRT_U"H5M M2?@*.Z$UM$0#X9[`+))M99@KC!L^WVV?MG,?,0,)Q6_B2 M]I&]ZKCHJFH;. M.WU((&HXZP+D6G/9'!BLI#9?U%*N=2>[V3"8F1R^J)U*^SC/13U;+4+KS\ZLZ'46"%;/D+X"*+T M+L;+?WFIE,(;P]6TU3[\'NE,IM91747P)`1)7G3O'S\1__-PE#[\'"<3_^#]02P,$%`````@`IU`T0-$ZP=[/ M%0``ZSP!`!P`'`!P9VAC9C,U-S(Y-2TR,#$Q,3(S,%]L86(N>&UL550)``.J M@AE/JH(93W5X"P`!!"4.```$.0$``-5=:V_C.);]OL#^!V[V2S<0Q['S=*%K M!LZCMH--JK))>GL:A45!L6A'6[+DE>0\_OV2E.2'R$M23LS+F1E@*M:YU+GF MN=3E%4W^]O?7:4R>:99':?)YI[>WOT-H,DK#*)E\WIGGG2`?1=$.R8L@"8,X M3>CGG23=^?O?_O5??ONW3N?RM:!)2$/RC[.[:W(=/-*87$?)S\<@IV24T:!@ MUUZBXHF;W'EO+I;FGPBO7[W8+_;W^_UR.#38>_3X8`,;Q;(&^;= M.*JAW=X!1_89\H`A>PMD7/O!OJ$D_[SS5!2S3]WNR\O+WNMC%N^EV809[A]T M:^!.B?STFD=KZ)>#&MOK_N/F^G[T1*=!)TKX=SI:6O%F5':]P6#0%5<9-(\^ MY<+^.AT%A>@S(R\"(OA?G1K6X1]U>OW.06_O-0]WV'=`R&]9&M,[.B:"P*?B M;<8$D$?36,CI6LXBSK,OMNPF=\+[A=SCML)N4=_CWZN,=PD%_W%TM M6A$MS/,NT]\D"&9E(S%75W=ATRWYB4^YY-88TDJ7-4?>@.:;*MOGW[!HE#>; MCM8:C/G7G69*GT5;.1WM3=+G+G.9J6F?_7^'_W]GO]_IGPIOL^S';9;F,SHJ MYOD#UW[=FO#A\XX*T%T0XIAAMLXJR$9U&^R?!B4,M7-BHYHL38?9^E4 MS:"Z7ZJZ^B-^C)L+8+7-$FG$FOEPH_[ M??Z?H^/CXQLZ?:19@Z0>ZK87;6CS'M7AG/6NF83OTQG&_G11),R7_$Z6,0D]]I$+,D]YQGKU_F2;@5!\)T-)_2I!!YW[8]V'O' M@&J?$-U%^<\[6LRS9/B8%UDP*N0'OPKC/"V"B5:9D0QPF1Q!=Y5.O(+"&+_-FA*W5M=Q^G=M9OK.I=\KZ#O28SL>_G;X_^RI#MZ MIF`GRPCG?0R1K+JX>=EE#ZOO+77P`H;5O;=9-`VRMP")#\3H< MHMWL^28.10)J$K`6=DEE0;YS&R*,W.CB\G5&DQP.^N9UYPI0$ZRZ??VBR[Y6 MW5GJX`KD.-2KNWX-LBS@ZM*$N@:*U=$P[?4^EW$(W0^1`)6P,'`?Z?=/;&+P ME,8AS;Y0FI\',\4D1(-S+@@]X4H-:I!+*>@8R//D)9AP-*G@I1Q0A"!JL9HQ MP@#'EH6:OEH=ZUA$D:B(F+7R79@YRA=GE`]4R:0:N>#Q`D:ZSQ8-I.MD$8`Y MS16U'.14L8:3&H\Q<@R39![$O+8DT3>-(BU,GIQPS.J4>ST`SQ''-P,FLM:\IEM)N MTZP8IW&4/LRS)'VF&9@BP4CWJ],,I.ME:@#,Z7HU+0?Y;7P-)S7><<8D\=6, M-3HLOB:@\00&HNK"-&:HE.&\_%NP-(Q.WL`Q0@*XK^RI*=:UO/6K3JMWJEO+ M];H*Y3CJZ]O:S)!T6+3N-LZ*8""&"*QG0@L]($Z!^'H2[:H=W/4Z\$H=I#4Z MYM4YCJ.;W](FLB$<2K<:(UH-<+R_C9#BP'N M?K9@0[^>,.BP3N<,9B+RM&%%)QZ,/L:A!G]+U>`P0Z7:!A8"%IH[KJ.C4T/10T M4,R44/MH`'%(J:#5`V(U#73Z>JG!L^5<`;1!5T>;60-@@*F7C>8/Y3QS8>I& M0(N=',12UO,XR'/%9@I:).+N&6K2TC8:ZS"<_314'-3KB8E`O7_'A9;+S<5= ME?LK*!$XB\H5)%?7D:]<=KYT7+JWKG>WN.7".?]=>N_HJ'=DW')!AN)MN0#1 M;FZYT,2A;+F@)B&GA0N8!ULNV'(6@\\0=6^%=E2)B*M\H[T4VD64>1,3&>I! M1!DV,6GB<"-*OYW&$N931!DX"YF>^1%15E3=1=2)?42=>!11)Y81=>)#1)W8 M1=2)3Q%EX"QD>NY'1%E1=1=1I_81=>I11)U:1M2I#Q%U:A=1ISY%E(&SD.F- M'Q%E1=5=1`WL(VK@440-+"-JX$-$#>PB:N!31!DX"YG>^1%15E2=151_WSJB MEE#\B&K2AB*JQJ%&U#H),*+Z^QY%E(FSD.E?7D24'=7W1-1[]PR!MWH$@=C[ MA`";/@*HK8271K$F)MK-0<94KOANO2*]$5,.=[-I97-7GC2>3Y.OP52Q8[L& MBBU:F3:P[=$"AR_<)A?@3<6(CV*(JK6CN;95D[!PN=_*3?`:3>?3^R!F?!F= M";V:SEA'A-^26_:M/`4YS;^QSODV'M,L2B:W6312"'S#9IR+_UWN5H&Q41L( M0?,.GI)2J[9(SALC(]$:^25.@_!7$I6M\O-69G6[Y)<@)P&94>81RTH8.!VS M_Y4W(C-^IU]=1N8VO@O1&"E;(U?++^%6^R74=R"WRB]AFT%^0=FM,QJN?`O" MY^))FLO8&F$%L(TKZ^&JL\`+3C,K4'YA9:J,267X9=$D2H)X$:5E'++/2;;< M76"6I2-*PWR7O#Q%HR?*?TD]!S M!Y8?R*YKP>Y_;F>F7O_F#D8BA)B1C?PCO&48L`F/,HB*M&`1I(B7=\:&\,YP MF-4_M8,M?SOY'M>^`*X-I^D\*<16*G1*0S>!+VV1!QQ#2"MCEW)ORUS>-=%-R4/>4E13]-""\04-%CXT2!]$[6OQ MHSU1U8ZS"`60A#T>>.V<5V#XHV:8Y[10K""'D0BS(#WIQ=1'#4.9[^BH*%+X M&NZ\]+PY4U'"4R8>H@$W^<9%Q)X.<9T+#)+RGV3.;Y/7ZCSV3ONTMG>N] MK5.5_FW-$.*A'35)=:OF8L.'O&R`_,*:Z/1^=1XU'^W/?<.?+PI_MI/B\,)" M_3S2A0L(=)_:Z"G7:8T:A9'2Z)C(60)';S#R1[B3&%>`=/W4/+S<3" M)N"\B#5CF'D18=8Z>!#5GL#]1%@7$82[$4^GCX+JGF=O?]$@TY693'ADX4(.*`7)6&I(8>>6.7MY/B MT.QC&/ZU+8968:4E)P73R_JQ&+M$3=]5-!U8>7?@1S0=F*/IP(]H.@#D<""B M:4LSAG;A!%/\:VL4[>,)8F>.)X"_JX`ZLG+OR(^`.C('U)$?`74$Z.'(GX"" M*?H04!`[Q%0-0TYF]KW)J)T'#T(*9"> M1*1U6Y5=_L*G0J"X_"Q:)R)\.]"@W_*WHMV.)6 M]ZR)FN(5K6"L^:DL?(M/?2U0AOL7GW[7"%O019Z+63,U12A>Y5!RP5A% M5%GX%J+ZZJ(,]R]$_:XZMJ#K6XA:5R,;(8I7BVRZ8*Y+JBP\"U%#O5*&>Q>B MOM:-HD8B(]P?XP60K`_O:EQ&T*2:@M3%_))+^5G2 MJJ*DQ!$521?:ZQOY]_&UU]=KKX^OO3ZLO3ZB]B!:DO8DDBZTIZ@]R0AL[35K M2\W+^-J#2AS\$J+V(%J2]B22+K1W:.1_B*^]0[WV#O&U=PAK[Q!1>Q`M27L2 M21?:4Q3T9`2V]IH%N^9E?.U!=2-^"5%[$"U)>Q))%]H[-O(_QM?>L5Y[Q_C: M.X:U=XRH/8B6I#V)I`OMG1CYG^!K[T2OO1-\[9W`VCM!U!Y$2]*>1-*%]DZ- M_$_QM7>JU]XIOO9.8>V=(FH/HB5I3R+I0GL#(_\!OO8&>NT-\+4W@+4W0-0> M1$O2GD32@?94;R9E!++VI#>/S-H#:36U)Y/7N4+'S,-(#W2@/'8> M@N%J07L,O4(-6SORK1QNSBB[(7T(7FEN//D-M,`[`,[@1/,<.`".[>ZY[NO M\O-.6NN_:>A/'*A=,L7#NI5/<:%BUBH^RBU_61-\%T&Q;6,N3NKT(FZLO-/% M3[D!,&]B:WG=33Z*_DRS./R=!G'Q=,Z^O*LDI*_&],YDB)?EV;G43/;T5B@Y MGPTE>1MV9D2$%2G-"+6SSPP_O)D?Y(NNQ M8$)7JT[PLFHMV/WST4R]?B;"2(SGH(F-_'0H+8ABV;731]Q[B9ST8X#Z(&]S108MU6;FR(-)FPP97NK"/TPKI@QK62,-"$#!D#:QPD+I?7'/2 M\>*A^C6]H.%\)$[22\6IU/6.Y"+WEMVQLW(NB#;.5.*P,7$I%'L^DFC*E.]K M2A;&9)R69X;O+O:_WZVF4PYW2E%H']HB10/U8711;HH"XOQ(HK"V0;$?"#?8 M^L2I3E7+EF&H-SJ5%C)#.(]TBK'70$NAMMQ?P*52E8M>8*@O2I67P4`X?Y2* M\Y/[=E)M_3/[%EHM@M*X=2\Q5?W21-RK]"&G7X)YW]7N>@)P3, M/OIQ4=6/'MB=&@[)E]T*%:+'Q=F\YBPS5-]8/B&O@A".\:![;VD6I>%E$EX$ MA:Z?&SB\#E<2;O;\&@A%`@H&L!9*,&%HPN&(LKA,BJAXNZ,3_B(G2`I%T0F& MN1>%CFZM"17&J21@`HKE%S6(`K`[=Z+K7MZJ>/ZHR-%CU9 MA6]UAS.6$OR=;\0PU\K?BD9NUCS!U.1718;&V>=807]_@60%TF<:96+0+8_\BYOBLH&-2_YD/YPDX=(5._452(US'VQ2$>WKAFI M,$Y+1S`!BW[?)7>N:H/W3)$%G;PM2)SS+Y^_L%((W`+O7`YV#E2ZT(-="L2& MB?QCA,^> ME`;N15%<)7QGG_""SM(\8JV^L0^*J)BKGQ)61DA2L7)E335:"_<"LJ`#::D@ ME2U9&I,5ZW<(R_HEUFV0%RN;1EF^Q`*M<%]B&9Q1O<0"3-!>8FGYJ-^;)6(?W'OKN)XGHOL-/_O((N"QRB.BK=O MX^IP+L4$:;-F,#?N:^^NO*N??1M(6_ZU):C=#W"E,;+2&EEICF^94S7H,JNI M3W"[2&G.'HMW=!S342%VN;E.@U`A6+,%VO%^)B<:)_U!<)>*L^.B.4R/&XJ$ MIC(M=R@BPMBED%;DSL?CRI\KEK2SUNF7.5.VJI9F984YV!F=D<C9=$Z\HT,6@7%R)YA'G#FO$N48G'V M8P2(N[V7'FG$4A\^:&,C73A1Q._1Y(GFQ7_-&0N:Q6_:1X@6[%P7%M0K:6B0 M+M5AI"$)I+(@"Q/$YXN:O?XIH[-!&T?,CC1&%-@`8VPQL6DA(N?/'37WMKYZ MIYU6NO%',RWUXD0IU^F+]>-(AW6N$#/Q2ATPT*4R3"SDS3J%@1=/(B5W_8-( M8X(VEAC=:`PG(!YC1#&0L9>/\V>0DGE+1WU331O%>*.6=DI!*?C_D=.\>AQ^ MH2'-@AA8GFUIAU[\USL$O`)0&V&^"-`QLG@=P,U)G>94#;A;]=UT1KR"C>ES MD!0/Z4/P>D''-,MH:/X:8$MTH9F<`J0&F6&*3<_)0F[EF_*R!5[C86V0NA$4 MQ7U+Z#G?=/_;N#ZYZ/XI?=$?XJDW1->;P25`;H`5IMJTE"S$QNR):(`O[@GJ MHZ6(:$3Q5JKZ]S4CQ?YF?[%_/`8Y97_\/U!+`P04````"`"G4#1`HCK[D?X3 M``##KP$`'``<`'!G:&-F,S4W,CDU+3(P,3$Q,C,P7W!R92YX;6Q55`D``ZJ" M&4^J@AE/=7@+``$$)0X```0Y`0``[5U;4^/(%7Y/5?Z#PKXD53'&-@9,S63+ MW&JHP$"`S6Z>MAJK;2LCJQU)!E-;^]_3+4N^2'TSE^G3VMYY6,#GR-\Y7ZMO MWU'KTX_S2>@]X3@)2/1YI[6[M^/A:$#\(!I]WIDE#90,@F#'2U(4^2@D$?Z\ M$Y&='__QYS]]^DNC\DV'ZC&)[QYU#[_9Z:7=-@QD&2\/6TK+3.MYO>?W<,@RB M;X_TRSR:D"CYO#-.T^EQL_G\_+P[?XS#71*/J.->IUD8[BPLC^=)L&']W"EL M6\U?KJ_N!V,\08T@8BDBT=N>)OT-SX'F?8A+B.SST,@#'ZS.+J?328H?MGQV#5_NKM< M0I_.T@A-=@=DTF0?-3DNS7="Z:HYW&.*$#4]9S M7E%P&[#Q/,61C_T".+O<-GU4?JT@96XT'OJ?U_#.BL&PX3&?YL+)R[V\WWZ* M0O2(0^S_ONAQ*![1-+[TYT%2@LFU6.)T\X_2QF`< MA,MF,8S)A)^O_.N(`":)Z2#R>8=^P8XW2^C7DZPC0N&.-XT#$E-#.N$RE/8% MT#,R04'$R?GFQR82+FD;1<8W07Y,NH6][-H'O]ZS>W^O>W!P<(TGCS@N)51N M"C"YYB<9#',?8OUI$+H28X:.#S2-)<&;['O>$?M^XZLW[CTD:HT%: M[1YY-O!Z'@%0*4;YY_"]M'L$3 M%J:Y:@$URU6D0!KS$MAM'+"YW`.=0)[02W^39+MJ"C[M5/ESJ)DNX\S3>P0CO5]1S#88GK"D>4M,@2>=!SG//UO`&26@M/5TBO)]BW+V M17904R_"6^3=].!9PI=-L22-7V%N"0MEV`49Q@?9\OZF\#806T*E0(RXR+[I M(5:RSZRZ+;9PA0P%9Z9'>[%G9P M2^)T2,*`/-"HR!..A>.-V!(J&V+$1?9-#_45A)*[0V9K#0/5.Z!C>N2_I\!3 M/'H1-OR*`=1L5X`6*38]C!?`=*95,EOHB9=,I3JFAV46A%2P`=^\-T`6:34] M?C)0.LU:9`L$#.;90E;N8X/5#YTL*\T-<.S MFA5`G5M#80Z5$07L@@S38V_1<)1WA36W0*6]FQY:"V"J]:W(#GK"!6O7?=-C M;X'O-"0);1`:F:]:0L]]%7&1?=,C\$9=\2(6H:XCLX7*@`QSSD$7T$BKZGPD MIE`9D$`N"#`]NI8A;CG?$?K80HEDYM/5')8_-]=YU]Y_B>_4E[ESQ[J M8E7^[*$N?Q9B]N/*P\M<7%F_*^MW9?VNK!]<+[>!UV!/=,INUE:WV^HJ>Z*J*>`\RX'# MZY&V(TL];%1-;2.K/'SP]WDL(.M0GZQ#6\DZ+)'%WQ:R@*PC?;*.;"7KJ$26 MX/D$"]CJZ;/5LY6M7IDM_C0!/EOM/6VV5J:6L;4"+G_LP8Y53VG+2OQ$L]#0 M.'V\-8\0+9#'$')K#;=T,63'?7.-YL%D M-KE'(0V-1CK"EY,IA>+?1+>S>#!&"4YN*+R;(0TGB$:W<3#@D/O*RX`F_I4Q MP5NPO;91G.5HUS*0Q9N.*R.CKI,-A,LC@+?$V[X$;UED3Y/!0EL_(*Q,J]08 M-)U2Y-LO_LI21`8SRU,SPB-V"*,AM4YZ+EY%N6N7E+N%M\?$+*?C6426T_%L8LOI>!:QY70\ MVU8]E2TLL9(G,35.(6_=(\$+1,VKGLTFT?.DQH8(4+8>X2%T=5/U(C3"[`T, M;'^<[7WWDP2GG+T#L25P"L7`X:VTMN;O+*`Q!X^S+.61?X_CIV"`6^W'EHI/ M?4_@_.H'`F^QMGW'R[3%(B$R>H6&P-D4XH:W>'OM^6U2WBRD3,+6]UB]?;QN M6GYU5T4J[92DTMS!*SR<-NJT4:>-.FT47'*=-NJT4:>-.FT43IZ=-NJT42!D M.6W4(K*<-FH36TX;M8@MIXW:MNK9W+`2"Z,B.^/D\58\(K!`)-%->"**O8:"*.;(;(`]UHJ$@LK>Z@K$,-;5[T'81TMPCK6$=:! MN+9Z#\*Z6H1UK2.L"W%]]0Z$M?9T"&-6=A'&$-=8P5Q_>Q9'S=R7JYE_][X2 M;^T"3MQTXJ83-YVX"2ZY3MQTXJ83-YVX"2?/3MQTXB80LIRX:1%93MRTB2TG M;EK$EA,W;5OUB/>R=(5.OH]Q4M6B)Q\X2`%T'>JV8JC<%\16LJS9*:G[`PBF MZ^'JB:<\#_NIKJW`6@E2*;;R/&I"2M*A MDJ1#FT@ZK$?Y22FJ(R5)1S:1=+0BJ4;SAIZ2I)Y-)/56)-5GXL"3'ZL6UI"T MIBBVZZ$H4@QHA*O"(D=0/"@+B@M?OK#XVT.,HB1[7_+O3EETRJ)3%IVR""^Y M]5<6<3PD\01%`WR-43*+L4!7%-C!ZX$D8(%HBE5X(FU1;&DJ[]+F(DP_@)YI M,>\XP109?D!SG"@[**$'V-QKH:]!I]4?ICC.@KJ)UM\#P^=4QP$LI3K@Z[#C M+XJ1O=H'A8*[=1M'*QDN!P%/-]#J>Z^30?`SB4/_"T9A.CZE";ND*]"YL@M6 M.8(E=9L@ZB`T_'$+U$S7A;@"-5>@]HH\VU:@YLXD<6>2N#-)S)/ESB2QB2UW M)HE%;+DS26Q;]6R(HXL--W$IO-38.(V\M8\4L70@,TJ![,01A;DA&C3:D9@2 M[0-%C)*2WYT:?.26-E*10PLNC=2.15QHM-K26Q+A7S_/"X98IB4UM9 M7#\0Y3LLH[8L7]Q(49G2[!OO@N3;(IHSG*(@/$,IVME(>KGXL2A?W&<+%*_A MG07)("1,TJ&_L,LU%]?S%A?TV!6]W\Y#/*$`$U>YZ"H77>6BJUP$F%Q7N>@J M%[]#SEWEHJM<=)6+KG+152ZZRD57N>@J%TVSZBH77>6BJUQTE8MP>B17N>@J M%UWEHGFR7.6B36RYRD6+V'*5B[:M>E9"J;A@D6=CG#3>2H<']$/+$]\JW)V1 MP8SIQP_TFSC"W>;'AE(N;B&%=+<)$[126D"]Q12*?Q[Y9RB59;YD!YZ"$MX/ M58O>1[6^PR.V78BBE%.H*S8#RP0?[H?NM+P/$:/_&+D(F*'7`J M*GA!CPA]>A?[[$Z^"-&(PT'I<["Y+^&4+T-,)[WH/4]CG"50,2ALFH&E@`]7 MOL2`PL3Y<$AG><$35E!1L@//10FO?`5A0OO@Y)OS.<@\G6\"-_[NXOX1YKEI`37,5J?Q`60-9OHV#"8I?'O`\ M/:&7_B9)=]44?-ZKD`L"3,AX%[/(9T\N]2._>'A)L&6C[062`6WT!1DV;[_E M40E[J_+G)AC;LA%NOG"7TW<9[;IR6%]1'"-VCTNZ+HFI=33P@OB8S2&MOBQ' M=4)7)M^F)(A2]K0-F46I3I>FXVP)0=N&!4\G?^T-R`E3>`=R;4TSK-^$-^]$ M;C"P.L<5Q.L@"B:SR67TA).4K5_O\/]F`6UD_0E#KL&8\@KV\Z@,$<@S&YG, M.28A!9-U34*]3VAHFBO]84\8`KSBE;?R>(JR")0T+NT,S?H5S8]/W!(TD!ZR M#$]RPHS$U"H&JJ?*V+S@ND9SUEEGCR2P5_J,\.4D>_?,370[BP=C1/N4&PKO M9DC#H0N7VS@8<,A]Y65`$__*F&HP)\TC/\O1KF4@BS<=\Q[;T7*R@7!Y!#48 M,.^PCR<9:IH,%MKJ#YQ]>)DQ:#JER%]1!UH6\#*<6:*:$1ZAE)V=\5UWG:>8 M[6%$(\7VI]S4GCFL)`B`5;UOIU,XD15;&KH?E2U1Q""TZ6P5H&1"*S6VCHFZ M36LC-,J.(F)]"^O\^TF">7MJ8DO@%(J!UV`&NO[(-'MB&L=/='+=:C^V5'SJ M>P+G5S^0&DQ)L\EUD1`9O4)#X&P*<==AZJ)#G(6@"]$32:^DZGZ/)M/KZ MY@IE%3M[E@RB".K'HJIBHFQFZ-:3-STN:T`K)G)T6Q1.2#SL8>/[%4Z\D9B3 M%W9NJVS]IK*WAY0J]AHL`39#%!W[S;>RA[H:G?/-":RC15C'.L(ZM9JWKT?& M.92=;V498]TZ3OI$![#SK>QB;/W$=9MW(DO3)[(2H7077GP?6Q=A_&CJS?2V MZ-+^MY_VM-]?E>=2$X$X-5YR5 M()538YY'30CNUG"%6@Y2/9/F>=2#X/79-J`5K=;#4[?P`#VC1_4!)L8X( M*[.%GGB)Z-HV?<),@7%Y,YZ2:)`=,2=X"D]A#YT+$>Z M/S/R2>13ZN,D&`;8OZF/^JFY%%EN.]I%->>G5\,:.- MBK?MJ^5E#UUZ\7SL>?NOXBP;?D]#.@6.1GHCG,##2JX$L7SL:?ROXJG_A((P M[ZM_QH_W08K[OD]3+1_89&Y6,B8+",JY_47?G;4N<7VMP,P>6@0!U$'C+T)3 M+LU,[V-+VUJ))VBKK'X4S5"XF'=2+)S:U*H%X#17P=:@W+045%O)4=LFCMJU MJ!@M!<4I`:Y:V,-1IQ9%GZ6@]I4<[=O$T3[(NLVWDL0IM:Y:V$-231X^+$5U MH"3IP":2#NKQ%%HIJD,E28X:E:6$/2VE,Y@E>LV4%2$;EZMUML"9@T,6CY*]F^'P'L$:\' MPMX!NFA:>1LH9U]@!CCU`L10"M2+$,HP^6^5E5L#9D$.'$JEN@BE/A%6D@"G M-/U+,!KC)/W7C*+$SE1U2$=VW!ADE13!-$UO:2,7F1,WT=/DR\O'\*SG#_FS`OO^" M9&_J*XXR>D!SS"F?U?,"SXY>&$">(N"$)3JO4F(*GA,)]EK4SPC"XQ72B$VM M9;$N!3;\\+BJIMC45A;K?&".K9_H")UO1EY@ M"I&V4/[Q:9I^]K(FBDA>D6#P/F,/:X;X"47I`Z&3K.(]WAIWF]#37O;$,4$I M2B@COHGP:8B2Y&;8'Z8XIICOQ^29LZ^A[6@O>\*0MJQL^-1<#_V*?B/]\Z'-D550)``.J@AE/JH(93W5X"P`!!"4.```$.0$` M`.U86V_;-A1^'[#_P.EI`RI+E*PD%NP6N31;@20-$A?K6\%(M$U4(C62:EP4 M^^\[U,66+W+B=%D%+,U#)?(['[]SCGA\R.&;>9J@+U0J)OC(PCW70I1'(F9\ M.K)R91,5,6:]>?WS3\-?;/OCR^CXZCZR7VA^LO1?571&TX@$NL%WHX]`9-7W^< M_J8F?W?\%U#?"X.CCLGW_=#%CY'OA_@(G.V4_%)3\#CYL%&"KLDWFOKM\AW? M`#W8Y4$_#((.[-R&HB#T#]NWK8,72!\V^#+P*IK1E"`HLUR-K)G66>@X]_?W MO7N_)^04C%SL?+R\N"UP5@D,YWT1J?,/YY!]Q,WX'' M"_H-?*4&#P8#IYBUD"9R2O452:G*2$07\"S7G*2]2*1%6K'GNS5O-IU%$S\X M]`;!;CA-J$GDN9#I&9V0/-$CZZ^<)$5$+42TENPNUW0%D/,&I%P0?J'TUXPN M(UOXG2NGGC#^#VP7VSZV(!T(#0GG0A,-WT7Q;D:RC/&)J%YAP/@?2I'0,5`@ M\_#AYMTVA\R4=;GVE'&#O^>OB.9-4 M02Z*D%S`0&5=07991B2)\N0)ADME[7;5:)V&)V=G(^XG1)[.B-15>MKG'\I/ ML)Z?;7GY%>A0P??;2UJ6:7D[SRA7].V?P^@\*NX"W_#'AF"EX`O M`W[#U.?RU_(V3U,BOY8AWQS>&73LPC^(]%E]1K"187!*"E1QH&\?>$+NH/W\ M7W1)==]_0R>HZ.I#TQ2/+,7*`E^.S22=C*Q&[V[7C?HGD-"#3KM&FF5V'#.* M=*ZJKE:O"8B,-C@VCAY.)@64*,V@?6^<7$K]3!OSL\4BR*RB7B&2@$KGW_8? MO_VOI?J8`G"Y7>=X(P'>_;P36M\HSA>"ZLCUTFN=9>%L][P[!:2$UXAOG^EVW#.4MQH6("J(=)N;-KNUL,V1C#P[?O;F* M:XW[2%BZOY^$VFYO"?4%0DQ9\^Z@;7E-YH*+%#+5:UP]3`G)"FN'"UZ^`9^] MY-M/2Y/Q._701"]&GJ9'T:@W%5\<*K99@+_VTO3O4.Q<:_S MO;$H"-N"4=U4%2U)HSA\.C7]!@X"'%S2](Y*JQ`-A7ECO"PV]3IA+%+"^#M- M4_.##>+S.P6;.C?2?YY M).7!^;&2#UHD'W17\F&+Y,/N2CYJD7S471$[H M1$@Z)G.J5I6W3G?&@5L36S?N8Q_5=QS&L+4FD:_4[ M(:1ZJJ64CI6"8(;QZ8_PJM)Y(BGYG`G&]1E3D(+U0>)WK=N]V8;OIE/K=KHO0UE;#34],F;_LB6R'=].I21>Q/(9/X#TH2 M/3LEDK[C,9VO%HJ'4/]MV1@Z9=\(C_\`4$L!`AX#%`````@`IU`T0)29TY`# M&P```N,``!@`&````````0```*2!`````'!G:&-F,S4W,CDU+3(P,3$Q,C,P M+GAM;%54!0`#JH(93W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`*=0-$"" MYZ([G0,``&\1```<`!@```````$```"D@54;``!P9VAC9C,U-S(Y-2TR,#$Q M,3(S,%]C86PN>&UL550%``.J@AE/=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`IU`T0+]>R6&C$P``]7T!`!P`&````````0```*2!2!\``'!G:&-F,S4W M,CDU+3(P,3$Q,C,P7V1E9BYX;6Q55`4``ZJ"&4]U>`L``00E#@``!#D!``!0 M2P$"'@,4````"`"G4#1`T3K!WL\5``#K/`$`'``8```````!````I(%!,P`` M<&=H8V8S-3`Q0````(`*=0-$"B.ON1_A,``,.O`0`<`!@```````$` M``"D@69)``!P9VAC9C,U-S(Y-2TR,#$Q,3(S,%]P&UL550%``.J@AE/ M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`IU`T0*V+F#U=!0``!R,``!@` M&````````0```*2!NET``'!G:&-F,S4W,CDU+3(P,3$Q,C,P+GAS9%54!0`# IJH(93W5X"P`!!"4.```$.0$``%!+!08`````!@`&`$0"``!I8P`````` ` end XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } EXCEL 10 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\T,C(P.&,W-E\P8S,P7S0U,SA?.31B.5\U8V$S M,3DT.34V,#0B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T#I%>&-E;%=O#I%>&-E;%=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@ M(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7S0R,C`X8S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^1F5E6]U M(&UA>2!P87D@:68@>6]U(&)U>2!A;F0@:&]L9"!S:&%R97,@;V8@=&AE(&9U M;F0N(%EO=2!M87D@<75A;&EF>2!F;W(@6]U2!F'0^0VQA'0^0VQA"!Y96%R'0^06YN=6%L(&9U;F0@;W!E'!E M;G-E65A'0^0VQA'0^0VQA'0^)FYB M'!E;G-E&%M<&QE(&ES(&EN=&5N9&5D('1O(&AE;'`@>6]U(&-O;7!A M'!E;G-E2!B92!H:6=H97(@;W(@;&]W97(N/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&%M<&QE#0H-"@T*#0I0=71N86T@1VQO8F%L($AE86QT:"!#87)E($9U M;F0-"@T**%531"`D*3QB'0^0VQA'0^0VQA65A'!E;G-E($5X86UP;&4L($YO(%)E M9&5M<'1I;VX-"@T*#0H-"E!U=&YA;2!';&]B86P@2&5A;'1H($-A'0^0VQA65A65A M'0^4&]R=&9O;&EO('1U'0^5&AE(&9U;F0@<&%Y2!I;F1I8V%T92!H:6=H97(@=')A M;G-A8W1I;VX@8V]S=',@86YD(&UA>2!R97-U;'0@:6X@:&EG:&5R('1A>&5S M('=H96X@=&AE(&9U;F0F(S@R,3<['0^26YV97-T;65N=',\F4@ M8V]M<&%N:65S('=O2!O6]U(&-A;B!L;W-E(&UO;F5Y(&)Y(&EN=F5S=&EN9R!I;B!T:&4@9G5N M9"X\+W`^/'`^5&AE('!R:6-E2!F86EL('1O(')E8F]U;F0N(%1H97-E(')I MF4@8V]M<&%N:65S+B!4:&4@:&5A;'1H(&-A2!A<'!R;W9A;"!P;VQI8VEE2!I;G9E2!O2!R97-U;'0@:6X@9W)E871E2!B92!A9'9E2!C M87)R>2!R:7-K2!T M:&4@1F5D97)A;"!$97!O'0^5&AE('!E65A2!A M;B!I;F1I8V%T:6]N(&]F(&9U='5R92!R97-U;'1S+B!-;VYT:&QY('!E&5S(%M497AT73QB&5S($-L87-S($$\+W1D/@T*("`@("`@("`@ M("`@("`\=&0@8VQA&5S($-L87-S($(\+W1D/@T* M("`@("`@("`@("`@("`\=&0@8VQA&5S($-L87-S M($,\+W1D/@T*("`@("`@("`@("`@("`\=&0@8VQA'0^0VQA'0^0VQA'0^8F5F;W)E('1A>&5S M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@("`@("`@(#QT9"!C M;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@("`@("`@(#QT9"!C;&%S"`H M3D0I/"]T9#X-"B`@("`@("`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'!E;G-E'0^/'`^ M069T97(M=&%X(')E='5R;G,@6]U(&AO;&0@>6]U7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#XT.#5"4$]3/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^4%543D%- M($=,3T)!3"!(14%,5$@@0T%212!&54Y$/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^1&5C(#,P+`T*"0DR,#$Q/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^1&5C(#,P+`T*"0DR,#$Q/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0@0FQO8VM= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&@^51E>'1";&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M4'5T;F%M($=L;V)A;"!(96%L=&@@0V%R92!&=6YD('-E96MS(&-A<&ET86P@ M87!P'!E;G-E'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E(%M(96%D M:6YG73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&@^'1";&]C:SPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^5&AE(&9O;&QO=VEN9R!T86)L M92!D97-C2!F=6YD('-H87)E2!S:&%R97,\+VD^(&)E9VEN;FEN M9R!O;B!P86=E($E)+3$@;V8@=&AE(&9U;F0F(S@R,3<['!E;G-E0G)E86MP;VEN=$1I'0^66]U(&UA>2!Q=6%L:69Y(&9O6]U'!E;G-E M($)R96%K<&]I;G0L($UI;FEM=6T@26YV97-T;65N="!297%U:7)E9"!;06UO M=6YT73PO=&0^#0H@("`@("`@(#QT9"!C;&%S2!F'!E;G-E'1=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&@^6]U&%M<&QE/"]S=')O M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&@^'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E($5X86UP M;&4@6TAE861I;F==/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&@^&%M<&QE/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'!E;G-E($5X86UP;&4@3F%R&%M<&QE3F%R M&%M<&QE(&ES(&EN=&5N M9&5D('1O(&AE;'`@>6]U(&-O;7!A'!E;G-E2!B92!H:6=H M97(@;W(@;&]W97(N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^4&]R=&9O;&EO('1U'0@ M0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&@^7,@=')A;G-A8W1I;VXM7,@86YD('-E;&QS('-E8W5R:71I97,@*&]R("8C.#(R M,#MT=7)N&%M<&QE+"!A9F9E8W0@9G5N9"!P97)F;W)M86YC92X@5&AE(&9U;F0F M(S@R,3<[65A'0^26YV97-T;65N=',\4YA'1";&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^1F]R('1H:7,@;F]N+61I=F5R2!I;B!C;VUM;VX@2!C;VYS:61E2P@<')O:F5C=&5D(&9U='5R92!E87)N:6YG2!T5!O2!B>2!I;G9E2!F86QL(&]R(&9A:6P@=&\@2!B M92!M;W)E('-U7-T M96US+B!/=7(@<&]L:6-Y(&]F(&-O;F-E;G1R871I;F<@;VX@82!L:6UI=&5D M(&=R;W5P(&]F(&EN9'5S=')I97,@86YD('1H92!F=6YD)B,X,C$W.W,@)B,X M,C(P.VYO;BUD:79E2!T;R!A9'9E&-H86YG92!R871E2!O2!E;65R M9VEN9RUM87)K970@:6YV97-T;65N=',L(&-A;B!B92!I;&QI<75I9"X@3W5R M('5S92!O9B!D97)I=F%T:79E2!;5&5X=%T\ M+W1D/@T*("`@("`@("`\=&0@8VQA2!B>2!I M;G9E2!I;G9E2!O2!R97-U;'0@:6X@9W)E871E4EN'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&@^2!O9B!2971U M2!S:&]W:6YG('1H92!F=6YD)B,X,C$W.W,@<&5R M9F]R;6%N8V4@>65A'0^5&AE(&)A'0^4&QE87-E M(')E;65M8F5R('1H870@<&%S="!P97)F;W)M86YC92!I'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&@^5=E8E-I=&5!9&1R97-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#YP=71N86TN8V]M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&@^'0^ M4V5P(#,P+`T*"0DR,#$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S2!2971U2!2971U M'0^079E'1";&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'`^069T97(M=&%X(')E='5R;G,@"!R971U2!A;F0@=VEL;"!V87)Y(&9O6]U(&AO;&0@>6]U$1E9F5R"!3:&]W;B!;5&5X=%T\+W1D/@T*("`@("`@("`\=&0@8VQA"!R971U2!A;F0@=VEL;"!V M87)Y(&9O&EM=6T@9&5F97)R960@'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^0VQA'!E;G-E'!E;G-E($5X86UP;&4\+W-T'!E;G-E17AA;7!L94%B5EE87)#;VQU M;6Y.86UE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y#;&%S'!E;G-E17AA;7!L95EE87(P M,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S&%M<&QE665A65A'!E;G-E17AA;7!L95EE87(Q,#PO=&0^#0H@("`@("`@(#QT9"!C M;&%S&EM=6T@9&5F97)R960@'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^0VQA'!E;G-E M'!E;G-E($5X86UP;&4\+W-T'!E;G-E17AA;7!L M94%B5EE M87)#;VQU;6Y.86UE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y# M;&%S'!E;G-E17AA;7!L M95EE87(P,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S&%M<&QE665A65A'!E;G-E17AA;7!L95EE87(Q,#PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S&%M<&QE+"!.;R!2961E;7!T M:6]N/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&@^'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S&%M<&QE3F]2961E;7!T:6]N0GE996%R0V]L=6UN M3F%M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^0VQA65A&%M<&QE3F]2961E;7!T:6]N665A65A'!E;G-E17AA;7!L94YO4F5D96UP=&EO;EEE87(P,SPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S&%M<&QE3F]2961E;7!T:6]N665A&EM=6T@9&5F97)R960@'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^0VQA'!E;G-E'!E;G-E($5X86UP;&4\+W-T'!E;G-E17AA;7!L94%B5EE87)#;VQU;6Y.86UE/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y#;&%S'!E;G-E17AA;7!L95EE87(P,3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S&%M<&QE665A65A'!E;G-E M17AA;7!L95EE87(Q,#PO=&0^#0H@("`@("`@(#QT9"!C;&%S&%M<&QE+"!.;R!2961E;7!T:6]N/"]S=')O;F<^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&@^'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&%M M<&QE3F]2961E;7!T:6]N0GE996%R0V]L=6UN3F%M93PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^0VQA65A&%M<&QE3F]2961E;7!T M:6]N665A65A'!E;G-E17AA;7!L94YO4F5D M96UP=&EO;EEE87(P,SPO=&0^#0H@("`@("`@(#QT9"!C;&%S&%M<&QE3F]2961E;7!T:6]N665A&EM=6T@9&5F97)R960@'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^0VQA'!E;G-E'!E;G-E($5X86UP;&4\+W-T'!E;G-E17AA;7!L94%B5EE87)#;VQU;6Y.86UE M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y#;&%S'!E;G-E17AA;7!L95EE87(P,3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S&%M<&QE665A65A'!E;G-E17AA;7!L95EE87(Q,#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^0VQA'!E M;G-E'!E;G-E'!E;G-E&%M<&QE06)S=')A8W0\+W1D/@T*("`@("`@("`\=&0@8VQA'!E;G-E M17AA;7!L94)Y665A65A&%M<&QE665A65A M'!E;G-E17AA M;7!L95EE87(P,SPO=&0^#0H@("`@("`@(#QT9"!C;&%S65A'!E;G-E17AA;7!L95EE87(Q,#PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^0VQA'!E;G-E'0^)FYB'!E;G-E'!E;G-E($5X86UP;&4\+W-T'!E;G-E17AA;7!L94%B5EE87)#;VQU M;6Y.86UE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y#;&%S'!E;G-E17AA;7!L95EE87(P M,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S&%M<&QE665A&5S('P@0VQA'0^0VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^8F5F;W)E('1A>&5S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S65A65A65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^8F5F;W)E('1A>&5S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S65A65A65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^8F5F;W)E('1A>&5S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^ M0VQA&5S(&]N(&1I65A65A&5S(&]N(&1I'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^869T97(@=&%X97,@ M;VX@9&ES=')I8G5T:6]N65A65A'!E;G-E'1=/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&@^'!E;G-E&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#XH;F\@9&5D=6-T:6]N(&9O'!E;G-E65A65A7!E.B!I;6%G92]J<&5G#0H-"B\Y:B\T04%14VM:2E)G04)!445!64%"9T%! M1"\R=T)$04%914)1649"05E'0E%92$)W64E#:$%+0V=K2D-H44]$=W=11GA1 M64="8U4-"D9H66%(4U5F1VAS:DA"65=)0W=G27E9;DM3;W!'4CAT34,P;TU# M56]+4VHO,G="1$%18TA"=V])0VA-2T-H36]':%EA2T-G;TM#9V\-"DM#9V]+ M0V=O2T-G;TM#9V]+0V=O2T-G;TM#9V]+0V=O2T-G;TM#9V]+0V=O2T-G;TM# M9V]+0V=O2T-J+W=!05)#045S06AW1$%324$-"D%H14)!>$5"+SA104AW04%! M455"05%%0D%114%!04%!04%!04%!14-!=U%&0F=C24-1;TPO.%%!=%)!04%G M141!=TE%07=51D)!44$-"D%!1CE!44E$04%14D)226A-545'13%&:$)Y2GA& M1$M":V%%24DP2WAW4E93,&9!:TTR2GEG9VM+1FAC64=2;VQ*:6-O2U-O,$Y4 M63,-"D]$:S91,%)&4FMD25-5<%161E975C%H6E=M3FM:5UIN84=L<6,S4C%D M;F0T95AQ1&A)5T=H-&E*:7!+5&Q*5U=L-6E:;7%+:G!+5VT-"G`V:7!Q$U81W@X:DIY=$Q4,4Y85S$Y:EHR=4AI-"M4;#5U9F\V M97)X.'90,#EF8C,K4&XV+SA104AW14$-"D%W14)!445"05%%0D%104%!04%! M04%%0T%W449"9V-)0U%O3"\X44%T4D5!06=%0T)!441"06-&0D%104%12C-! M045#07A%14)317@-"D)H2D)5461H8U)-:4UO14E&14M2;V)(0D-337I5=D%6 M66Y,4D-H66M.3T5L.%)C64=2;VU*>6=P2VI5,DYZ9S5/:TY%4E5:2%-%;$L- M"E4Q4E96;&195U9P:EI'5FU:,FAP86Y.,&186C-E2&PV9V]/16A984AI26U+ M:W!/56Q:85AM2FUA;W%/:W!A86YQ2VUQ&-B M2'E-;DLP=%!5,61B6#).;F$T=5!K-65B;C9/;G$X=E`P.69B,RM0;C8O.6]! M1$%-0D%!25)!>$5!4'=$<"]!4&<-"C-W>&1E0E!$;'AC*TA.1FUN;#`R,FMK M:VMS66U:,DU3:W-35GE35'IM=%A59D-(:$]Y#11,&TT6F-"65E.36A: M,UEK04%F3&<-"EI*2$I)561724%*1G(T8V8X:S@X3"\X05E+=&8O4DLQ=&%J M8U,R=&Y*3D):,T8W275-45%&03F)N;G$R;F39F6FE724ES8DUZ35=%4D=*-%0X MFTR M:TQ33SAU,7-Y=WIU5#5J3BL-"CE4,T,Y9C13,#)B4B]#=6IA6F-T1S`Y;%I1 M,C!J4FML4WE)1DI"24)X:V5G<$ID,$]4='-Y:B]W9W9H4"]O5CE#+SA!0F9$ M+T%013`-"F8X24PT5"\V1F91=B]"9D0O=T1%,64Q8E-R>2MU1FMT=&4Q4%1K M0T)41F%X,C=+5&LO369-:6,U-7@Q>'=/3W5E8SA*5T=S87@T5C`-"F)5-VYX M8G)3>C-T;$1C>4Q(0EI"47IO1TE'8F-N1U0V;6YP,D5R,G9C,68K148X2B]W M1%%R-D8O-$PT9B]I85`K148X2B\X05%R-D8-"B]W0T,K2"\T;6PO-%(W52\K M:'8Q-R]V>EIF.$%Y4%(O=VHR<"]W1%$S-CDO,S5S=B]K96EY-T)D+W=!,S5I M9CA)3#14+W=#:%@P3"\-"D%-1CA0+WA.2"]#0RM%+RMH6#!,+W=!1CA0.$$X M5%=6-%-S3EDQ:G=R;S)P,U!I,U=L;G9B2TD4O-%%8=VXO,$LK M:&8K0RM(+T%/2F\O=T-%1CA*+SE#=F]8+V=V:"\X06EA6"\-"D%)4C=5+SA! M;V(Y92]W0R].;"\X:C!F.$DY<68O43,V.2\S-7-V.$$U2&]S=7=89C@S-6EF M.$E,-%0O-D9F478O0F9$+W=$13!F.$$-"D-#*T4O=T1O5CE#+SA&.%`O=T%4 M4R\X04-086XO=T)$9G(S+T%(-7-V+VME:B]H2'14+S9'+UAV*R].;"]W1$DY M1FPR0S%`K148X2B\X05%R-D8-"B]W0T,K2"\T;6HO:$)F0V8O47(V1B\T M3#1F.$$T;6PO-%(W52]W1&]B.64O-S@R6"]W06HP9CA!0U!A;B]W0D1F$Y,+W=J,G`O.41F%`K148X2B]W1%%R-D8O-$PT9B]I M85`K148X2B\X05%R-D8O=T-#*T@O-&USEIF+TDY2"]# M4&$-"FXO,$XK=F8Y*V),+T%/4C9,3'-&,R].*UEN+T-#*T4O*VA8,$PO=UAW M+SA!>$Y(+T%!9W9H4#A!-D9F478O0F9$+SA!13%L945R1%<-"DY9.$LV3G%D M>C1T,7!:-S)Y:'5:1FIGD4O-%$-"EAW;B]!3D-V;U@O9W9H+RM*;R\T M45AW;B]W0D-V;U@O04E,-&8O:6%8+VA(=%0O-D$Y,+W=J,G`O.41F%`K148X M2B\X05%R-D8O=T-#*T@O-&UJ+VA"9D-F+U%R-D8O-$P-"C1F.$$T;7-R=VQ9 M87AR2&A84G14=69&=71,4&4R54YZ27-C1FM&1$]G66=:='EC6E!Q83%V*T5E M,5`X039'+UAV*R].;"\X04DY1VX-"EE(9&%C,S5I9CA)3#14+S9&9E%V+T)F M1"]W1$4P9CA!0T,K12]W1&]6.4,O.$8X4"]W0513+SA!0U!A;B]W0D1F2\X06ME:7DW0F0O>F9M M2B]W04E,-%0O04]H6#!,+W=8=R\O04).2"]#0RL-"D4O.$%O5CE#+W=$0F9$ M+SA45U8T4W-.63%J=W)O,G`S4&DS5VQN=F)+1S5K5T]#>4-H;E%-44TR-4]- M;C%.83,O0U!A;B\P3BMV9CD-"BMB3"]!3U(V3D]W3S8P-79Z12\T45AW;B]W M0D-V;U@O04E,-&8O:6%0*T5&.$HO.4-V;U@O9W9H+W=$:6%8+VA(=%0O04]H M=C$W+W8-"GI:9B]!0U!2+W=!23EQ9B]!14XK=F8X069M>2\K4C9,3'-&,R]. M*UEN+T-#*T4O*VA8,$PO=T%&.%`X03A44B]W9W9H4"]O5CE#+S@-"D8X4"]! M3513+W=$0U!A;B]!3D1F5!2 M6F1G=2\U=GI%+S116'=N+S!+*VAF*T,K2"\-"D%/2F\O=T-%1CA*+SE#=F]8 M+V=V:"\X06EA>79#5FAR1W-E1F1',4\U.%'=7455--D)I M0FTS2GAK*W!R5R]W0T4-"F4Q4"]!2TEIF+TDY2"]#4&%N+S!. M*W9F.2MB3"]!3U(V3$QS1C,O3BM9;B]#0RM%+RMH6#`-"DPO=UAW+SA!>$Y( M+T%!9W9H4#A!-D9F478O0F9$+SA!13!V+T%!:C)P+SA!43,V.2]W0BMB3"\U M2&\O-%(W52\K:'8Q-R]V>EIF.$$-"GE04EID9W4O-79Z12]W0T5&.$HO.4-V M;U@O9W9H+SA!:6%0*T5&.$HO=T11G1112LK96Y3=&(O:$AT5"\V M1R]8=BLO3FPO.&HP861G9#%P>F9M2B]W9W9H4"]!2T9F478X07=8=R\-"B]% M,&8X24PT5"\V1F91=B]!05AW+W=$>$Y,+W=J,G`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`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`U23=F8G8R3'EX1S5L2$%Y979B:DIW2V\V-S1N='1(=5HT<$Q7-W5% M=&)C6&0W3$%%,C)K0DPT:V9C=TQ$.3-)8U(-"F@R*U$X8W)L6$=O=&TY4E=6 M-&HQ>3(P1S)T<$QH2DIPF-.-5)3,75*46A31G=(3$9J-7-1 M>6ES9S-J-7-":4,T*U9S-DMI=61S9D=';#,K:VTO$Q/ M-W@-"G),1T5"3U!M:61*3U-.<6ML.6TQ.792-&]V8U145S1L1DQI:D9-46Q& M3&EJ1D%#555U2TU504I24S1O>%%!;$9,:6I&04-5575+354-"D%*4E,T;WA1 M06Q&3&EJ1D%#555U2TU504I24S1O>%%!;$9,:6I&04-5575+355!2E)3-&]X M44%L1DQI:D9!0U55=4M-54%C2#A74#D-"E8T6B\W0W`O.4I,;7%/;F1Q=F9& M;B]5*T=F.$%S2VXO04Y*3&UQ3VYD<3%O-W,T.%IU=E0Y4WIF.4MW3$0O:V5V M0W8O048K>2]W1'`-"DAC5G8S+U-S2%0O*U(W.$LO=T18-TPO-E(S1E98,DUS M3#A34%AQ2UA&1TMW4%)%;W!C55EO05-I;'A2:6=#2S5->3(P#9'=6,K2$)M8G6UR;4UA944S,TAM>6)).6DO33(X-4$R M64AZ02]+5GE$:T5I&13>518175M5S!K:W-J1FUD:D5P3$5N:VMN M;DY49CA);#1C+W,W*WHO-T$-"C!J-T(U=FXO04=B-T9(-5AM63(W.74S1S=( M1V-:>'A7,VEH2W'56:71D03%056M+0FI,87E7>7%$:R]+ M9DUL434-"C1Z,'AY3V5U2U!W,B]W0U-C*T9E0V8X06E65VXO;VQ+-F)&8S,X M3E(O=T%7-3A++SEG<3$O=T122S!D4F1$;V-C.412:G)W869I:D8-"E5333=! M-%`P;WAZ,$Y0>%)I9T)M3W9";S=!-%`P<"M+355!37AZ,$Y'3W9"<"M+355! M33=!-%`P;WAZ,$Y0>%)I9T)M3W9";S=!-%`-"C!P*TM-54%96&IB5')Z5B]# M3W-A6G!Q=TGE&15AE<%5S4T99.$%K-'AZ:DA'8VI!.%=E1CE3 M,2LK$]L6$7AF2R]L:D5/ M3VMJ:7!F:4(T:3%F4TY8,&5X,%IR0U`W6$1C5%-09#(W>EDX=&]106]74DU: M.#`-"C5Z;F]+>DQF6&9&,#)0.$%I66%#4"LT6$UF.$$R-6]56$Q:0V1A3E`T M;F(W>G).8R]T:6%'5S-T9$@P;2MT6G0P8VMD-6901TAJ2W(-"G=Y:49W8VMU M0W9404)Y9'A#.#=:*T5D6'19,3`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`K<%IV.$%P5T9P=B])*V5& M4"MV,E@O04Y)-VET,B\V5FAA6B]Y4'9H5"]!2R]:=B]33S1Q<2L-"GAJ:%!J M4C=(4E,T;WA83V5O2E)3-&]X44%L1DQI:D9!14YZ371T8E-Z>4-1<$5H9&A( M1S!J14%:-%914W@Y9T-4,G)N4&AV371Z-%H-"FQN:D5G4UA5.5)D4DI',&)! M1SEN4$MS05903-0:&T-"E=E35-"2F14,48Q16MB4G-!8C)C.'%W0E4K>$%) M-S!U<%9T1'`V*U10,G,O*U-J860O,D-O+SA!,&1.6#%P:79K>CER5"]K;S)N M9CD-"F=M4"]!3DA45FY6*T4Q=R]X;C!J.$Y"+WAB:G=R+S)#8E0O,%-T9$II M=6,K1V8X07E4:G=P+S)#8E0O,%-L9$)C;5IB859R5T]/4S0-"D-%>'!)-5)7 M8DA!3$%%9UHW-$]043E+=&)'8W1X*TM-5GA7;F5)9%@Q;E1F0VE73#9F6C9H M<2MK;E9*<'!R9#5O:S)I1&-I>&E21'D-"F)G145U8T)-64]C:G!F1$]P+S(S M-&(P#16+S="3G`-"B]W0VE6<2]Q+VE8461'=59T.5DQ=E1,0S1:0DES5C%D M>'A-5DI)1$%-46-:0D=F63%2*T=M0CA.+T-M95`K2E9A9CA!;VQ+3#9H8E$- M"C901D=+6&I/3R]P44U(3T\S5VU32FEJ1DQL8T$U1T0P3V%/330W*VQ!0UEO M>%-J0GIJ=#%O>75!8VI"-DA.04-9;WA3.%IX,SE+0F<-"C5X,C8P04II:D9, M;&-!-4=$,$]A3TTT-RML04-9;WA3:D)Z:G0Q;WEU06-J0C9(3D%(;5AX4R\U M1S=W,R]W0F56.2\V371A:C`O=%4-"G9X5"]!3U)U.$YF.656.2\V371A:3`O M=%A245!/>'9X175O.39P94-0*U-L,G8X03)#8G8O=T)(5W189%(W,5,X1"\X M;$QT9BMW5&0-"B]W1&\V,7`Q.6EC1CAA*V8U2')'2TU5;W=C-#=D84UR9TA) M=V5H>EA-96U*:6I&5CE3=7A9,F-K+VM4,TQR9TQ$8G!U:VM9:T%!1&<-"D1K M:FMK2T]R14%%:6PT9#%O87ET*W)71C596$9L8V9:<&],;WAL9WAJ4U%%1TXS M56=R279F,6]U3WAQ-&]X6$]F.$IJ<#AF:$=B>$0-"F525#)D&I:;'D-"GEW5$U-16=#36AI<$MH:30K5FTO:6I&53E) M,4]$5G)D-VUZ5GIA-WES57A!,GIR9TAZ135Y54]307A!,UDS1$ML5TXS2S1" M>4U(;V,-"C!81EDX<"M-1FAA86@T;SA->%@Y3%Q3%1U,6)556YU969I-7EI,&MZ2W9V0UAH>%%D=F@O4T(Y3$M0+T%/ M2G`S=S4P=7C%0-3%S M-F@P3E5V0D@O2E,W6"]S13-F+T%+3W1A<79&2F%);D)Z:S5P3CDO>5!6.%59 M<%)G-7@R-C!:6$%/4F<-"CE$;75C.4541D=+6&I/3R]P44U(3T\S5V="3559 M<&-R9TA)=V5H>E)X;DAF,&]!5$9'2U593V-D=71'5G=$:UE0435O051&1TM8 M:D\-"D\O<%%-2$]/,U=G0DU567!C&Y(9C!O051&1TM564]C M9'5T1U9W1&M94%$U;T%41D=+6&I/3R]P44U(3T\S5V="354-"EEP8W)G2$EW M96AZ4GAN2&8P;T%41D=+55E/8V1U=$=6=T1K65!1-6]!."\K3#,O2'8T6B\W M0S,O04QA6$Y:;6YD<3%0:2M2-4AH9UH-"C4O=%DX9CA!8G!C,6PV9#)R96=C M1TXS6'`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`V4V1J;U!$.7`T:S!J=SE,1"]:*VM486#5F.6]Y3$5) M-7`-"G!*=G8K451U0FLR-#(T24=C:C=T4G=E17!P9$-T3DIV4EII,61,;4\V M365794LR;&LS+UEO1TMJ8D9T,GAL:'1/>4ID<7%3$U.05`O8TMM2"]T>E9J=U@T<#$W55!&-C965%S M71(2'1(0CAN>E!V4W5"=#1P8U59 M<$9V53AW*TMF.$$-"GE.,VAR+W)Y=G8X03!:83%&<#-A<'9I<"]W06ID-&$O M-CAR-R]W0D=7=%$V9#)R;V](;30S-&EB54]H<6PT2"]!3U-M5W8X03)#8G8- M"B]W0DA7=%AD439'<69G9B]!2DM:82\X05E*=2\O4C%R5E8Y:4U&+T58>B]) M.5IX4FEL>%)I=5DY451&1TMJ=7`T8E,R;'5,<6%/1S,-"FA1>5-3>4U&5D9! M>5=*4$%!2$]4565M,SEN<6QL2&5A8F0R.35A4UHR5#(X9VM2G5038T M4'I,.#9C:FH-"C5H-FEI-%=,1TM-5DA&4$1.2DUK33!C:G=0-6-Q<7=*:F)A M1S)S3W@R%1!5$9'2UA&1TM"0UEO>%,T;WA106U+354-"G5+ M355!2FEJ1DQI:D9!0UEO>%,T;WA106U+355U2TU5065F9D=$+VHS.$UF.6AB M+T%.=$QM$EJ64E)>7!Y1&=G2#9I=68K1W1V1&$K1TIB93%I:FAT-&14 M,4M/3TM.47%O;W9P=T9!2$%!2$=+6%5R;V12:79K;CER9B]K;RL-"FTO.$%9 M2FHO05!2,#%F5RM+*U-0,G50*U-K86(O=T)G;5`X03E(5%9&6#144V@X6CE+ M9D1)9CA!1G0O0VXO64IT4#A!,%-L9$QI=6(-"BM'6"]!0U1B=VXO,D-B5"]! M3D5P6%164S))930S1D=+9%)42D3(O-T).,R\V3W1A=#9J,W$-"G`T12\U2UIB M9CEG;3@O.$%2,7)4>$=X1T,K3F90.&HQ>D9'2V126$UE<6589D98+T%*1S=W M,2\Q-5@S+T%+371A9S`W=%9J-'(O.$$-"DDS94=F*W9+*R\X05)L'(U+VME=#1O>%1Q2S5J,51Y-S1Q+SA! M23-E1W8K=DLK+SA!4FQR54=N9'%S9D9F+VMB=D10.$$Q-5@S+V]Y,7%V<#,- M"F%U:6=E8FIF:4IT439'<69G8B]K<&QT+S)#8G8O=T)(5W183E$V1W%N9U@O M04I+8F)F.$%92G90+U(Q59A4'I# M<7AO141U9S-Y2S)&1S553`X3DY:>%17=#5E,U8Q=F%+,W11;31O M;3-E-4QS<6<-"D%U9WAN4'I$04E"27AO+VE,-6XS4$,S:4$O.$%!5)Y4F5- M3'1*-35*-&LO,&%W;&QE85%Y34-75FI$.7-N4D4-"C-(>D,O27=U*TQ8:RM) M4FHK+S16.%%$+T%)1EHO=T1Y4E9V=WHT-71T93%Z*WEH<$]Q5T9Y8F0W;%=U M=DI+5=::51)>D%*2UI-.&UC;V-V1S504S1P,49# M0C9J8U4-"EEP,49-43-&1TMD4E%!,T9'2V1244$S1D=+9%)103-&1TMD4E%! M,T9'2V1244(U-3A99BM08G=X+W=":&(O,C!U87E.3S=6F8K:V1X5S-F.4MX3DDO=T-39V5%+RMV,F(-"B]W0DDW:7)R-T=/12M.2'17 M2TU5-FEU53E9<#9K3'HW1DE.32MZ:3=/1E)R:D]X36M!7).1T0Q M,DT-"GEK031Y331Y335'1&=J27-F0TU%1VA81VHS5V\V:&4V9F-B:VQH;3AP M1DU*9SAN>4973TY"2$=!07=%654W:&Y02D)4=55R9%1",6H-"GAN9BM'6F)U M=S%F*WHY4C%)9EI$84="2DQ22GI/.'$9N84YO+TQJ M4F]M>3=.2U-!=FMU=&%$941)-4I$9%A'49"5DYQ,4AO4#!Y4G184MF2VXU2W,U5F=Z069+031!,T%B,GI0:')B=S)N:&E7 M,W19;S1B94A5.5-J:FEJ54MQ2TPV8T)10G=!0GAG5F(-"G0O0T]M44YQ:&DK M,E)N55A$4VU+-FMH6D(U:GDW561#3)%:V1V<#)S,S)Q=&9'4TUW>E)Z+V%T<4E!>&L-"C-J-U5U9'E+=GE0:&HX M=3=V845$4S9#5GI8=WDO=T-38F5%+RMW5&%F*VE5<2]Q*VLS="]C'=/3W5E42M(96=A;$XX4"]$ M37-F:3-83&1(,'4Q6EE9-'))FL-"CA1-DIR*VHR3G`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`K:#`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`-"F%P3$)E>GDR.#AD,6946$MS9W0U<$)G4TUW0C-2;V1W=V5#331*0C8K M5#1E1U0W+T%)%(-"C1G5S9T2$UK M3#1S>G19;WE%-"MZ-%!Y=7FH-"F5(=WA,1DI.2F-/;7%A:W)44T)1,&A&.5!L;3)G3&LY M5&=!96=&6F144PK,3,O=T%L2C`S+T%,0DU8+V\V879R=79K5#D- M"G)Z+VMP3VTO.6=M3"]W0DA45DY4-%13:CA2.4PO1$5F.%5IR;68K-%90;"MA4%6(O04A&97)*9%D-"B]IGDW+V5O9E`X;6$U M;B]U1E0U9FUJ,79&1TMD:6H-"D9F5VYW9S-&1TMD:6I&041C55EP,DM-54%. M>%)I;EEO>%%!,T9'2V1I:D9!1&-567`R2TU504YX4FEN66]X44$S1D=+9&EJ M1D%$8U4-"EEP,DM-54%.>%)I;EEO>%%!,T9'2V1I:D9!1&-567`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`P6F%5+U(-"BLQ3BM,4#A!>4](:&HO%)I9T)-55EP8U4- M"EEO051&1TM81D=+045X4FEL>%)I9T)-55EP8U59;T%H=6I-='1-,7)(2$IC M0D-9,&MC;W).:F=-=T)+9VYQ441J,%!3=5HK1U)M8G<-"G9+,3%(2$AC2%9. M4TUI4G585EC9$<%A286LQ-4A:4TYP:T9V8UAG>'-I M=4HR:&IB:UIY-F\U2$=4.3`X.&,-"F12>C-W>4UZ948U5W5O-#0W9S9P<5)K M4TYY-G$S,C9F259I05=!4%%K1%!O3VQ(5691-G)&9DE0-U@S+T%#57)49CA! MD1L>4(Q-31/36HT6"\X:S`X2F8Y9VDP+SA!4DM6 M,#%5=&E8=657-FA!DDU:'!W:VIB M8U1L1U8R57`Y,V%D=4YV1F1.-$9T-&)'*SA6869:47@R,6AA86]S9'1B47%% M:6A6#9K,7-W*T@Y1V6]P>5)T4&UZ23)E33A$2$DU-C1O9D1(22M'9FA,04H-"B]W0TI2 M6CE0*W5+5C%&8WHX3"\K4V%E178K=U)A9CA!;VQ+3V]D1&LO:78O04UJ;#19 M+S8X%DO-4A,=W8-"B]W0F56+SA!*VI,4W!.2"]! M26$K67I4+T%(;"MI4'1-;B\S1F5R2#9X+T975#1%+S5+:F)F.6=I."\X05(Q ME(V.$UK;F=J2#8P6D\P2&%C;DA(1U)4<4LK59',B\-"C="1C4O=T-J M61O3S`U3T]/ M36EJ;F-"9S0Y861244$P6DI00D=0,6]Y9&]/,#5/3T]-:6Y554%.-3-!64\- M"E!79UI*4$)'4#%P,49!1&-N841T3U1J:FI);S4S05E/4%=N555!3D=35'=2 M:CEA36YA1'1/5&IJ:DEP,49!1&5D=T=$:C%O1U-4=U(-"FHY861244$S2C)G M-U1K-#0T>4M/9'='1&HQ<#%&0412:VLX15DO5VI*,F61O3S`U3T]/36EN555!958O1G(O:V-00R\X03$U6"]!4#9- M=$M84BLQ2'@-"F(O-4A$=W8O04YE5B]W1"MJ3%-J4BLQ9DQ:<"]V3#E%9F): M3B]U2SE76&17*S9F<%=0-$4M/9'='1&HQ M<#%&04=6&I'9DYL5')K-'AN;V,T M-'IK9D0-"D=2-79#,'-S:T5L=37=X;%$X:$%Y1EAC4754,$=30C8-"FM6>DAW M>&QE8G=T3$Q*0DIB=2MQ86UZ47E&4SA:3CE/4W)B4U9Y3VAW4U!1;6PQ2#!/ M<7(T+SA!,G=F*U-L-EHO=T)G:4PO,&1.6#(-"D18>"\K,D0O04UL3#!Z+W-% M4F8K:G!Q;7!S6%,K22MM+VAF+T%-:WHX2F8Y9VDP+SE%<%A4,7I0=W4O-4IN M-%(O=T-W4F%F*VE5CA)+SEG:3`O.45P4C%(,$]3*TQ(+TDU948O M.$$-"G)Y=B]!4#!:859*;R]W1$144&EZ+W=!:FPT6"]!3W9++W=$+T%%6F%5 M+U(O-&$K6'I4+V58-DDK>GEF+T%(1F5R2#9X+T975#1#+S4-"DML8F8Y9VDX M+W=$4C%R5W1R2#A66EAG2"]K<59T+S)#3'HO,&1A,4=89C%H-"B]W0U)Y.$PO05!8;&8O.$%O>3!P M*VHO=S!Z-'1F.&IL-%@O-CAR+R]!3D=7;%`P9BM'=FPX,"\S;"])*S!Y9B]! M2$9E69!4"]!0U9+ M,B\W0D8U+S9/=&%J3"\X065O9E`X;6$U;B]U1E0U9FUJ,D=I;'A2:79Q>C0- M"EE3:6QX4FEG0DM+6$9'2T%%;W!C55EO05-I;'A2:6="2TM81D=+045O<&-5 M66]!4VEL>%)I9T)+2UA&1TM!16]P8U59;T%3:6QX4FD-"F="2TM81D=+045O M<&-566]!4VEL>%)I9T)+2UA&1TM!16]P8U59;T$X<"M,;B])-&5&+RMV2R\O M05!2;'!2;R]A;"M,=B])-&5&+RL-"G9++R]!4%)L<%-A4#)R-69.4#A!95@V M22LQ>68O8U8V2]W0G=Q9DPX,&5V M,%5U2TU6.5=F1&E5575+355!2E)3-&]X44%L1DQI:D9!0U55=4M-54$-"DI2 M4S1O>%%"1&14<&)7,#`X:7E-:U-&,D5C8E-/44)K-U951FU0;T%#5#)&8W@X M35HP=79#,',X87E+:W5Q86TV:5-.;S-!3CE/4G4-"E9G1U4K;TE"2&-6,48Q M36QR87I4>4-2:VE1=7=J:F%2>4%-;F%Q9W-X.4%!4V5W5AZ3T%B=%=Y0D1N>6E-3'8K5&\O0W5O,W0V,G(R M97%.8E-8;6U89W1(;G0T,FEJ;7I"1DU'16(-"DUX5$%M0S0S3FMR;FI/05A# M>'595AX8B\U2$QW=B]W0F56+SA!*VI,4VYA4"]!03%5*TYD+UHV M9#0-"G(X2WIA:&0R.7)%8D\O55!02455;F9A;D=3979"+TMS,U-V1TAH;$YU M+WA&;WDO5RMI2"]!3$Y8>E=:46LX43)L,E!S37!Q4FIG:VT-"BMR3V3!P9$@O:'(U9DY0.35F>5`- M"G,X;R\S2F5R2F19+VER2SA!9CA!2E5R8B]S15AN+V\V,')6,6HK2W-R-&8O M05!*57)B+W-$,VXO04M/=$MJ3"]!4&5O+U`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`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`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`R2TU504YX4FEN66]X M44$S1D=+9&EJ1D%$8U59<#)+355!3GA2:6Y9;WA103-&1TMD:6I&041C55D- M"G`R2TU504YX4FEN66]X44$S1D=+9&EJ1D%$8U59<#)+355!3GA2:6Y9;WA1 M03-&1TMD:6I&041C55EP,DM-54%.>%)I;EEO>%%!,T8-"D=+9&EJ1D%$8U59 M<#)+355!3GA2:6Y9;WA103-&1TMD:6I&041C55EP,DM-54%.>%)I;EEO>%%! M,T9'2V1I:D9!1&-567`R2TU504X-"GA2:6Y9;WA103-&1TMD:6I&041C55EP M,DM-54%.>%)I;EEO>%%!,T9'2V1I:D9!1&-567`R2TU505%85G1$9#)S,71D M=WAZ,CAY1T\-"E=+5E%Y3W!'0W)!.$5%2$)"6L-"E5M M371B6$5L=DE-14AH-#)6:#`W15I(2%$Q>FYW=6=3,3A+>3(X6FMA3TQ69%1J M57EY3DDU078W9T1C>D5S>#E34U-E<$Y(5691-G8-"D9F2$@W62\O04-5-U10 M.$%S1'AF*VIP-BMY8U8X8B]T:R\X04I4=$TO=T-W4$8O-D]N<5HW1E$S4'%( M-%=F.$%*35!#2"]92',O.$$-"C!1;&12:75:*T99+S1T:#11+S=!.6XO-DE3 M=&Y56615:W5R3G1.=DQ+,W1K9DXP;'AA3DTX<35(0TU*14-(1S=K:"MO-#1W M5VA--2L-"EAX>&%7>DUT.7!EC-.%A!2E)M43534D=Y5I*:%IH=%IV;%IC-$]1 M0S173VAX6$PO0WHO:VT-"DAH1"]!3$$Y;B\V25-T2%=D1W9T475L;'10165Q M-EA'14-M1S!J=%=2:FMN8V9.:&1S.#0T3T]">#%Z:F%6-$IV9$LP=7HP-GG=B;T]R6&9J6%AK=6(K=V=U<%9I=#=!24=E3E=) M54%)I=4$X1F%:F8- M"C)%1C%+GAQ>$-G,GA/36YJ2DYB4"]!06I'4Q28TQ(5%EO>%A-+SA)>'$S+U$X94EV.$%V>'`O M+W=!:3!F.$%#36%T+W="1'@T:2\-"C%65-:S%S+SA)>'$S+U$X94EV.$%V>'`O+W=!:3!80W@P,DM-5GI0 M+T%!:D=R9CA!43AE278K+T<-"FXO.$%Y3%(O=VI'$8O,S0P+R]W0U)A4#A!:$=.5R]W M0V@T.%)F.2M.4"]W1&M7:3173VUX4FEU6B\-"C12:E9V*V@T.%)F.2M.4"]! M4&M7:B]H1TY7+S9(:GA&+W="*TY0.$$O:U=I-%=/;7A2:75!.$9A6G)M=65$ M9$(Q83'`O=T0X:3!80W@P,DM-5GI0+T--870O,%!(:4PO04PX868O M.$$-"DET2"]!06I''$S+U$X94EV*R]';B\-"D%0>4Q28TQ( M5%EO>%A!94-T33%Z6%!"=6$8O,S0-"C`O.$$K4F%,:%DV8D9'2S5N+VA' M3E$8O=T(K3E`X02]K5VHO:$=.5R\V2&IX1B\S-#`O+W=#4F%,:%DV M8D9'2S5N+T%)4FH-"E9V.$%O95!%6"]F:E0O.$$U1F\O-%)J5G8K:#0X4F8Y M*TY0+T%0:U=I-%=/;7A2:75!.$9A6G)M=65$9$(Q83B]W:D=R9CE$>#1I+S'$S+U$X94EV*R]';B]W1'D-"DQ28TQ(5%EO>%A!945T33%Z5TY+;G5B M;GAR'`-"B]W1#AI,%A#>#`R2TU6>E`O0TUA="\P4$AI3"]!3#AA9B\X M04ET2"]!06I''`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`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

5,R;3A9,F1J<&0-"GEF.$%H M24Y"5W=S4EHR:G9(2F1L-W=U2D=24W-75W59,DQY1E9*9&IN:&E#-#!D-2]B M=&=D8R]S:4YR;5G%9$Q%-E)P=6112C)% M9VI:6%AC1E)(1SE1-%<-"E1S.%58051&1TM81D=+0D-9D]L=C5C&I:,D]L,THO-%-$459S3$579&\W>'E86F4X3&E2:U5R1FQR M;4YI.&A64UA9-3199W5.2&]-,G)78U=S46%76&ME*VU1>6(-"DEO6&M%83@T M85)L0E=-3G192UA+-VER0F-K159F>%AL+VAI>#%'>3A964(Q;S9J3G)&.5!Q M6FY345=N,D)H3CEN,G5614UJ9CAE94,-"D,P>7(X;5%I1D8Y4GA28T=*:6I& M3&EJ1D%H359G86@T=#!E>'5,:3-K;75:DEY07I$:#!04F=4 M,&U+."LP6%)T46@P5#1B849E5VMI3G`Q=$9C86ER1&8-"D-$8C)W:D543756 M3&EE4TM20C`O8TUW3U5'9E%S55A!5$9'2UA&1TM"0UER03%$>&)O.6IC6$9V M2DYC>EA517AG:W0W5WIM=5I1=VH-"FIK2C)2;WI&47,P5UA!,F=Y2T-14T)8 M45ER:E!%0U)A3#0R,'I85W-,:S)B5V0U0F-Y,DYL2F-33E!),7`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`-"E580W@Y;556.%HO.$Y3*TYV*V=8-&,O.$(U+R]!23E2 M+W=!3E,K3G8K9U@T8R\X04%E9B]!3U!56$-X.6U55CA:+SA!1%5V:F(O;T8- M"BM(4"]!04AN+W=$:C%(+T15=FIB+V]&*TA0.$%W2&XO05!J,49WB]W04(U+SA!-#E28TQ(,EI26'AN+W=!3E,K3G8K9U@T M8R\X04%E9B\-"D%/4%5F.$Y3*TYV*V=8-&,O=T1!968X02M055A#>#EM558X M6B]W1$15=FIB+V]&*TA0.$%W2&XO05!J,4@O1%5V:F(O04M"9FAZ+W<-"DAN M+RM055A#>#EM558X6B\X3E,K3G8X06]&*TA0+T%E9B\T.5(O=S%,-#(O-D)F M:'HO=TAN+SA!:C%&=W-F6FQ&9D=F+T15=FIB+V\-"D8K2%`O065F+W=#4%5F M.$%$579J8B]O1BM(4"]!04AN+W=$:C%&=W-F6FQ&9D=F+T%!,4PT,B\V0F9H M>B]W04(U+SA!-#E2+WDUC-6,Y+U-P M:SE#;W)5+SEK/0T*#0H-"BTM+2TM+3U?3F5X=%!A7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B M=7)N.G-C:&5M87,M;6EC XML 11 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
Label Element Value
Risk/Return: rr_RiskReturnAbstract  
Document Type dei_DocumentType 485BPOS
Document Period End Date dei_DocumentPeriodEndDate Aug. 31, 2011
Registrant Name dei_EntityRegistrantName PUTNAM GLOBAL HEALTH CARE FUND
Central Index Key dei_EntityCentralIndexKey 0000357295
Amendment Flag dei_AmendmentFlag false
Document Creation Date dei_DocumentCreationDate Dec. 29, 2011
Document Effective Date dei_DocumentEffectiveDate Dec. 30, 2011
Prospectus Date rr_ProspectusDate Dec. 30, 2011
Putnam Global Health Care Fund
  
Risk/Return: rr_RiskReturnAbstract  
Risk/Return [Heading] rr_RiskReturnHeading PUTNAM GLOBAL HEALTH CARE FUND
Objective [Heading] rr_ObjectiveHeading Goal
Objective, Primary [Text Block] rr_ObjectivePrimaryTextBlock Putnam Global Health Care Fund seeks capital appreciation.
Fees and expenses pghcf357295_FundFeesAndExpensesAbstract  
Expense [Heading] rr_ExpenseHeading Fees and expenses
Expense Narrative [Text Block] rr_ExpenseNarrativeTextBlock The following table describes the fees and expenses you may pay if you buy and hold shares of the fund. You may qualify for sales charge discounts if you and your family invest, or agree to invest in the future, at least $50,000 in Putnam funds. More information about these and other discounts is available from your financial advisor and in How do I buy fund shares? beginning on page 57 of the fund’s prospectus and in How to buy shares beginning on page II-1 of the fund’s statement of additional information (SAI).
Expense Breakpoint Discounts pghcf357295_ExpenseBreakpointDiscountsAbstract  
Expense Breakpoint Discounts [Text] rr_ExpenseBreakpointDiscounts You may qualify for sales charge discounts if you and your family invest, or agree to invest in the future, at least $50,000 in Putnam funds. More information about these and other discounts is available from your financial advisor and in How do I buy fund shares? beginning on page 57 of the fund’s prospectus and in How to buy shares beginning on page II-1 of the fund’s statement of additional information (SAI).
Expense Breakpoint, Minimum Investment Required [Amount] rr_ExpenseBreakpointMinimumInvestmentRequiredAmount 50,000
Shareholder fees rr_ShareholderFeesAbstract  
Shareholder Fees Caption [Text] rr_ShareholderFeesCaption Shareholder fees (fees paid directly from your investment)
Annual fund operating expenses rr_OperatingExpensesAbstract  
Operating Expenses Caption [Text] rr_OperatingExpensesCaption Annual fund operating expenses (expenses you pay each year as a percentage of the value of your investment)
Expense Example rr_ExpenseExampleAbstract  
Expense Example [Heading] rr_ExpenseExampleHeading Example
Expense Example Narrative [Text Block] rr_ExpenseExampleNarrativeTextBlock The following hypothetical example is intended to help you compare the cost of investing in the fund with the cost of investing in other funds. It assumes that you invest $10,000 in the fund for the time periods indicated and then, except as indicated, redeem all your shares at the end of those periods. It assumes a 5% return on your investment each year and that the fund’s operating expenses remain the same. Your actual costs may be higher or lower.
Portfolio turnover pghcf357295_PortfolioTurnoverAltAbstract  
Portfolio Turnover [Heading] rr_PortfolioTurnoverHeading Portfolio turnover
Portfolio Turnover [Text Block] rr_PortfolioTurnoverTextBlock The fund pays transaction-related costs when it buys and sells securities (or “turns over” its portfolio). A higher turnover rate may indicate higher transaction costs and may result in higher taxes when the fund’s shares are held in a taxable account. These costs, which are not reflected in annual fund operating expenses or the above example, affect fund performance. The fund’s turnover rate in the most recent fiscal year was 35%.
Portfolio Turnover, Rate rr_PortfolioTurnoverRate 35.00%
Strategy [Heading] rr_StrategyHeading Investments
Strategy Narrative [Text Block] rr_StrategyNarrativeTextBlock For this non-diversified fund concentrating in the health care industries, we invest mainly in common stocks (growth or value stocks or both) of large and midsize companies worldwide that we believe have favorable investment potential. Potential investments include companies that manufacture health care supplies or provide health care-related services, and companies in the research, development, production and marketing of pharmaceuticals and biotechnology products. We may purchase stocks of companies with stock prices that reflect a value lower than that which we place on the company. We also consider other factors that we believe will cause the stock price to rise. We may consider, among other factors, a company’s valuation, financial strength, growth potential, competitive position in its industry, projected future earnings, cash flows and dividends when deciding whether to buy or sell investments. We may also use derivatives, such as futures, options, certain foreign currency transactions, warrants and swap contracts, for both hedging and non-hedging purposes, and may engage in short sales of securities.
Strategy Portfolio Concentration [Text] rr_StrategyPortfolioConcentration For this non-diversified fund concentrating in the health care industries, we invest mainly in common stocks (growth or value stocks or both) of large and midsize companies worldwide that we believe have favorable investment potential.
Risk [Heading] rr_RiskHeading Risks
Risk Narrative [Text Block] rr_RiskNarrativeTextBlock

It is important to understand that you can lose money by investing in the fund.

The prices of stocks in the fund’s portfolio may fall or fail to rise over extended periods of time for a variety of reasons, including both general financial market conditions and factors related to a specific company or industry. Growth stocks may be more susceptible to earnings disappointments, and value stocks may fail to rebound. These risks are generally greater for small and midsize companies. The health care industries may be affected by technological obsolescence, changes in regulatory approval policies for drugs, medical devices or procedures and changes in governmental and private payment systems. Our policy of concentrating on a limited group of industries and the fund’s “non-diversified” status, which means the fund may invest in fewer issuers than a “diversified fund,” can increase the fund’s vulnerability to adverse developments affecting a single industry or issuer, which may result in greater losses and volatility for the fund. The value of international investments traded in foreign currencies may be adversely impacted by fluctuations in exchange rates. International investments may carry risks associated with potentially less stable economies or governments, such as the risk of seizure by a foreign government, the imposition of currency or other restrictions, or high levels of inflation or deflation. International investments, particularly emerging-market investments, can be illiquid. Our use of derivatives may increase these risks by increasing investment exposure or, in the case of many over-the-counter instruments, because of the potential inability to terminate or sell derivatives positions and the potential failure of the other party to the instrument to meet its obligations. Our use of short selling may result in losses if the securities appreciate in value.

The fund may not achieve its goal, and it is not intended to be a complete investment program. An investment in the fund is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency.
Risk Lose Money [Text] rr_RiskLoseMoney It is important to understand that you can lose money by investing in the fund.
Risk Nondiversified Status [Text] rr_RiskNondiversifiedStatus Our policy of concentrating on a limited group of industries and the fund’s “non-diversified” status, which means the fund may invest in fewer issuers than a “diversified fund,” can increase the fund’s vulnerability to adverse developments affecting a single industry or issuer, which may result in greater losses and volatility for the fund.
Risk Not Insured Depository Institution [Text] rr_RiskNotInsuredDepositoryInstitution An investment in the fund is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency.
Performance pghcf357295_FundPastPerformanceAbstract  
Bar Chart and Performance Table [Heading] rr_BarChartAndPerformanceTableHeading Performance
Performance Narrative [Text Block] rr_PerformanceNarrativeTextBlock The performance information below gives some indication of the risks associated with an investment in the fund by showing the fund’s performance year to year and over time. The bar chart does not reflect the impact of sales charges. If it did, performance would be lower. Please remember that past performance is not necessarily an indication of future results. Monthly performance figures for the fund are available at putnam.com.
Performance Information Illustrates Variability of Returns [Text] rr_PerformanceInformationIllustratesVariabilityOfReturns The performance information below gives some indication of the risks associated with an investment in the fund by showing the fund’s performance year to year and over time.
Bar Chart Does Not Reflect Sales Loads [Text] rr_BarChartDoesNotReflectSalesLoads The bar chart does not reflect the impact of sales charges. If it did, performance would be lower.
Performance Past Does Not Indicate Future [Text] rr_PerformancePastDoesNotIndicateFuture Please remember that past performance is not necessarily an indication of future results.
Performance Table Closing [Text Block] rr_PerformanceTableClosingTextBlock Monthly performance figures for the fund are available at putnam.com.
Performance Availability Website Address [Text] rr_PerformanceAvailabilityWebSiteAddress putnam.com
Annual Total Returns rr_BarChartTableAbstract  
Bar Chart [Heading] rr_BarChartHeading Annual total returns for class A shares before sales charges
Bar Chart Closing [Text Block] rr_BarChartClosingTextBlock

Year-to-date performance

through 9/30/11

-8.11%

Best calender quarter

Q3 2010

12.45%

Worst calender quarter

Q1 2001

-22.70%
Year to Date Return, Label rr_YearToDateReturnLabel Year-to-date performance
Bar Chart, Year to Date Return, Date rr_BarChartYearToDateReturnDate Sep. 30, 2011
Bar Chart, Year to Date Return rr_BarChartYearToDateReturn (8.11%)
Highest Quarterly Return, Label rr_HighestQuarterlyReturnLabel Best calender quarter
Highest Quarterly Return, Date rr_BarChartHighestQuarterlyReturnDate Sep. 30, 2010
Highest Quarterly Return rr_BarChartHighestQuarterlyReturn 12.45%
Lowest Quarterly Return, Label rr_LowestQuarterlyReturnLabel Worst calender quarter
Lowest Quarterly Return, Date rr_BarChartLowestQuarterlyReturnDate Mar. 31, 2001
Lowest Quarterly Return rr_BarChartLowestQuarterlyReturn (22.70%)
Average Annual Total Return rr_AverageAnnualReturnAbstract  
Caption rr_AverageAnnualReturnCaption Average annual total returns after sales charges (for periods ending 12/31/10)
Performance Table Narrative rr_PerformanceTableNarrativeTextBlock

After-tax returns reflect the historical highest individual federal marginal income tax rates and do not reflect state and local taxes. Actual after-tax returns depend on an investor’s tax situation and may differ from those shown. After-tax returns are shown for class A shares only and will vary for other classes. These after-tax returns do not apply if you hold your fund shares through a 401(k) plan, an IRA, or another tax-advantaged arrangement.

Class B share performance does not reflect conversion to class A shares.
Performance Table Uses Highest Federal Rate rr_PerformanceTableUsesHighestFederalRate After-tax returns reflect the historical highest individual federal marginal income tax rates and do not reflect state and local taxes.
Performance Table Not Relevant to Tax Deferred rr_PerformanceTableNotRelevantToTaxDeferred Actual after-tax returns depend on an investor’s tax situation and may differ from those shown.
Performance Table One Class of after Tax Shown [Text] rr_PerformanceTableOneClassOfAfterTaxShown After-tax returns are shown for class A shares only and will vary for other classes.
Putnam Global Health Care Fund | Class A
  
Shareholder fees rr_ShareholderFeesAbstract  
Share class rr_ShareholderFeesColumnName Class A
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice 5.75%
Maximum deferred sales charge (load) (as a percentage of original purchase price or redemption proceeds, whichever is lower) rr_MaximumDeferredSalesChargeOverOther 1.00% [1]
Redemption fee (as a percentage of total redemption proceeds) rr_RedemptionFeeOverRedemption 1.00%
Annual fund operating expenses rr_OperatingExpensesAbstract  
Share class rr_OperatingExpensesColumnName Class A
Management fees rr_ManagementFeesOverAssets 0.63%
Distribution and service (12b-1) fees rr_DistributionAndService12b1FeesOverAssets 0.25%
Other expenses rr_OtherExpensesOverAssets 0.38%
Total annual fund operating expenses rr_ExpensesOverAssets 1.26%
Expense Example rr_ExpenseExampleAbstract  
Share class rr_ExpenseExampleByYearColumnName Class A
1 year rr_ExpenseExampleYear01 696
3 years rr_ExpenseExampleYear03 952
5 years rr_ExpenseExampleYear05 1,227
10 years rr_ExpenseExampleYear10 2,010
Annual Total Returns rr_BarChartTableAbstract  
2001 rr_AnnualReturn2001 (19.84%)
2002 rr_AnnualReturn2002 (20.38%)
2003 rr_AnnualReturn2003 18.50%
2004 rr_AnnualReturn2004 7.15%
2005 rr_AnnualReturn2005 13.56%
2006 rr_AnnualReturn2006 2.99%
2007 rr_AnnualReturn2007 (0.63%)
2008 rr_AnnualReturn2008 (17.12%)
2009 rr_AnnualReturn2009 25.17%
2010 rr_AnnualReturn2010 2.06%
Putnam Global Health Care Fund | Class B
  
Shareholder fees rr_ShareholderFeesAbstract  
Share class rr_ShareholderFeesColumnName Class B
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice none
Maximum deferred sales charge (load) (as a percentage of original purchase price or redemption proceeds, whichever is lower) rr_MaximumDeferredSalesChargeOverOther 5.00% [2]
Redemption fee (as a percentage of total redemption proceeds) rr_RedemptionFeeOverRedemption 1.00%
Annual fund operating expenses rr_OperatingExpensesAbstract  
Share class rr_OperatingExpensesColumnName Class B
Management fees rr_ManagementFeesOverAssets 0.63%
Distribution and service (12b-1) fees rr_DistributionAndService12b1FeesOverAssets 1.00%
Other expenses rr_OtherExpensesOverAssets 0.38%
Total annual fund operating expenses rr_ExpensesOverAssets 2.01%
Expense Example rr_ExpenseExampleAbstract  
Share class rr_ExpenseExampleByYearColumnName Class B
1 year rr_ExpenseExampleYear01 704
3 years rr_ExpenseExampleYear03 930
5 years rr_ExpenseExampleYear05 1,283
10 years rr_ExpenseExampleYear10 2,144
Expense Example, No Redemption rr_ExpenseExampleNoRedemptionAbstract  
Share class rr_ExpenseExampleNoRedemptionByYearColumnName Class B (no redemption)
1 year rr_ExpenseExampleNoRedemptionYear01 204
3 years rr_ExpenseExampleNoRedemptionYear03 630
5 years rr_ExpenseExampleNoRedemptionYear05 1,083
10 years rr_ExpenseExampleNoRedemptionYear10 2,144
Putnam Global Health Care Fund | Class C
  
Shareholder fees rr_ShareholderFeesAbstract  
Share class rr_ShareholderFeesColumnName Class C
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice none
Maximum deferred sales charge (load) (as a percentage of original purchase price or redemption proceeds, whichever is lower) rr_MaximumDeferredSalesChargeOverOther 1.00% [3]
Redemption fee (as a percentage of total redemption proceeds) rr_RedemptionFeeOverRedemption 1.00%
Annual fund operating expenses rr_OperatingExpensesAbstract  
Share class rr_OperatingExpensesColumnName Class C
Management fees rr_ManagementFeesOverAssets 0.63%
Distribution and service (12b-1) fees rr_DistributionAndService12b1FeesOverAssets 1.00%
Other expenses rr_OtherExpensesOverAssets 0.38%
Total annual fund operating expenses rr_ExpensesOverAssets 2.01%
Expense Example rr_ExpenseExampleAbstract  
Share class rr_ExpenseExampleByYearColumnName Class C
1 year rr_ExpenseExampleYear01 304
3 years rr_ExpenseExampleYear03 630
5 years rr_ExpenseExampleYear05 1,083
10 years rr_ExpenseExampleYear10 2,338
Expense Example, No Redemption rr_ExpenseExampleNoRedemptionAbstract  
Share class rr_ExpenseExampleNoRedemptionByYearColumnName Class C (no redemption)
1 year rr_ExpenseExampleNoRedemptionYear01 204
3 years rr_ExpenseExampleNoRedemptionYear03 630
5 years rr_ExpenseExampleNoRedemptionYear05 1,083
10 years rr_ExpenseExampleNoRedemptionYear10 2,338
Putnam Global Health Care Fund | Class M
  
Shareholder fees rr_ShareholderFeesAbstract  
Share class rr_ShareholderFeesColumnName Class M
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice 3.50%
Maximum deferred sales charge (load) (as a percentage of original purchase price or redemption proceeds, whichever is lower) rr_MaximumDeferredSalesChargeOverOther 0.65% [1]
Redemption fee (as a percentage of total redemption proceeds) rr_RedemptionFeeOverRedemption 1.00%
Annual fund operating expenses rr_OperatingExpensesAbstract  
Share class rr_OperatingExpensesColumnName Class M
Management fees rr_ManagementFeesOverAssets 0.63%
Distribution and service (12b-1) fees rr_DistributionAndService12b1FeesOverAssets 0.75%
Other expenses rr_OtherExpensesOverAssets 0.38%
Total annual fund operating expenses rr_ExpensesOverAssets 1.76%
Expense Example rr_ExpenseExampleAbstract  
Share class rr_ExpenseExampleByYearColumnName Class M
1 year rr_ExpenseExampleYear01 523
3 years rr_ExpenseExampleYear03 885
5 years rr_ExpenseExampleYear05 1,271
10 years rr_ExpenseExampleYear10 2,351
Putnam Global Health Care Fund | Class R
  
Shareholder fees rr_ShareholderFeesAbstract  
Share class rr_ShareholderFeesColumnName Class R
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice none
Maximum deferred sales charge (load) (as a percentage of original purchase price or redemption proceeds, whichever is lower) rr_MaximumDeferredSalesChargeOverOther none
Redemption fee (as a percentage of total redemption proceeds) rr_RedemptionFeeOverRedemption 1.00%
Annual fund operating expenses rr_OperatingExpensesAbstract  
Share class rr_OperatingExpensesColumnName Class R
Management fees rr_ManagementFeesOverAssets 0.63%
Distribution and service (12b-1) fees rr_DistributionAndService12b1FeesOverAssets 0.50%
Other expenses rr_OtherExpensesOverAssets 0.38%
Total annual fund operating expenses rr_ExpensesOverAssets 1.51%
Expense Example rr_ExpenseExampleAbstract  
Share class rr_ExpenseExampleByYearColumnName Class R
1 year rr_ExpenseExampleYear01 154
3 years rr_ExpenseExampleYear03 477
5 years rr_ExpenseExampleYear05 824
10 years rr_ExpenseExampleYear10 1,802
Putnam Global Health Care Fund | Class Y
  
Shareholder fees rr_ShareholderFeesAbstract  
Share class rr_ShareholderFeesColumnName Class Y
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice none
Maximum deferred sales charge (load) (as a percentage of original purchase price or redemption proceeds, whichever is lower) rr_MaximumDeferredSalesChargeOverOther none
Redemption fee (as a percentage of total redemption proceeds) rr_RedemptionFeeOverRedemption 1.00%
Annual fund operating expenses rr_OperatingExpensesAbstract  
Share class rr_OperatingExpensesColumnName Class Y
Management fees rr_ManagementFeesOverAssets 0.63%
Distribution and service (12b-1) fees rr_DistributionAndService12b1FeesOverAssets   
Other expenses rr_OtherExpensesOverAssets 0.38%
Total annual fund operating expenses rr_ExpensesOverAssets 1.01%
Expense Example rr_ExpenseExampleAbstract  
Share class rr_ExpenseExampleByYearColumnName Class Y
1 year rr_ExpenseExampleYear01 103
3 years rr_ExpenseExampleYear03 322
5 years rr_ExpenseExampleYear05 558
10 years rr_ExpenseExampleYear10 1,236
Putnam Global Health Care Fund | before taxes | Class A
  
Average Annual Total Return rr_AverageAnnualReturnAbstract  
Share class rr_AverageAnnualReturnColumnName Class A
Label rr_AverageAnnualReturnLabel before taxes
1 year rr_AverageAnnualReturnYear01 (3.80%)
5 years rr_AverageAnnualReturnYear05 0.42%
10 years rr_AverageAnnualReturnYear10 (0.62%)
Putnam Global Health Care Fund | before taxes | Class B
  
Average Annual Total Return rr_AverageAnnualReturnAbstract  
Share class rr_AverageAnnualReturnColumnName Class B
Label rr_AverageAnnualReturnLabel before taxes
1 year rr_AverageAnnualReturnYear01 (3.39%)
5 years rr_AverageAnnualReturnYear05 0.60%
10 years rr_AverageAnnualReturnYear10 (0.78%)
Putnam Global Health Care Fund | before taxes | Class C
  
Average Annual Total Return rr_AverageAnnualReturnAbstract  
Share class rr_AverageAnnualReturnColumnName Class C
Label rr_AverageAnnualReturnLabel before taxes
1 year rr_AverageAnnualReturnYear01 0.37%
5 years rr_AverageAnnualReturnYear05 0.86%
10 years rr_AverageAnnualReturnYear10 (0.77%)
Putnam Global Health Care Fund | before taxes | Class M
  
Average Annual Total Return rr_AverageAnnualReturnAbstract  
Share class rr_AverageAnnualReturnColumnName Class M
Label rr_AverageAnnualReturnLabel before taxes
1 year rr_AverageAnnualReturnYear01 (1.98%)
5 years rr_AverageAnnualReturnYear05 0.40%
10 years rr_AverageAnnualReturnYear10 (0.88%)
Putnam Global Health Care Fund | before taxes | Class R
  
Average Annual Total Return rr_AverageAnnualReturnAbstract  
Share class rr_AverageAnnualReturnColumnName Class R
Label rr_AverageAnnualReturnLabel before taxes
1 year rr_AverageAnnualReturnYear01 1.82%
5 years rr_AverageAnnualReturnYear05 1.37%
10 years rr_AverageAnnualReturnYear10 (0.27%)
Putnam Global Health Care Fund | before taxes | Class Y
  
Average Annual Total Return rr_AverageAnnualReturnAbstract  
Share class rr_AverageAnnualReturnColumnName Class Y
Label rr_AverageAnnualReturnLabel before taxes
1 year rr_AverageAnnualReturnYear01 2.32%
5 years rr_AverageAnnualReturnYear05 1.88%
10 years rr_AverageAnnualReturnYear10 0.22%
Putnam Global Health Care Fund | after taxes on distributions | Class A
  
Average Annual Total Return rr_AverageAnnualReturnAbstract  
Share class rr_AverageAnnualReturnColumnName Class A
Label rr_AverageAnnualReturnLabel after taxes on distributions
1 year rr_AverageAnnualReturnYear01 (4.69%)
5 years rr_AverageAnnualReturnYear05 (0.78%)
10 years rr_AverageAnnualReturnYear10 (1.52%)
Putnam Global Health Care Fund | after taxes on distributions and sale of fund shares | Class A
  
Average Annual Total Return rr_AverageAnnualReturnAbstract  
Share class rr_AverageAnnualReturnColumnName Class A
Label rr_AverageAnnualReturnLabel after taxes on distributions and sale of fund shares
1 year rr_AverageAnnualReturnYear01 (1.28%)
5 years rr_AverageAnnualReturnYear05 0.24%
10 years rr_AverageAnnualReturnYear10 (0.66%)
Putnam Global Health Care Fund | MSCI World Health Care Index (ND)
  
Average Annual Total Return rr_AverageAnnualReturnAbstract  
Label rr_AverageAnnualReturnLabel MSCI World Health Care Index (ND)
Index No Deduction for Fees, Expenses, Taxes [Text] rr_IndexNoDeductionForFeesExpensesTaxes (no deduction for fees, expenses or taxes other than withholding taxes on reinvested dividends)
1 year rr_AverageAnnualReturnYear01 2.41%
5 years rr_AverageAnnualReturnYear05 1.88%
10 years rr_AverageAnnualReturnYear10 0.76%
[1] Applies only to certain redemptions of shares bought with no initial sales charge.
[2] This charge is phased out over six years.
[3] This charge is eliminated after one year.

XML 12 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 13 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6
Putnam Global Health Care Fund
PUTNAM GLOBAL HEALTH CARE FUND
Goal
Putnam Global Health Care Fund seeks capital appreciation.
Fees and expenses
The following table describes the fees and expenses you may pay if you buy and hold shares of the fund. You may qualify for sales charge discounts if you and your family invest, or agree to invest in the future, at least $50,000 in Putnam funds. More information about these and other discounts is available from your financial advisor and in How do I buy fund shares? beginning on page 57 of the fund’s prospectus and in How to buy shares beginning on page II-1 of the fund’s statement of additional information (SAI).
Shareholder fees (fees paid directly from your investment)
Shareholder Fees Putnam Global Health Care Fund
Class A
Class B
Class C
Class M
Class R
Class Y
Share class Class A Class B Class C Class M Class R Class Y
Maximum sales charge (load) imposed on purchases (as a percentage of offering price) 5.75% none none 3.50% none none
Maximum deferred sales charge (load) (as a percentage of original purchase price or redemption proceeds, whichever is lower) 1.00% [1] 5.00% [2] 1.00% [3] 0.65% [1] none none
Redemption fee (as a percentage of total redemption proceeds) 1.00% 1.00% 1.00% 1.00% 1.00% 1.00%
[1] Applies only to certain redemptions of shares bought with no initial sales charge.
[2] This charge is phased out over six years.
[3] This charge is eliminated after one year.
Annual fund operating expenses (expenses you pay each year as a percentage of the value of your investment)
Annual Fund Operating Expenses Putnam Global Health Care Fund
Class A
Class B
Class C
Class M
Class R
Class Y
Share class Class A Class B Class C Class M Class R Class Y
Management fees 0.63% 0.63% 0.63% 0.63% 0.63% 0.63%
Distribution and service (12b-1) fees 0.25% 1.00% 1.00% 0.75% 0.50%   
Other expenses 0.38% 0.38% 0.38% 0.38% 0.38% 0.38%
Total annual fund operating expenses 1.26% 2.01% 2.01% 1.76% 1.51% 1.01%
Example
The following hypothetical example is intended to help you compare the cost of investing in the fund with the cost of investing in other funds. It assumes that you invest $10,000 in the fund for the time periods indicated and then, except as indicated, redeem all your shares at the end of those periods. It assumes a 5% return on your investment each year and that the fund’s operating expenses remain the same. Your actual costs may be higher or lower.
Expense Example Putnam Global Health Care Fund (USD $)
Class A
Class B
Class C
Class M
Class R
Class Y
Share class Class A Class B Class C Class M Class R Class Y
1 year 696 704 304 523 154 103
3 years 952 930 630 885 477 322
5 years 1,227 1,283 1,083 1,271 824 558
10 years 2,010 2,144 2,338 2,351 1,802 1,236
Expense Example, No Redemption Putnam Global Health Care Fund (USD $)
Class B
Class C
Share class Class B (no redemption) Class C (no redemption)
1 year 204 204
3 years 630 630
5 years 1,083 1,083
10 years 2,144 2,338
Portfolio turnover
The fund pays transaction-related costs when it buys and sells securities (or “turns over” its portfolio). A higher turnover rate may indicate higher transaction costs and may result in higher taxes when the fund’s shares are held in a taxable account. These costs, which are not reflected in annual fund operating expenses or the above example, affect fund performance. The fund’s turnover rate in the most recent fiscal year was 35%.
Investments
For this non-diversified fund concentrating in the health care industries, we invest mainly in common stocks (growth or value stocks or both) of large and midsize companies worldwide that we believe have favorable investment potential. Potential investments include companies that manufacture health care supplies or provide health care-related services, and companies in the research, development, production and marketing of pharmaceuticals and biotechnology products. We may purchase stocks of companies with stock prices that reflect a value lower than that which we place on the company. We also consider other factors that we believe will cause the stock price to rise. We may consider, among other factors, a company’s valuation, financial strength, growth potential, competitive position in its industry, projected future earnings, cash flows and dividends when deciding whether to buy or sell investments. We may also use derivatives, such as futures, options, certain foreign currency transactions, warrants and swap contracts, for both hedging and non-hedging purposes, and may engage in short sales of securities.
Risks

It is important to understand that you can lose money by investing in the fund.

The prices of stocks in the fund’s portfolio may fall or fail to rise over extended periods of time for a variety of reasons, including both general financial market conditions and factors related to a specific company or industry. Growth stocks may be more susceptible to earnings disappointments, and value stocks may fail to rebound. These risks are generally greater for small and midsize companies. The health care industries may be affected by technological obsolescence, changes in regulatory approval policies for drugs, medical devices or procedures and changes in governmental and private payment systems. Our policy of concentrating on a limited group of industries and the fund’s “non-diversified” status, which means the fund may invest in fewer issuers than a “diversified fund,” can increase the fund’s vulnerability to adverse developments affecting a single industry or issuer, which may result in greater losses and volatility for the fund. The value of international investments traded in foreign currencies may be adversely impacted by fluctuations in exchange rates. International investments may carry risks associated with potentially less stable economies or governments, such as the risk of seizure by a foreign government, the imposition of currency or other restrictions, or high levels of inflation or deflation. International investments, particularly emerging-market investments, can be illiquid. Our use of derivatives may increase these risks by increasing investment exposure or, in the case of many over-the-counter instruments, because of the potential inability to terminate or sell derivatives positions and the potential failure of the other party to the instrument to meet its obligations. Our use of short selling may result in losses if the securities appreciate in value.

The fund may not achieve its goal, and it is not intended to be a complete investment program. An investment in the fund is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency.
Performance
The performance information below gives some indication of the risks associated with an investment in the fund by showing the fund’s performance year to year and over time. The bar chart does not reflect the impact of sales charges. If it did, performance would be lower. Please remember that past performance is not necessarily an indication of future results. Monthly performance figures for the fund are available at putnam.com.
Annual total returns for class A shares before sales charges
Bar Chart

Year-to-date performance

through 9/30/11

-8.11%

Best calender quarter

Q3 2010

12.45%

Worst calender quarter

Q1 2001

-22.70%
Average annual total returns after sales charges (for periods ending 12/31/10)
Average Annual Total Returns Putnam Global Health Care Fund
Share class
Label
Index No Deduction for Fees, Expenses, Taxes [Text]
1 year
5 years
10 years
before taxes Class A
 Class A before taxes   (3.80%) 0.42% (0.62%)
before taxes Class B
 Class B before taxes   (3.39%) 0.60% (0.78%)
before taxes Class C
 Class C before taxes   0.37% 0.86% (0.77%)
before taxes Class M
 Class M before taxes   (1.98%) 0.40% (0.88%)
before taxes Class R
 Class R before taxes   1.82% 1.37% (0.27%)
before taxes Class Y
 Class Y before taxes   2.32% 1.88% 0.22%
after taxes on distributions Class A
 Class A after taxes on distributions   (4.69%) (0.78%) (1.52%)
after taxes on distributions and sale of fund shares Class A
 Class A after taxes on distributions and sale of fund shares   (1.28%) 0.24% (0.66%)
MSCI World Health Care Index (ND)
   MSCI World Health Care Index (ND) (no deduction for fees, expenses or taxes other than withholding taxes on reinvested dividends) 2.41% 1.88% 0.76%

After-tax returns reflect the historical highest individual federal marginal income tax rates and do not reflect state and local taxes. Actual after-tax returns depend on an investor’s tax situation and may differ from those shown. After-tax returns are shown for class A shares only and will vary for other classes. These after-tax returns do not apply if you hold your fund shares through a 401(k) plan, an IRA, or another tax-advantaged arrangement.

Class B share performance does not reflect conversion to class A shares.
GRAPHIC 14 BarChart1.jpg IDEA: XBRL DOCUMENT begin 644 BarChart1.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``8$!08%!`8&!08'!P8("A`*"@D) M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_ MVP!#`0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P``1"`$L`AP#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#I_`/@WPQ= M>!/#EQ<^'-%FGETVVDDDDL8F9V,2DL25R23SFM74?"'A.RLY)QX0TFX9*[DE8\F4GS;GGJVG@Z1Q:P>`;2;5@[K+IRZ?9B6 M((L;,S,6$1&)X3\KD_O!QPVW>TWPGX+U+3K6^LO#>A2VMU$D\+_V;$NY&`*G M!7(R".M8^C:5JNBZC;ZG#HU_+81_;(H-.^TQ27<*SFVD+2.\NULRPSN3YC-^ M]3W"]?X2TV;1_"NC:9@I)=T.3MLRC_P@OA/ M_H5]"_\`!?#_`/$T?\(+X3_Z%?0O_!?#_P#$U>U;2KR^N%DMM>U/3D"!3%:Q MV[*3D_,?,B<\)6&L:QX5T;4[GQ;K2SWME#BR[!=_P`WYB?\(+X3_P"A M7T+_`,%\/_Q-'_""^$_^A7T+_P`%\/\`\365X2L-8UCPKHVIW/BW6EGO;*&Y MD6."R"AG0,0,VY.,GU-:W_"/:G_T-^O?]^;+_P"1Z-.P.ZTYOS$_X07PG_T* M^A?^"^'_`.)H_P"$%\)_]"OH7_@OA_\`B:7_`(1[4_\`H;]>_P"_-E_\CT?\ M(]J?_0WZ]_WYLO\`Y'HLNP7?\WYB?\(+X3_Z%?0O_!?#_P#$T?\`""^$_P#H M5]"_\%\/_P`32_\`"/:G_P!#?KW_`'YLO_D>C_A'M3_Z&_7O^_-E_P#(]%EV M"[_F_,3_`(07PG_T*^A?^"^'_P")H_X07PG_`-"OH7_@OA_^)K*\)6&L:QX5 MT;4[GQ;K2SWME#C_`(1[4_\`H;]>_P"_-E_\CT678+O^;\Q/^$%\)_\`0KZ%_P"" M^'_XFC_A!?"?_0KZ%_X+X?\`XFE_X1[4_P#H;]>_[\V7_P`CT?\`"/:G_P!# M?KW_`'YLO_D>BR[!=_S?F)_P@OA/_H5]"_\`!?#_`/$T?\(+X3_Z%?0O_!?# M_P#$UE>$K#6-8\*Z-J=SXMUI9[VRAN9%C@L@H9T#$#-N3C)]36M_PCVI_P#0 MWZ]_WYLO_D>C3L#NM.;\Q/\`A!?"?_0KZ%_X+X?_`(FC_A!?"?\`T*^A?^"^ M'_XFE_X1[4_^AOU[_OS9?_(]'_"/:G_T-^O?]^;+_P"1Z++L%W_-^8G_``@O MA/\`Z%?0O_!?#_\`$T?\(+X3_P"A7T+_`,%\/_Q-+_PCVI_]#?KW_?FR_P#D M>C_A'M3_`.AOU[_OS9?_`"/19=@N_P";\Q/^$%\)_P#0KZ%_X+X?_B:/^$%\ M)_\`0KZ%_P""^'_XFLKPE8:QK'A71M3N?%NM+/>V4-S(L<%D%#.@8@9MR<9/ MJ:UO^$>U/_H;]>_[\V7_`,CT:=@=UIS?F)_P@OA/_H5]"_\`!?#_`/$T?\(+ MX3_Z%?0O_!?#_P#$TO\`PCVI_P#0WZ]_WYLO_D>C_A'M3_Z&_7O^_-E_\CT6 M78+O^;\Q/^$%\)_]"OH7_@OA_P#B:/\`A!?"?_0KZ%_X+X?_`(FE_P"$>U/_ M`*&_7O\`OS9?_(]'_"/:G_T-^O?]^;+_`.1Z++L%W_-^8G_""^$_^A7T+_P7 MP_\`Q-'_``@OA/\`Z%?0O_!?#_\`$UE>$K#6-8\*Z-J=SXMUI9[VRAN9%C@L M@H9T#$#-N3C)]36M_P`(]J?_`$-^O?\`?FR_^1Z-.P.ZTYOS$_X07PG_`-"O MH7_@OA_^)H_X07PG_P!"OH7_`(+X?_B:7_A'M3_Z&_7O^_-E_P#(]'_"/:G_ M`-#?KW_?FR_^1Z++L%W_`#?F)_P@OA/_`*%?0O\`P7P__$T?\(+X3_Z%?0O_ M``7P_P#Q-+_PCVI_]#?KW_?FR_\`D>C_`(1[4_\`H;]>_P"_-E_\CT678+O^ M;\Q/^$%\)_\`0KZ%_P""^'_XFC_A!?"?_0KZ%_X+X?\`XFLKPE8:QK'A71M3 MN?%NM+/>V4-S(L<%D%#.@8@9MR<9/J:UO^$>U/\`Z&_7O^_-E_\`(]&G8'=: MC_A'M3_Z&_7O^_-E_P#(]%EV"[_F_,3_`(07PG_T*^A?^"^' M_P")H_X07PG_`-"OH7_@OA_^)I?^$>U/_H;]>_[\V7_R/1_PCVI_]#?KW_?F MR_\`D>BR[!=_S?F)_P`(+X3_`.A7T+_P7P__`!-'_""^$_\`H5]"_P#!?#_\ M365X2L-8UCPKHVIW/BW6EGO;*&YD6."R"AG0,0,VY.,GU-:W_"/:G_T-^O?] M^;+_`.1Z-.P.ZTYOS$_X07PG_P!"OH7_`(+X?_B:/^$%\)_]"OH7_@OA_P#B M:7_A'M3_`.AOU[_OS9?_`"/1_P`(]J?_`$-^O?\`?FR_^1Z++L%W_-^8G_"" M^$_^A7T+_P`%\/\`\31_P@OA/_H5]"_\%\/_`,32_P#"/:G_`-#?KW_?FR_^ M1Z/^$>U/_H;]>_[\V7_R/19=@N_YOS$_X07PG_T*^A?^"^'_`.)H_P"$%\)_ M]"OH7_@OA_\`B:RO"5AK&L>%=&U.Y\6ZTL][90W,BQP604,Z!B!FW)QD^IK6 M_P"$>U/_`*&_7O\`OS9?_(]&G8'=:U/\`Z&_7O^_-E_\` M(]%EV"[_`)OS$_X07PG_`-"OH7_@OA_^)H_X07PG_P!"OH7_`(+X?_B:7_A' MM3_Z&_7O^_-E_P#(]'_"/:G_`-#?KW_?FR_^1Z++L%W_`#?F)_P@OA/_`*%? M0O\`P7P__$T?\(+X3_Z%?0O_``7P_P#Q-97AFPUC5-.FN+CQ;K2NE[=VP"06 M0&V*XDB4\VYYVH"??/3I6M_PCVI_]#?KW_?FR_\`D>C3L#NM.;\Q/^$%\)_] M"OH7_@OA_P#B:/\`A!?"?_0KZ%_X+X?_`(FE_P"$>U/_`*&_7O\`OS9?_(]' M_"/:G_T-^O?]^;+_`.1Z++L%W_-^8G_""^$_^A7T+_P7P_\`Q-'_``@OA/\` MZ%?0O_!?#_\`$TO_``CVI_\`0WZ]_P!^;+_Y'H_X1[4_^AOU[_OS9?\`R/19 M=@N_YOS$_P"$%\)_]"OH7_@OA_\`B:/^$%\)_P#0KZ%_X+X?_B:RO#-AK&J: M=-<7'BW6E=+V[M@$@L@-L5Q)$IYMSSM0$^^>G2M;_A'M3_Z&_7O^_-E_\CT: M=@=UIS?F)_P@OA/_`*%?0O\`P7P__$T?\(+X3_Z%?0O_``7P_P#Q-+_PCVI_ M]#?KW_?FR_\`D>I/!-S=76A,U_=27<\5[>6WGR*BLZQ7,L:DA%5<[47H!19= M@N[7N1?\(+X3_P"A7T+_`,%\/_Q-?-/[2VDZ=H_CNPM])L+2Q@;38Y&CM85B M4L991N(4`9P`,^PKZYKY3_:M_P"2AZ=_V"H__1TU9UDN4VPS;GJSZ+^&_P#R M3OPM_P!@JU_]$K71XKGOAO\`\D[\+?\`8*M?_1*UT>*U6QA+=C<48IV*,4R1 MN*YSX;_\D[\+?]@JU_\`1*UTN*YSX;_\D[\+?]@JU_\`1*TNI70Z'%&*=BC% M,D;BC%.Q1B@!N*,4[%&*`&XHQ3L48H`;BC%.Q1B@!N*,4[%&*`&XHQ3L48H` M;BC%.Q1B@!N*,4[%&*`&XHQ3L48H`;BC%.Q1B@!N*,4[%&*`&XHQ3L48H`;B MC%.Q1B@!N*,4[%&*`&XHQ3L48H`;BC%.Q1B@!N*,4[%&*`&XHQ3L48H`;BC% M.Q1B@!N*,4[%&*`&XHQ3L48H`;BC%.Q1B@!N*,4[%&*`,?Q5/I5KX?O9_$4L M<6DQH'N#(Q"LH(^4@%-0\.7,,GB#1=+L'U(SV]@TL M#V<96"/_`$=D)\N5,NLKK&0%D<[7W+O/J&K:KIVCVRW&KW]I80,XC62ZF6)2 MQ!.T%B!G`)Q[&LG_`(3GPC_T-.@_^#"'_P"*J&:1NEHCG_&-WIUQ\&]52^M+ M33C_`&$)CILVT?9&>,^2FT@8(D7:O`^9.!D8JS\0-*T;Q#I=D'MK349]6>*R MLYGQ*$B?+RRP$Y5'$(ED#C[QC0'=A5K7_P"$Y\(_]#3H/_@PA_\`BJLZ=XK\ M.ZG>1VFFZ_I-W=R9V0P7D1"ZJV."5!!(SVR,^HKG?ARLR^&Y%N7CDG&I:B)'C0HK-]MFR0 MI)(&>V3CU-=!J*7O/2L'X%O\`L%6O_HE: MZ3%XN8;.)IY([?;OV+RQ&YE'`R>O M;C)P*HZ[XGMM'N9XI+6[N$M;<7=[+`$VVD!+XD?O"O_ M`%^R_P#I'<5OW_2L'3_^1[\*_P#7[+_Z1W%57V,L+\2/7J*7%&*P/1$HI<48 MH`2BEQ1B@"*Y,RVTK6L<&I6NDCCN#J6HF1(W+JK?;9\@,0"1GO@9]!2ZE6]TZ:OE#]K# M_DHNG?\`8*C_`/1TU?6&*^4/VL/^2BZ=_P!@J/\`]'35G5^$VPWQGT;\-A_Q M;KPM_P!@JU_]$K6MK4%C/I5RFKF,:>$WW'FR;(]B_,V\Y`V8'S`_*5R#D$BL MOX:C_BW/A7_L%6O_`*)6MO4;"TU.SDM-2M;>[M),;X;B,2(V"",J00<$`_A5 MK8S?Q'F6C:1IU_XMCTZXT^T?0)$O;JVTB>%3':[5L%4M`1B)SOED"D!@MP20 MK.PKM?A_/-=>`O#=Q=2R37$NF6TDDLC%F=C$I+$GDDGG-3?\(EX<_L[^S_[` MTC[!YOG_`&;[%'Y7F8V[]NW&['&<9QQ6WBA*PY2NC'U;5+RQN5BM=`U/4D*! MC+:R6RJ#D_*?,E0YXSTQR.>N*/PV_P"2<^%>"?\`B56G_HE*Z;%I4L2%8\`DXQSC'&%]2U^^L;Q[;33 MQT9K"/[7#< M32/=V[S8\MH0`H61,9\TYSGH*S+?7?%TV/\`B8:"/^X7,?\`VYH47+9"=:-/ MXG;[SK-<_MB:&6WM='TF^M9MT_O(K2*W8Q(L+S+),#(HW"2?8-T@ M&8R04!92\G1Z;##1V!P?I3\48K`],9CGH:,=>#3\48H`9V!P?I1CGH:?BC%`&7K&H75AY7V7 M1M0U/?G=]E>!?+QC&?-D3KD],]#G'&A-=+;PS++ M)#)`[ZGJ+-%(5+1DWL^5.TD9'3@D>A-3U*^R=-BOD[]K'_DHNG?]@J/_`-'3 M5]9XKY-_:S_Y*-IW_8*C_P#1TU15^$UP_P`9]'_#7_DG/A7_`+!5I_Z)6NDK MG/AI_P`DY\*_]@FT_P#1*UTF*M;&5 M]_Z,M:9I_:MZ!Y^,W1+J/>J'@K_DI5K_`-@J[_\`1UK5_4>]4?!/_)2K7_L$ MW?\`Z.M:=?8G!?&OG^1ZM12XHQ7.>D)12XHQ0`E%+BC%`"44N*,4`<_\0+F[ ML?`^O7NG74EI>6EE-7()HEVQ1AU9B6,2;2W9ZGX M?L]2D+W$VIH=Y?\`T?4[FW&2JKTCD48P@XZ`ECU9B8AX5T9;R"YBL_*\GRRL M$4KQVY,8`C9H%(C9E"IM8J2-B8(VK@:8)I+4YI-;URSLWL->N+>VU!LS2W<" M"4VT)*(`B`'=)),TBVZD$LB@L'D1XV[JVGANK:*XM98YK>5!)'+&P974C(8$ M<$$GR6=W:O;[H[N4SS,7;>TF00^_.X,NU=I!!0(@7`5<7K:WAM;:* MWM8HX;>)!''%&H544#`4`<``<8II"=F/HI<48IDB44N*,4`)12XHQ0`E%+BC M%`"44N*,4`)12XHQ0`E%+BC%`"44N*,4`)12XHQ0!P'Q<_U'AG_L+?\`MI%/^OV7_ M`-([BMV_Z5A:9_R/OA3_`*_9O_2.XJJ^QCA/C1['12XHQ7.>H)12XHQ0`E%+ MBC%`$-S,MM;2SR"0I$A=A'&TC$`9X502Q]@"3VKG/AO,MSX9EGC$@274]1=1 M)&T;`&]G/*L`5/L0".]=+,2!)=3U%U$D;1L`;V<\JP!4^Q`([TNI5M#IZ^3/VL_^2C:=_V"H_\` MT=-7UIBODS]K3_DHVG?]@F/_`-'35G5^$UP_QGTC\-!_Q;CPK_V";3_T2M=) MBN<^&?\`R3CPI_V";3_T2E=!(=7UG3?"B6+Z?9ZAJ^DG5)IIK=YHDVB#@;;G`SC.,X%"=P<;&ABN;^&@_XM MQX5_[!-I_P"B5J_J_B70=&N5M]8UO3+"X9!(L5U=QQ,5)(#`,0<9!&?8U1^& MF!\-_"F>/^)5:?\`HE*+ZA;0Z/%&*7C.._I0,'..W6F2)BC%+E<`Y&#T.:., MX[^E`"8HQ2C!SCMUHRN`5]_Z,M:CT_M4OQ3_ M`.1N\-?]>5]_Z,M:BT_M710/.QOQ$NH]ZI>"/^2EVO\`V";O_P!'6M7=1[U2 M\#_\E+M?^P3=_P#HZUIU]B<%\:^?Y'K&*,4HPAS7,>F)BC%5 M]2NQ8V13V=K#+);O%.8PZ MRK.8-A8.8QF08W%]H!R6`R1);^*;5M7L=*O+6[L=2NDWBWG",8R?-**QC9ER MRP3,,$@",ABI*ABX^5F_BC%4](U.#5K=[FS5S:[RL4Q`VSK@'S$YR4.2`Q`W M8W#*E6-W*X!R,'H?BYRBTD MS*OO"7AQ0=OA_2!]+*/_`.)IWPYTNPT[XE0C3K&UM/,TF[W^1$L>[$UMC.!S MU/YULZAT-4O!'_)2[7_L$W?_`*.M:JO%):(G!SDYI-]_R/5\48I1@YQVZT97 M`.1@]#FN<]$3%&*7C.._I0,'..W6@!,48IAS1QG'?TH`3%&*48.<= MNM&5P#D8/0YH`3%&*7C.._I0,'..W6@!,48IAS1QG'?TH`3%&*48. M<=NM&5P#D8/0YH`3%&*7C.._I0,'..W6@!,48IAS1QG'?TH`3%&*4 M8.<=NM&5P#D8/0YH`\_^+W_'OX9_["W_`+:7-9FG=JU/B^1Y'A@9Y_M8\?\` M;I@<&-W7I^I9O^E8>F?\C[X4_P"OV;_TCN*W+_I6'I?_`"/WA3_K M]F_]([BJK[&.$^-'LN*,4HPAS7,>J)BC%+QG'?TH&#G';K0` MF*,4N5P#D8/0YHXSCOZ4`5=1OK/3+*2\U*[M[.TCQOGN)!&BY(`RQP!DD#ZF ML#X;3PW?AF6XM98YK>;4]1DCEC8,KJ;VV M1GU'6L#X9C_BV_A3_L$VG_HE*Z7%6MC.6YQFG>$M2TS2?#T=CJUG_:>CV+:: MMQ-8L\,L#>7UB$H8/^YB^;?C[_R\C;TFAZ9#HVB:?I=JTCV]E;QVT;2$%BJ* M%!)``S@>@J_BC%"5@;;$Q7-?#,?\6X\*?]@FT_\`1*5TV*YKX9C_`(MOX4_[ M!-I_Z)2CJ'0Z3%&*7%&*9(F*,4N*,4`)BC%+BC%`"8HQ2XHQ0`F*,4N*,4`) MBC%+BC%`'F'Q3_Y&[PU_UY7W_HRUJ+3^U3?%3_D;O#7_`%Y7W_HRUJ'3^U;T M#SL;\1+J/>J?@?\`Y*7:_P#8)N__`$=:U:1HUE;3"WEN9)9;B^99"$225GED\H; M1SSM-=1-*JK$8U*A%9#DF4'. M[C:1@YR,6V\0^,)L?Z?H"_\`<+F/_MS347+9$3K0IZ2=CH/#]IXDTCP]+#_9 M^D3:@^H7-QY?]HR+$(YII)OO^03N!DVXVX(&$II="M-)O19BU=+F. MZ,>6>*VEDW_8H&*C;%MVQEAM.R)=JJ2K1XUQK_C"'/\`Q,-`/_<*F'_MS5CP M7XIU[4/%ZZ5K$FERV\EC-I:M-J6I?:[>XEW6\>/]6,L<_[/RM''M'!\GS/O2N!MXI<48I%O M4\P^*?\`R-WAK_KROO\`T9:U%IW:IOBI_P`C=X:_Z\K[_P!&6M0Z=VKHH'FX MWXB;4.AJEX'_`.2F6O\`V";O_P!'6M7=0Z&J?@?_`)*9:_\`8)N__1UK55]B M,%_$7S_(]9Q1BEQ1BN8]03%&*CNIX;2VEN+J:.&WA0R22R,%5%`R6)/``'.3 M4>FW]GJEE'>:;=V]Y:29V3V\@D1L$@X8$@X((^HI#L6,48K)B\2Z#-I,VJ0Z MWI"?XAZU>M[^SN/LWV>[MY?M,)N(-D@;S8Q MMRZX/S+\ZS`] MZEQ3`3%&*7%&*!"8HQ2XHQ0`F*,4N*,4`)BC%+BC%`"8HQ2XHQ0`F*,4N*,4 M`>??&#_CW\,?]A;_`-M+FLK3NU:WQA_X]_#'_86_]M+FLG3NU;4.IY^.W7I^ MI9O^E8>E?\C]X4_Z_9O_`$CN*W+_`*5B:5_R/_A3_K]F_P#2.XJZ^QEA/C1[ M/BC%+BC%UBCAMX=3U*..*- M0JHHOIP%`'``'&*74KH=1BODG]K?_DH^F_\`8)C_`/1TU?6^*^2/VN/^2D:; M_P!@F/\`]'35%7X32A\9]*?#(?\`%M_"G_8)M/\`T2E=+BN;^&7_`"3;PG_V M";3_`-$I7352V(>XW%&*=13)&XKFOAD/^+;^%/\`L$VG_HE*Z>N9^&7_`"3; MPG_V";3_`-$I2ZE=#I,48IU%,D;BC%.HH`;BC%.HH`;BC%.HH`;BC%.HH`;B MC%.HH`\N^*O_`"-WAK_KROO_`$9:U!I_:K'Q7_Y&[PS_`->5]_Z,M:KZ?VKH MH'FXWXB74>]5/`O_`"4RV_[!-W_Z.M:MZCWJIX$_Y*9;?]@F\_\`1UK3Q&Q& M"^-?/\CUS%&*=17,>J>7?%7_`)&[PU_UY7W_`*,M:@T[M5CXK_\`(W>&?^O* M^_\`1EK5?3NU=%`\W&_$2ZAWJIX%_P"2F6W_`&";S_T=:U;U#O57P)_R4VV_ M[!-Y_P"CK6G7V(P7QKY_D>MXHQ3J*YCU3R[XJ_\`(W>&O^O*^_\`1EK4&G=J ML?%?_D;O#/\`UY7W_HRUJOIW:NB@>;C?B)M0Z&J?@;_DIEM_V";O_P!'6M7- M0Z&JG@7_`)*;;?\`8)O/_1UK3Q&Q&"_B+Y_D>MXHQ3J*YCU3*\1W-M8Z+<7= MY8W&H16^V86UM;&XED=6#)L0`Y8,%(/`!&20!D)UU:WUB#^VII MH[OR].G0C-FBGR5:/S"JQH$#N@WR*V%&Y4KH/%OBRT\--9Q36MY>W5UO:*WM M0FXHFW>Y+LJ@`N@QG/S#`(!(QH_B+YGW/"WB`_\``K/_`.2*5F]@YXQW:7S, M%;+7KB[N/$NJ>8FIK<6\.CQP:/(1.J17`#RP^<6C#_:YE'F21;"B%RN2M6=- M\*WUOIVE3R1R1>,+M)YY)XD_T:PEE>:0R,"65C#]LG1$W'S"_(PN^+7D^(1C M^_X5\0#_`(%9_P#R15OPSXYMM>US^RAI.J6%R;=[E6NO)*LJ,BL`8Y'.$_^OV;_P!([BKK[&.$ M^-'M6*,4ZBN4]8IZD+S[%(-,^SB[.%1KC.Q,D`L0.6P,G;D;B,;ESN'-1^)+ MRR\+>)M1U".WO9=#\_$MLIABO/*A$C;`2^S#%HC\S8:-NARHZ/6]/?5-)NK& M.^O-/,Z;/M-FRK-&#UV,RD`XR,XR,Y&#@C(L?",$&A7&CW6HZA>Z?<;DEAF\ MI%,)@\GR%6.-!'&``P$84[AG/)!3N4K=3!UCQG?^&9;NPU?^S]1U(?9#:&!) M+1)S.\P\O;F9MRK;R.,9+DA%7=@-9B\4W]K]EN;Y;>[T1+2:YO=3@MI(5C$? MFE\Q%G:-H_+C1HFR[-*2`ODNM:#>#(Y)#=7&L:I-K"O&T6IL(!-"$655546( M1$;9YQ\R$_O#SD+MO6OAJS@M[&!I+B>"UFDNC'*PVSW#R>89I```6#EG"C"! MFR%!5-JU'H/TR1M7L;Z'5X;,AW,4MAE93#&R*?*GY*LY5@S`?*`X`W`;VS/A MK;PVGAB6WM8HX;>'4]2CCBC4*J*+Z$_P#L$VG_`*)2NEKF_AC_`,DV\)_]@FT_]$I7 M2U:V(>YSMIXJM;G5H[-;2\2WFN);.WOF">3//%O\R-0&,@(\J7ED53Y9P3E= MW0UP>F:/JD>K:99RV$D=OIVLWVJM?&2,PS1S_:MJ(`QDWC[4N=R*OR/AC\N[ MO:$#2Z"5S7PR_P"2;>$_^P3:?^B4J_J^DWM_0^'>@:E-\/_#,L?BW7+='TNU988XK(K&#$N%&ZW+8'09)/ MJ32Z@EH>BT5Y5XSD\0Z)K^CV-IXOUAXKRWN9I#+;V18&-H`N,6XX_>MGZ#\9 MK`:_<8W^,-9&?2WLO_D>N.MF%*A/DG>YZ.'RFOB*?M86MZGI]%>97ZZ_;YV> M,-9/UM[+_P"1ZS_#MUXCU+QC#I,_B[5EMGL9[DLEO9!]R20J!DV^,8E;/'8? MBJ68T:TU3C>['6RC$4:3K3M9>9Z[17-_\(YJG_0Z>(/^_-A_\C4?\(YJG_0Z M>(/^_-A_\C5W7/,MYG245Y5XSD\0Z)K^CV-IXOUAXKRWN9I#+;V18&-H`N,6 MXX_>MGZ#\9;#_A(+C&_QAK(SZ6]E_P#(]<5;,*5"?).]STL/E-?$4_:PM;U/ M4**\ROTU^WSL\8:R<>MO9?\`R/6?X=NO$>I>,8=)G\7:LML]C/*_$$T]LDD<3;+-=JN4+#`MP#DQIU]/]5?`?_)3;;_L$WG_HZUKI)/AV9/O^ M*O$!_P"`V?\`\CTVP^&ZZ?J:ZA:>*?$$=XL+P"3;9G".R,PP;?')C3G&>/K3 MJU5-:(6'PLJ4DY-?U\CO**YO_A'-4_Z'3Q!_WYL/_D:C_A'-4_Z'3Q!_WYL/ M_D:L;G;;S.2^*_\`R-WAG_KROO\`T9:U7T[M70:M\/3J]Y;76H>*_$$T]LDD M<3;+-=JN4+#`MP#DQIU]/*?$$=XL+P"3;9G".R,PP;?')C3G&>/K3JU5-:(6'PLJ4DY-?U\CO**Y MO_A'-4_Z'3Q!_P!^;#_Y&H_X1S5/^AT\0?\`?FP_^1JQN=MO,Y+XK_\`(W>& M?^O*^_\`1EK5?3NU=!JWP].KWEM=:AXK\033VR21Q-LLUVJY0L,"W`.3&G7T M]S38_AR(_N>*O$`_X#9__(]:TJBANCDQ&&E5=XM?U\C'U#H:J>!/^2FVW_8) MO/\`T=:UTLGP[,GW_%7B`_\``;/_`.1Z98?#A;#4UU&T\4^(([Q87@$FVS.$ M=D9A@V^.3&G.,\?6G5JJ:T1.'PLJ4E*37]?([RBN;_X1S5/^AT\0?]^;#_Y& MH_X1S5/^AT\0?]^;#_Y&K&YVV\SDOBQ_R-WAG_KROO\`T9:U6T[M70ZM\/#J M]W:W6H>*_$$T]LDD<3;+-=JN4+#`MP#DQIU]/`2;;,X1V1F&#;XY,:G+,K?+L9=\*+MP'#+^>IZE17-_\(YJG_0Z>(/\`OS8?_(U'_".:I_T.GB#_ M`+\V'_R-6]SFMYG245Y3XUE\0Z'KVCV-IXOUAXKRWN99#+;V18&-H`N,6XX_ M>MGZ#\9+!O$%QC?XOU@?2WLO_D>N*MF%*A/DG>YZ6'RFOB*7M:=K>IZE17FM M]%KT`RGC#63];>R_^1ZS?#]SXCU'QC#I,_B[5UMGL9[DLEO9!]R20J!DV^,8 ME;/'8?BJ68T:LU3C>['6RC$4:3K3M9>9ZY17-_\`".:I_P!#IX@_[\V'_P`C M4?\`".:I_P!#IX@_[\V'_P`C5W7/,MYF#\8_^/7PQ_V%_P#VTN:QM.[5TVL^ M`I=:6U74_%GB"9;:;SXALLEVOL9,\6XS\KL,'CGZ5#'\.!']SQ3X@'_`;/\` M^1ZTI5%#='+BG:!%;W=Y:K/JGERM:W,D#,HMKAMI9"#CPKE;+3C)C M?JOB`_\`<;O/_CM=KK/@*76DM5U/Q9X@F6VF\^(;+)=K[&3/%N,_*[#!XY^E M01_#@1_<\4^(!_P&S_\`D>KA**^)7,*].I-KVSRV\\=U?37*L@MYI!@2,P!W1H=PP>",X)!Z M^3X>&3[_`(K\0'_@-G_\CU##\,HH=0M+Z/Q1X@6ZM',D+XLSM8HR$X^SX/RN MPY]:'PQ+%)-)<.FJ:DK32!0TA%]/EFV@+D]3@`>@%9=3LMH=37R+^UW M_P`E)TW_`+!,7_HZ:OKNOD3]KS_DI.F_]@F+_P!'35-3X32C\1]+_#$?\6U\ M)_\`8(M/_1*5TV*YOX8#_BVOA/\`[!%I_P"B4KIL52V(>XW%&*=BC%,0W%?^CK6L\N_P!ZA\_R M9KF?^X5/E^:/6\48IV*,5]:?"'EWQ3_Y'+PS_P!>5_\`^C+2K&C_`,-0?%3_ M`)'+PQ_UY7__`*,M*GT?^&OELT_WE_(^VR;_`'%>K)=8_BK%\$?\E/MO^P1> M?^CK6MK6/XJQO`__`"5"V_[!%Y_Z.M:SR[_>H?/\F:YG_N%3Y?FCUO%&*=BC M%?6GP@W%&*=BC%`#<48IV*,4`-Q1BG8HQ0`W%&*=BC%`#<48IV*,4`-Q1BG8 MHQ0`W%&*=BC%`#<48IV*,4`-Q1BG8HQ0`W%&*=BC%`#<48IV*,4`-Q1BG8HQ M0!QVO>(8+Z_T[1]!UNW6YGU$V5[)9212SVFV">7&U@RJQ:#:=ZGC=@`X(JOX MGO+#X>7VIRG[3J%O=W&FP.8&?S95O&M87D2,9.2$9Q&,G+;%Z+76:QI-IJ]L ML%\DA".)(Y(9GAEC;!&Y)$(9#@LI*D9#,#P2#6;PWI;:='8F"3[*B,H03R#+ M,ZR&0G=DR[U#B4G>&RP8$DE:E:',6TVM:AH=RT>I:X-1M+@K>V=O;6*7*2LL M;+%&7+0B())YF"SOAE!DRK*8M-\1>(1%9:G=KI]]9:E:6HL8[0M&L]Q*D9!3 M0LIVPI$RJ6645T;>#])-M'`C:I$%=I&DAU6ZCEE9@H+2R+(&D("J MH+EMH``P.*TK72+"TN89[:UCB>&W%I"$X6&$'.R-?NH#A<[0,[$SG:N$%T5/ M"M_#J6DK)#JD>J.CLLMQ'&(U+'YOE7LFUE*9+90HVY]V]MC%4M'TBPT:V:WT MNUCMH6&/^O*__P#1EK4FC]J9 M\5_^1P\,?]>5_P#^C+2GZ/VKY;-/]Y?HC[C)O]Q7JR[JWW3]*Q/!7_)3[7_L M$7G_`*.M:V]6^Z?I6+X)_P"2H6O_`&"+S_T=:U&7?[U#Y_DRLS_W"I\OS1ZS MBC%.Q1BOK#X4;BC%.Q1B@!N*,4[%&*`&XHQ3L48H`;BC%.Q1B@!N*,4[%&*` M(+I)FMIEM9(X[@H1&\B%U5L<%E!!(SU`(SZCK7,_#-9E\+RK=21R7`U34A(\ M:%%9OMT^2JDD@9Z`DX]3UKH]2CO)+*1=,N+>WNSC9+<0-,B\C.45T)XR/O#G MGGH>>^&:S+X7E6ZDCDN!JFI"1XT**S?;I\E5))4$]`2<>IZTNH^AU.*^0_VO M?^2E:;_V"(O_`$=-7U]BOD+]K[_DI6F_]@B+_P!'35-3X32C\1],?#`?\6U\ M)?\`8(M/_1*5TV*YKX8#_BVGA+_L$6G_`*)2NFQ5+8A[B8HQ2XHQ0(3% M5_\`^C+2I]'_`(:A^*O_`".7AC_KRO\`_P!&6E3:/_#7R^:?[R_1'VN3_P"X MKU8_6/XJQ_`W_)4+;_L$7G_HZUK8UC^*LCP+_P`E1MO^P1>?^CK6L\N_WJ'S M_)FN9_[A4^7YH]=Q1BEQ1BOK#X0\N^*O_(Y>&/\`KRO_`/T9:5-H_P##47Q6 M_P"1R\,?]>5__P"C+2I='_AKY?-/]Y?R/MLG_P!Q7JR76/XJQO`W_)4+;_L$ M7G_HZUK9UC^*L?P+_P`E0MO^P1>?^CK6L\N_WJ'S_)FN9_[A4^7YH]=Q1BEQ M1BOK#X03%&*7%&*`$Q1BEQ1B@!,48I<48H`3%&*7%&*`$Q1BEQ1B@!,48I<4 M8H`3%&*7%&*`$Q1BEQ1B@!,48I<48H`3%&*7%&*`$Q1BEQ1B@!,48I<48H`3 M%&*7%&*`$Q1BEQ1B@!,48I<48H`\L^+'_(X>&/\`KRO_`/T9:4_1^U-^+/\` MR.'AC_KRO_\`T9:4[1^U?+9I_O+]$?;Y-_N*]67=6^Z?I6+X)_Y*A:_]@B\_ M]'6M;6K?=/TK&\$?\E0M?^P1>?\`HZUJ,O\`]ZA\_P`F7F?^X5/E^:/6\48I M<48KZP^%$Q1BEQ1B@!,48I<48H`3%&*7%&*`$Q1BEQ1B@!,48I<48H`ANC,M MM,UK'')%Y6NHXX[@ZIJ1D2-RZJWVZ?(5B`6`/0D#/H.E'4?0ZK%?(/[7W_`"4K M3?\`L$1?^CIJ^O\`%?(/[7__`"4O3/\`L$1?^CIJBIL72^(^FOA?_P`DT\)? M]@BT_P#1*5L:AJEO87-G!/'>.]T^R,P66ZA`L-MXSMU,C0W'BO38IEDD:3S(YAIPDC;<3 ME&5V4I]W:=N-O%=-X%MX;&^\5:?90QVUA::HL=M;0J$BA5K.VV%RL5KX>U74T*!C-:26 MRHIR1M/FS(V>,\#'(YZXH?#'(^&?A+`)_P")19]/^N*5U%$O^P1 M:?\`HE*.H=#D_BO_`,CEX8_Z\K__`-&6E2Z/_#4?Q8_Y'+PO_P!>5_\`^C+2 MI-'_`(:^8S3_`'E^B/M,G_W%>K'ZQ_%63X$_Y*C;?]@B\_\`1UK6MK'\59/@ M/_DJ-M_V"+S_`-'6M9Y=_O4/G^3-&/^O*__`/1EI4FC_P`-1_%C_DH?/\F:YG_N%3Y?FCUX9)/!&/UHR=H.TY...,BG45]8? M"C>=P&#CUH&23P1C]:=10`W)V@[3DXXXR*.=P&#CUIU%`#1DD\$8_6C)V@[3 MDXXXR*=10`WG=P&#CUH&23P1C]:=10`W)V@[3DXXXR*. M=P&#CUIU%`#1DD\$8_6C)V@[3DXXXR*=10`WG5_%K_D5_P#^C+2C1^U?+9I_O+]$?;9-_N*]67=6^Z?I M6/X&_P"2HVO_`&"+S_T=:5L:M]T_2L?P-_R5&U_[!%Y_Z.M*C+_]ZA\_R9>9 M_P"X5/E^:/7!DD\$8_6C)V@[3DXXXR*=17UA\,-YW`8./6@9)/!&/UIU%`#< MG:#M.3CCC(HYW`8./6G44`-&23P1C]:,G:#M.3CCC(IU%`#>=P&#CUH&23P1 MC]:=10`W)V@[3DXXXR*.=P&#CUIU%`&5K.IW>GF+[)H>HZIOSN^R/;KLQC&? M-E3KDXQGH&VFEC@DN'1"RPQE0\A`R%7<0N3T&2!ZD5S'PQE>;PM++)!);N^J:FS0R%2\ M9-].2K;25R.AP2/0FEU'T.JKX_\`VP?^2EZ9_P!@B+_T=-7V#7Q_^V#_`,E+ MTS_L$1?^CIJFIL72^(^F_A?_`,DS\)?]@BT_]$I73US/PN_Y)GX1_P"P1:?^ MB4KI\52V)>XE%+BC%`A*YCX7_P#),_"7_8(M/_1*5U&*YCX7?\DS\(_]@BT_ M]$I1U'T.2^+'_(Y>%_\`KRO_`/T9:5)H_P##3/BS_P`CEX7_`.O*_P#_`$9: M4_1_X:^7S3_>7Z(^SR?_`'%>K'ZQ_%63X"_Y*E;?]@B\_P#1UK6MK'\597@' M_DJ5M_V"+S_T=:U&7?[U#Y_DS7,_]PJ?+\T>PT4N*,5]6?#'E?Q9_P"1R\+_ M`/7E?_\`HRTI^C_PTSXM?\CEX7_Z\K__`-&6E/T?^&OE\T_WE_(^TR?_`'%> MK)=8_BK)\!?\E1MO^P1>?^CK6M;6/XJR?`/_`"5*V_[!%Y_Z.M:C+_\`>H?/ M\F:YG_N%3Y?FCV&BEQ1BOJSX82BEQ1B@!**7%&*`$HI<48H`2BEQ1B@!**7% M&*`$HI<48H`2BEQ1B@!**7%&*`$HI<48H`2BEQ1B@!**7%&*`$HI<48H`2BE MQ1B@!**7%&*`$HI<48H`\I^+G_(X>%_^O*__`/1EI1H_:E^+O_(X>%_^O*__ M`/1EI2:/VKY?-/\`>7Z(^UR?_<5ZLNZM]T_2LCP+_P`E1M?^P1>?^CK2M?5O MNGZ5D>!/^2I6W_8(O/\`T=:5&7_[U#Y_DR\R_P!PJ?+\T>OT4N*,5]6?#B44 MN*,4`)12XHQ0`E%+BC%`"44N*,4`)12XHQ0!#=3I;6TT\BR,D2%V$<;2.0!D M[54%F/H`"3V%PKF/AA,EUX6EGC$BI+JFINHDC:-P#? M3D;E8!E/J"`1W%+J.VAU=?'O[87_`"4S3/\`L$1?^CIJ^P\5\>_MA_\`)3-, M_P"P1%_Z.FJ9[%TOB/ISX7#_`(MGX1_[!%I_Z)2NHQ7,_"T?\6R\(_\`8'L_ M_1*5T^*I$O<3%&*X#6O$OB#0;VVL]1&E37&IHIMO(BD"63-=6UOAR7S.`;M6 MR!#GRB,+O^3H_"NHWMZVKV>J-;27FF7@M'GMXVBCFS!%,&$;,Q3`F"XW-DKG MC.`7"QN8KE_A']$NEMM:UW2M.N'02+%=WD<+ ME22`P#$'&01GV-9_PO(7X8^$2Q`']D68Y_ZXI1U"VAR7Q;_Y'+PO_P!>5_\` M^C+2G:/_``U4^-=_9Z=XK\*S:A=V]K$;._4//($4G?:G&2>O!_*LW2O&'AE- MN_Q%HR_6^B'_`+-7S690D\0VEV/L,IJ1C@DF^K.@UC^*LOP!_P`E2MO^P/>? M^CK6JVJ^,?#+YV>(M&;Z7T1_]FI?A;>VNJ_$I;C3+F"\@@TJY266WD$BQL\U ML5#%<@$A'P#UVGT-1E\)+$Q;7?\`)FF8U(/`S2:Z?FCVO%&*`020""0<'VI- MR[0VY=IQ@YX.>E?4GQ1Y7\6_^1R\+_\`7E?_`/HRTIVC_P`-)\7/^1R\+?\` M7E?_`/HRTI='_AKY?-/]Y?R/L\H_W)>K)=8_BK*\`?\`)4K;_L$7G_HZTK5U MC^*LKX?_`/)4K;_L#WG_`*.M*C+_`/>H_/\`)FN9?[A4^7YH]CQ1B@$$D`@D M'!]J3#GI7U9\.+BC%&1N"Y&XC(%`()(!!(.#[4`&*,4FY=H;< MNTXP<\'/2ER-P7(W$9`H`,48H!!)`()!P?:DW+M#;EVG&#G@YZ4`+BC%&1N" MY&XC(%`()(!!(.#[4`&*,4FY=H;(B>S-PL@E,1[2)@CRAZ]:R[;P-XEM\;/$FCGZZ-+_\`)56/BG?P MW7PV\;P:UICV5M#83K!+?O`8[E]K"-HPLC$'>(RNX*VYDP,]%^(^DZ%XGTFR M5K:QU2YUB2'3[.=L3".*3,DLL!.4C<6XED#C[QCCSOPBUS5,+1J2YIQNSLI8 MVO2AR0G9$=QX,\3SC#^(]&'TT67_`.2JF\(>!M0T;Q0-9U+6;2]*VZI=VUE M9Q8WSW$JQQID@#+,0!DD#ZFN=^&$\-WX6EN;26.>WFU34Y(I8F#(ZF_G(92. M"".016SK7B+1-",0UO6--TXRDB/[7=)#OQC.-Q&<;ES]1ZUC_#"XAN_"LMS: M31SV\VJZG)%+$P9'4W\Y#*1P00<@BEU';0ZO%?'?[8G_`"4S3/\`L$1?^CIZ M^Q<5\=_MB_\`)3=,_P"P/%_Z.GJ9[%4_B/I[X6_\DR\(_P#8'L__`$2E;.HZ M5;ZA=6=Q/)>H]H^^,07DT",<@_.J,%D'RCAP1UXY.YYZG@G7;B>\FU;Q'97,D[QW`:'2S&?.BGCFMPQ:9B8HS&5$:;,B1 MV+;V+UU'AO1Y]+74)KZZCNK_`%"Y^U7,D,)ABW"*.(!$+,5&R),Y9LG<>`0! MM8HQ18+L;BN8^%O_`"3+PC_V![/_`-$I74XKE_A:/^+8^$/^P/9_^B4HZAT+ MWBG5Y]$L[.YAM8[F.6_M;.4/,8S<RQ;U^5MQ#.IVG;D9YXP"K76?&=AK^K_8ICICJ]C& MEC&)`0C#][*VYG"LQ=`GEA6Y(8@$&H:$/C+QI_PCFIQ6GV2WDS")]L]WY$MU MEF'E6:;&^T3C;S'E.9(AGY^);_QI#;>);[2+?3KV]:RL+B[F>W4,[21"!_L\ M:=79]4MH_/A-K(39LSP1"4R(]JWF#R9Q\A, MA#@O#$P5=@%2VG@73K'QA;:]8S7L)B2\WVQO)WB>2XD21G"&38HRKDH%P2P; MJBT:AH2:1XJ_M:WTY;*R\R^N?WDL:RYBA@$C(;CS,?-&^QC"=H,HP0%4.R=/ MBN/U?P1_:NF&.ZU6X75)IDFN;Z%=A?:KJJHN3L6/S"\0R?+E5)#O;>7[+%"! MG%_$'3O#%Y-ILGB6'4)KJ)95M4TXW9GV-L\P[+;YRF5CRQ&T$J,@L,X46A^` M1?06UO=ZS)YWEA+B#5M1>V!D`,:M.LAB5F#(54L"V],`[USOZW<>+K#3(;>* MV_M>\N9F66\TJWAMOL<(4P328=`DL; M>[O]*U)2+N.6&PCMH[,/;NQ?S'I8 MUSPYX(TJZ6WU.;70Y02R%=4U*5((R2!),RR%84^5OGD*K\C\_*V+&@6G@;PY MXBN;BQENH+R*&:W:\O;F[DMMJX>9$FF8PEE\HE@K;AY3YQL;%WQ['J.N:1<: M3::!JIFF218+K[3`EM')\\:-.@FW21=':,I(&1@"A;*#,L?"MY)XSFDO]+DD MLI+F[>X6XF233&@E1E7R+?>66X.1YC,BAO.N^6#)0J<4[I+[@=6>2:!K]E8IJ/ MAZVMK74GVP0V=Q()3:P$NY+R$G=)+,T;W#@DLBD*7D1)']%Q5HS:&XHQ3L48 MIB&XHQ3L48H`;BC%.Q1B@!N*,4[%&*`&XHQ3L48H`;BC%.Q1B@!N*,4[%&*` M&XHQ3L48H`;BC%.Q1B@!N*,4[%&*`&XHQ3L48H`;BC%.Q1B@!N*,4[%&*`&X MHQ3L48H`;BC%.Q1B@!N*,4[%&*`&XHQ3L48H`;BC%.Q1B@!N*,4[%&*`&XHQ M3L48H`;BC%.Q1B@!N*,4[%&*`&XHQ3L48H`;BN8^'7_(OW?_`&&-4_\`2^XK M?U/3K+5;&2RU2SMKVSEQO@N(EDC?!!&58$'!`/U%OL?%?'/[8_ M_)3M,_[`\7_HZ>E/8JGN?3_PL_Y)CX0_[`]G_P"B4KJ,5S/PL_Y)CX0_[`]G M_P"B4KJ,4T2]QN*,4[%&*`&XKE_A9_R3'PA_V![/_P!$I758KE_A9_R3'PA_ MV![/_P!$I0'0Z;%&*=BC%`#<48IV*,4`-Q1BG8HQ0`W%&*=BC%`#<48IV*,4 M`-Q1BG8HQ0`W%&*=BC%`#<48IV*,4`-Q1BG8HQ0`W%&*=BC%`#<48IV*,4`- MQ1BG8HQ0`W%&*=BC%`#<48IV*,4`-Q1BG8HQ0`W%&*=BC%`#<48IV*,4`-Q1 MBG8HQ0`W%&*=BC%`#<48IV*,4`-Q1BG8HQ0`W%&*=BC%`#<48IV*,4`-Q1BG M8HQ0`W%&*=BC%`#<48IV*,4`-Q1BG8HQ0`W%&*=BC%`#<48IV*,4`075M#=V MLUM=PQSV\R&.6*50R.I&"K`\$$'!!KE_A?;0VGA66VM(8X+>'5=3CBBB4*B* M+^I-'4?0ZO%?''[8__`"4[3/\` ML#Q?^CIZ^R<5\;_MD_\`)3M,_P"P/%_Z.GJ9[%0W/J'X6?\`),/"'_8'L_\` MT0E=1BN9^%8_XMAX0_[`]G_Z(2MG48=4DNK-M-O+*WMD?-TEQ:-,\JY'",)$ M"'&[DA^HXXP6A,Y^7QQ:6S,M]I>K6^!ECB78N\F,EYX%Q,(R M/,&0-K[=G0-8CUB&Y_T6YL[JTF^SW-K<[#)"^Q7`)1F0Y21&RK$8;!P00.%U MC1M8UK5[C5;+0M1TW/V.:[M[^ZA=[QK:[@FB2`)-(D>U$N1@F-2\RDYY9>M\ M'6=Y'-KVH7]G)8G5+\74=K,Z-+$JVT$.'V,R9)A9AM9OE9JZ7&$"F&TCM61CDG-6(4&V)QD\9)K9_P"$8U;_`*'CQ%_WXT__ M`.1:+A8Z;%&*YG_A&-6_Z'CQ%_WXT_\`^1:/^$8U;_H>/$7_`'XT_P#^1:+A M8Z;%&*YG_A&-6_Z'CQ%_WXT__P"1:/\`A&-6_P"AX\1?]^-/_P#D6BX6.FQ1 MBN`\%:9KFN>#=!U:[\:Z\ES?V$%U*L5O8!`SQJQ"@VQ.,GC)-;/_``C&K?\` M0\>(O^_&G_\`R+1<+'38HQ7,_P#",:M_T/'B+_OQI_\`\BT?\(QJW_0\>(O^ M_&G_`/R+1<+'38HQ7,_\(QJW_0\>(O\`OQI__P`BT?\`",:M_P!#QXB_[\:? M_P#(M%PL=-BC%P"!GC5B%!MB<9/&2 M:V?^$8U;_H>/$7_?C3__`)%HN%CIL48KF?\`A&-6_P"AX\1?]^-/_P#D6C_A M&-6_Z'CQ%_WXT_\`^1:+A8Z;%&*YG_A&-6_Z'CQ%_P!^-/\`_D6C_A&-6_Z' MCQ%_WXT__P"1:+A8Z;%&*X#P5IFN:YX-T'5KOQKKR7-_8074JQ6]@$#/&K$* M#;$XR>,DUL_\(QJW_0\>(O\`OQI__P`BT7"QTV*,5S/_``C&K?\`0\>(O^_& MG_\`R+1_PC&K?]#QXB_[\:?_`/(M%PL=-BC%P"!GC5B%!MB<9/&2:V?^$8U;_H>/$7_`'XT_P#^1:+A8Z;%&*YG_A&-6_Z' MCQ%_WXT__P"1:/\`A&-6_P"AX\1?]^-/_P#D6BX6.FQ1BN9_X1C5O^AX\1?] M^-/_`/D6C_A&-6_Z'CQ%_P!^-/\`_D6BX6.FQ1BN`\%:9KFN>#=!U:[\:Z\E MS?V$%U*L5O8!`SQJQ"@VQ.,GC)-;/_",:M_T/'B+_OQI_P#\BT7"QTV*,5S/ M_",:M_T/'B+_`+\:?_\`(M'_``C&K?\`0\>(O^_&G_\`R+1<+'38HQ7,_P#" M,:M_T/'B+_OQI_\`\BT?\(QJW_0\>(O^_&G_`/R+1<+'38HQ7`>"M,US7/!N M@ZM=^-=>2YO[""ZE6*WL`@9XU8A0;8G&3QDFMG_A&-6_Z'CQ%_WXT_\`^1:+ MA8Z;%&*YG_A&-6_Z'CQ%_P!^-/\`_D6C_A&-6_Z'CQ%_WXT__P"1:+A8Z;%& M*YG_`(1C5O\`H>/$7_?C3_\`Y%H_X1C5O^AX\1?]^-/_`/D6BX6.FQ1BN`\% M:9KFN>#=!U:[\:Z\ES?V$%U*L5O8!`SQJQ"@VQ.,GC)-;/\`PC&K?]#QXB_[ M\:?_`/(M%PL=-BC%(O^_&G_P#R+1<+ M'38HQ7`>$M,US6-*GN;GQKKRR1W][:@1V]@!MANI85/-L>2L8)]\].E;/_", M:M_T/'B+_OQI_P#\BT7"QTV*,5S/_",:M_T/'B+_`+\:?_\`(M'_``C&K?\` M0\>(O^_&G_\`R+1<+'38HQ7,_P#",:M_T/'B+_OQI_\`\BT?\(QJW_0\>(O^ M_&G_`/R+1<+'38HQ7`>$M,US6-*GN;GQKKRR1W][:@1V]@!MANI85/-L>2L8 M)]\].E;/_",:M_T/'B+_`+\:?_\`(M%PL=#=6Z75K-;RF18Y4,;&*1HW`(P= MK*0RGT(((Z@UR_PNMTM?"LMO&9&CBU74XU,LC2.0+^X`W,Q+,?4DDGJ34_\` MPC&K?]#QXB_[\:?_`/(M:GAK18]!TE;&*YN;O]]-65Y7)V*J_>= MN`H&,4`:6*^-_P!LK_DI^E_]@>+_`-'SU]E8KXU_;+_Y*?I?_8'B_P#1\]*6 MQ4-SZC^%8_XM?X/_`.P/9_\`HA*ZG%-=`@;#WDC!7E25X[69TM_+E>)WF95(A0/'(-\ MA53Y;D$A21TN*\N\=Z9);3>,;.QTNY/_``D&@K86(L[1WCDNR]X7$C(I6++7 M,;%Y"JDNQSPQ!<:/0;75]/N]8O\`2K:[BEU"P2*2ZA0Y,(EW%-QZ`D(3CKC! MQ@C-_%I_NMCKL47` M3%&*7%&*!"8KF[CQKH$#8>\D8*\J2O':S.EOY\+B1D4K%EKF-B\A5278 MYX8@N-';6WB;2KG6#ID-Q(;G>\2N;>189)$SOC28KY;NNU\HK%AL?(&QL;6* MX.YUD:S\0=+L6TS6HK?2KR1HISIDZ1RS?9I4,C2LHC$`5W08)9Y&4@*B[I.] MQ17>.],DMIO&-G8Z7\+B1D4K%EKF-B\ MA5278YX8@N-';6WB;2KG6#ID-Q(;G>\2N;>189)$SOC28KY;NNU\HK%AL?(& MQL;6*XB[N#J?Q"T>2Q35IA8O-!GRPVD"^7(#8N(XP5=OW2,%>5)7CM9G2W\N5XG>9E4B%`\<@ MWR%5/EN02%)'2XKR[QWIDEM-XQL['2[D_P#"0:"MA8BSM'>.2[+WA<2,BE8L MMG7*/K!!NX+V7,5FEM>+$K1>1A,+.[%B[;I7V MY"LH3U'%%P$Q1BEQ1B@0F*YNX\:Z!`V'O)&"O*DKQVLSI;^7*\3O,RJ1"@>. M0;Y"JGRW()"DCI<5Y=X[TR2VF\8V=CI=R?\`A(-!6PL19VCO')=E[PN)&12L M66N8V+R%5)=CGAB"XT=Y_;M@=<_LB-KF6\'#F*UEDBB.W?MDE53'&VW!VLP. M&7CYESJ8KC42*\\<0W6@6%S9SQ3.NM7\D8*\J2O':S.EOY\+B1D4K%E MKF-B\A5278YX8@N-'H,VK6<6L0:67D>^F0R;(H7D$:\X:1E!6,-M8*7*[BK! M>""TRK\F0B M%%]1Q1<&)BC%+BC%`A,5@:AXMT>QN+BWDFN9KJ"8P26]K9S7,H81QR$[(T9B MH6:++@;09%!()`KH,5QGB!(M%\;:9KK6%R;-K.\@N9;&RDN)&GD:T\LND2LY MRENPWD8`102,J"7&7I_&N@0W5M"+R2<7#P1I<6MK-<6X:8J(E::-3&A;S(R` MS#AT/1@3TF*\^T71M0AT3X;:%>6DB-IUM%<:BK#?"#;VPC$3,N5+B>2*1!T_ M<,P.4&?0L47`3%&*7%&*!"8K`U#Q;H]C<7%O)-?Y82XABDDM@9`#&K3JIB5G#(5 M5F!;S$P#O7._BO&O#&E:CI3^&].OM&N4NK6'3(I;%89)+:Z,<"*]W+.F8%EA M.=JL+='L;BXMY)KF:Z@F,$EO:V< MUS*&$<8F`=ZYW\5XUX7\*:W%9Z)H-NWV6"+^RK[7%N[!SY4]K#;8 MCM[@.J2;C;1J0JN%Q*6<'8A]FQ0F#0F*,4N*,4"$Q6+>>)]&LI)([N_BADCO MX=+*N&!:ZE5&CB48^8E94/&0!DDC:V-O%<9\24BL]`CEM["YEEGUC3KB86-E M)/(_E7,#O(XB5F.(H?O'LJKUVBBXS8N?$VE6VL#3)KB07.](F<6\C0QR/C9& M\P7RT=MR81F#'>F`=ZYVL5YIK%K=_P!L:WIBV-ZUSJ/B+3=3MG2VD:%K>'[% MYC-,!Y:$?9IOE9@QVC`.Y<^F8HN%A,48I<48H$)BOC3]LS_DJ&E_]@>+_P!' MSU]F8KXS_;,_Y*AI?_8'B_\`1\]3+8J.Y]2?"K_DE_@__L#6?_HA*ZFOB3P_ M^TAXOT+0=-TFTT[0'MK"VBM8FE@F+E(U"@L1*!G`&<`5?_X:E\;?]`OPY_X# MS_\`QZBX['V917QG_P`-2^-O^@7X<_\``>?_`./4?\-2^-O^@7X<_P#`>?\` M^/4[BL?9E%?&?_#4OC;_`*!?AS_P'G_^/4?\-2^-O^@7X<_\!Y__`(]1<+'V M917QG_PU+XV_Z!?AS_P'G_\`CU'_``U+XV_Z!?AS_P`!Y_\`X]1<+'V917QG M_P`-2^-O^@7X<_\``>?_`./4?\-2^-O^@7X<_P#`>?\`^/47"Q]F45\9_P## M4OC;_H%^'/\`P'G_`/CU'_#4OC;_`*!?AS_P'G_^/47"Q]F45\9_\-2^-O\` MH%^'/_`>?_X]1_PU+XV_Z!?AS_P'G_\`CU%PL?9E%?&?_#4OC;_H%^'/_`>? M_P"/4?\`#4OC;_H%^'/_``'G_P#CU%PL?9E%?&?_``U+XV_Z!?AS_P`!Y_\` MX]1_PU+XV_Z!?AS_`,!Y_P#X]1<+'V917QG_`,-2^-O^@7X<_P#`>?\`^/4? M\-2^-O\`H%^'/_`>?_X]1<+'V917QG_PU+XV_P"@7X<_\!Y__CU'_#4OC;_H M%^'/_`>?_P"/47"Q]F45\9_\-2^-O^@7X<_\!Y__`(]1_P`-2^-O^@7X<_\` M`>?_`./47"Q]F45\9_\`#4OC;_H%^'/_``'G_P#CU'_#4OC;_H%^'/\`P'G_ M`/CU%PL?9E%?&?\`PU+XV_Z!?AS_`,!Y_P#X]1_PU+XV_P"@7X<_\!Y__CU% MPL?9E%?&?_#4OC;_`*!?AS_P'G_^/4?\-2^-O^@7X<_\!Y__`(]1<+'V917Q MG_PU+XV_Z!?AS_P'G_\`CU'_``U+XV_Z!?AS_P`!Y_\`X]1<+'V917QG_P`- M2^-O^@7X<_\``>?_`./4?\-2^-O^@7X<_P#`>?\`^/47"Q]F45\9_P##4OC; M_H%^'/\`P'G_`/CU'_#4OC;_`*!?AS_P'G_^/47"Q]F45\9_\-2^-O\`H%^' M/_`>?_X]1_PU+XV_Z!?AS_P'G_\`CU%PL?9E%?&?_#4OC;_H%^'/_`>?_P"/ M4?\`#4OC;_H%^'/_``'G_P#CU%PL?9E%?&?_``U+XV_Z!?AS_P`!Y_\`X]1_ MPU+XV_Z!?AS_`,!Y_P#X]1<+'V917QG_`,-2^-O^@7X<_P#`>?\`^/4?\-2^ M-O\`H%^'/_`>?_X]1<+'V917QG_PU+XV_P"@7X<_\!Y__CU'_#4OC;_H%^'/ M_`>?_P"/47"Q]F45\9_\-2^-O^@7X<_\!Y__`(]1_P`-2^-O^@7X<_\``>?_ M`./47"Q]F45\9_\`#4OC;_H%^'/_``'G_P#CU'_#4OC;_H%^'/\`P'G_`/CU M%PL?9E%?&?\`PU+XV_Z!?AS_`,!Y_P#X]1_PU+XV_P"@7X<_\!Y__CU%PL?9 ME%?&?_#4OC;_`*!?AS_P'G_^/4?\-2^-O^@7X<_\!Y__`(]1<+'V917QG_PU M+XV_Z!?AS_P'G_\`CU'_``U+XV_Z!?AS_P`!Y_\`X]1<+'V917QG_P`-2^-O M^@7X<_\``>?_`./4?\-2^-O^@7X<_P#`>?\`^/47"Q]F45\9_P##4OC;_H%^ M'/\`P'G_`/CU'_#4OC;_`*!?AS_P'G_^/47"Q]F45\9_\-2^-O\`H%^'/_`> M?_X]1_PU+XV_Z!?AS_P'G_\`CU%PL?9E%?&?_#4OC;_H%^'/_`>?_P"/4?\` M#4OC;_H%^'/_``'G_P#CU%PL?9E%?&?_``U+XV_Z!?AS_P`!Y_\`X]1_PU+X MV_Z!?AS_`,!Y_P#X]1<+'V97QG^V;_R5#2_^P-%_Z/GH_P"&I?&W_0+\.?\` M@//_`/'J\R^)OC[5/B+KT&K:W!907,-LMJJVB,J%`SL"0S, XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 17 94 1 true 11 0 false 2 false true R1.htm 010000 - Document - Risk/Return Summary {Unlabeled} Sheet http://putnam.com/role/RiskReturnSummary Risk/Return Summary false false R8.htm 040000 - Disclosure - Risk/Return Detail Data {Elements} Sheet http://xbrl.sec.gov/rr/role/RiskReturnDetailData Risk/Return Detail Data true false All Reports Book All Reports pghcf357295-20111230.xml pghcf357295-20111230.xsd pghcf357295-20111230_cal.xml pghcf357295-20111230_def.xml pghcf357295-20111230_lab.xml pghcf357295-20111230_pre.xml BarChart1.jpg true true